CA2109805A1 - The use of nucleic acid analogues in diagnostics and analytical procedures - Google Patents

The use of nucleic acid analogues in diagnostics and analytical procedures

Info

Publication number
CA2109805A1
CA2109805A1 CA002109805A CA2109805A CA2109805A1 CA 2109805 A1 CA2109805 A1 CA 2109805A1 CA 002109805 A CA002109805 A CA 002109805A CA 2109805 A CA2109805 A CA 2109805A CA 2109805 A1 CA2109805 A1 CA 2109805A1
Authority
CA
Canada
Prior art keywords
nucleic acid
pna
analogue
strand
acid analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002109805A
Other languages
French (fr)
Inventor
Ole Buchardt
Michael Egholm
Peter E. Nielsen
Rolf H. Berg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27220741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2109805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK98691A external-priority patent/DK98691D0/en
Priority claimed from DK98791A external-priority patent/DK98791D0/en
Application filed by Individual filed Critical Individual
Publication of CA2109805A1 publication Critical patent/CA2109805A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6832Enhancement of hybridisation reaction
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

THE USE OF NUCLEIC ACID ANALOGUES
IN DIAGNOSTICS AND ANALYTICAL PROCEDURES
ABSTRACT
Methods of capture, recognition, detection, identification or quantitation of nucleic acids and diagnostics uses generally are described in which are used (a) a peptide nucleic acid (PNA) comprising a polyamide backbone bearing a plurality of ligands at respective spaced locations along said backbone, said ligands being each independently naturally occurring nucleobases, non-naturally occurring nucleobases or nucleobase-binding groups, each said ligand being bound directly or indirectly to a nitrogen atom in said backbone, and said ligand bearing nitrogen atoms mainly being separated from one another in said backbone by from 4 to 8 intervening atoms;
(b) a nucleic acid analogue capable of hybridising to a nucleic acid of complementary sequence to form a hybrid which is more stable against denaturation by heat than a hybrid between the conventional deoxyribonucleotide corresponding to said analogue and said nucleic acid; or (c) a nucleic acid analogue capable of hybridising to a double stranded nucleic acid in which one strand has a sequence complementary to said analogue, so as to displace the other strand from said one strand. Preferred compounds have the formula:- wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7' is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60, each k and m is, independently, zero or one; and each 1 is independently from zero to 5;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.

Description

-1- 2~

THE USE OF NUCLEIC ACID ANALOGUES
IN DIAGNOSTICS AND AN YTICAL PROCEDURES

The present invention relates to th0 use of certaln nucleic acid analogues in the fleld of dlagnostics, for instance in the capture, recognition, detection, identification or quantitation of one or more chemical or microbiological entities.
Oligodioxyribonucleotides (oligo-DNA's) are finding increasing use in diagnostics procedures. They are for instance finding use in testing for the presence of specific micro-organisms or for testing for the presence of generic predispositions, for instance to disease, in forensic science and in microbiology generally. The uses of oligo-DNA's in this field are of course dependent upon the ability of such oligo-DNA's to hybridise to complementary nucleic acid sequences. By way of example, labelled oligo-DNA probes are used in hybridisation assays to probe immobilised target DNA's for the presence of specific sequences. In amplification procedures, the hybridisation property of oligo-DNA's is utilised to hybridise oligo-DNA primers to template molecules to be amplified.
Oligo-DNA's as long as 100 base pairs in length are now routinely synthesised using a solid support method and fully automatic synthesis machines are commercially available.
Attention has nonetheless been given to the possibility of constructing synthetic DNA-analogues capable of hybridising to natural DNA in a sequence specific manner and yet having chemical properties advantageously distinct from DNA itself.
This work has been largely motivated by the possible use of such compounds in "anti-sense" therapeutics where the use of conventional oligo-DNA's encounters difficulties because such unmodified oligonucleotides have a short half life in vivo due to the natural presence of nucleases, are difficult and costly to prepare in any quantity and are poor at penetrating cell membranes.

' : :

- `
-2- 210~(~0 j For instance, In~ernational (PCT) Patent Application WO86/05518 dlscloses DNA analogue~ havlng a backbone bearlng a sequence of ligands, typlcally nucleotlde bases, suppo~edly capable of sequence speciflc hybridlsatlon to naturally occurrlng nuclelc aclds. A number of dlfferent backbone structures are disclosed. No speclflc exempllficatlon of the provision of such compounds is given and there are no data showing the affinlty of the claimed analogues for DNA.
International (PCT) Patent Appllcatlon WO86/05519 clalms dlagnostlc reagents and systems comprlslng DNA analogues of the same kind but once agaln, there ls no exempllflcatlon.
International (PCT) Patent Appllcation WO89/12060 describes oligonucleotide analogues based on various building blocks from which they are synthesised. Whilst there is exemplification of the building blocks, there is no example of actually preparing an oligonucleotide analogue from them and hence no indication of the performance of the analogues.
Furthermore, it is known to modify the DNA backbone with the aim of increasing reslstance to nuclease and generally improving the sultabillty of the DNA for use in anti-sense therapeutic methods. Other attempts to design DNA analogues are discussed in the introductory portion of W086/05518 mentioned above.
The universal experience has been that modifications of the backbone of natural DNA lead to a decrease in the stability of the hybrid formed between the modified oligonucleotide and its complementary normal oligonucleotide, assayed by measuring the Tm value. Consequently, the conventional wisdom in this area is that modifi~ations of the backbone always destabilise the hybrid, i.e. result in lower Tm values, and therefore the modification should be as minor as possible in order to obtain hybrids with only a slight decrease in Tm value as the best obtainable result.
The present invention relates to the use in diagnostics or in analysis of nucleic acid analogues of novel structure, preferably having the previously unknown property of forming ~ ' ~, ,. " , " '' . ' ~ ' ;
~ ~' '. ' ,. i.

2 1 0 ~3 ~
hybrids with complementary sequence conventional nuclelc ~clds which are more stable in terms of Tm value than would b~ a similar hybrid formed by a conventional nucleic ~cld of corresponding sequence and/or exhibltlng greater ~electlvely for the complementary sequence compared to sequences involvlng a degrees of mis-match than would be exhlbited by sald corresponding conventional nuclelc acid of corresponding sequence.
The invention provides a nuclelc acld analogue for use in the capture, recognitlon, detection, ldentification or quantitation of one or more chemical or microbiological entities, which analogue is (a) a peptide nucleic acid (PNA) comprising a polyamide backbone bearing a plurality of ligands at respective spaced locations along said backbone, said ligands belng each independently naturally occurrlng nucleobases, non-naturally - occurring nucleobases or nucleobase-binding groups, each said ligand being bound directly or indirec.tly to 3 nitrogen atom in said backbone, and said ligand bearing nitrogen atoms mainly being separated from one another in said backbone by from 4 to 8 intervening atoms.
(b) a nucleic acid analogue capable of hybridising to a nucleic acid of complementary sequence to form a hybrid which is more stable against denaturation by heat than a hybrid between the conventional deoxyribonucleotide corresponding to said analogue and said nucleic acid; or (c) a nucleic acid analogue capable of hybridising to a double stranded nucleic acid in which one strand has a sequence complementary to said analogue, so as to displace the other strand from said one strand.
The separation of the nitrogen bearing atoms in the backbone of nucleic acid analogues defined in paragraph (a) above (PNA's) is preferably by five atoms. In nucleic acid analogues having the Formula I (below) this has been found to provide the strongest affinity for DNA. However, it may in some cases be deslred to reduce the strength of binding ': " ' ' ' ' - ~

~4~ 21 0~
between the PNA ' S and DNA by spaclng one or more of the l$gands by a less than optimal spacing, e.g. by a sp~clng of more than 5 atoms, e.g. by up to 14 atoms or more.
Preferably not more than 25% of lnterllgand spacings will be 6 atoms or more. Mor~ preferably not more than 10 to 15%
of interligand spacings will be 6 atoms or more. The aza nitrogen atoms which carry the ligands (directly or via linker groups are not themselves counted in the spacings referred to above.
10 An alternative or additional method for reducing the strength of DNA bindlng is to omit certain of the ligands, putting in their place a moiety which contributes little or nothing to the binding of DNA, e.g. hydrogen. Preferably, not more than 25% of the ligand positions will be occupied by non-binding moieties, e.g. not more than 10 to 15%.
Representative ligands include either the four main naturally occurring DNA bases (i.e., thymine, cytosine, adenine or guanine) or other naturally occurring nucleobases (e.g., inosine, uracil, 5-methylcytosine or thiouracil) or 2~ artificial bases (e.g., bromouracil, azaadenines or azaguanines, etc.) attached to a peptide backbone through a suitable linker.
In preferred embodiments, the nucleic acid analogues used in the invention have the general formula (I):

Ll L2 Ln Al A2 An \C 1 `D 1'`C 2'B ~D 2-G ~~-- n,B n , I

(I) ~ , .
r, , .

' '"' ' . . ' ' ' : ' `i .

_5_ 2 10~3(~

wherein:
n is at least 2, each of Ll-Ln ls lndependently selected from the group 5 consisting of hydrogen, hydroxy, (Cl-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurrlng nucleobases, aromatic moleties, DNA lntercalatorQ, nucleobase-blndlng groups and reporter llgands, at least one of Ll-Ln being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-bindlng group;
each of Al-An is a single bond, a methylene group or a group of formula (IIa) or (IIb):
~ 7 1 ~ 7 1 ~ 7 1 ~ 7 _ c y c ~ or _ c y c c 12 p 12 q R2 r 12 s (IIa) (IIb) where:
X is 0, S, Se, NR3, CH2 or C(CH3)2;
Y is a single bond, 0, S or NR4;
each of p and q is an integer from l to 5, the sum p+q being not more than lO;
each of r and s is zero or an integer from l to 5, the sum r+s being not more than lO;
each Rl and R2 is independently selected from the group consisting of hydrogen, (Cl-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group cons$sting of hydrogen, (Cl-C4)alkyl, hydroxy- or ~ '~'' '' , ' ~

-6- 2~ ~'ii (), alkoxy- or alkylthio-subst~tuted (Cl-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
each of ~ n ls N or R3N+, where R3 i9 as deflned above;
each of Cl-Cn is CR6R7, CHR6CHR7 or CR6R7CH2, where R6 is hydrogen and R7 is selected from the group consistlng of the side chains of naturally occurrlng alpha amlno aclds, or R6 and R7 are lndependently selected from the group conslstlng of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, ~C1-C6)alkoxy, (Cl-C6)alkylthlo, NR3R4 snd SR5, where R3 and R4 are as defined above, and R5 ls hydrogen, (Cl-C6)alkyl, hydroxy-, alkoxy-, or alkylthlo- substltuted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each of D1-Dn is CR6R7, CH2CR6R7 or CHR6CHR7, where R6 and R7 are as defined above;
each of Gl_Gn-l is - O S O O
- N - C -, - N - C -, - N -.S -, or - N - S -in either orlentation, where R3 is as deflned above;
Q is -C02H, -CONR'R'', -S03H or -S02NR'R'' or an activated derlvative of -C02H or -S03H; and I is -NHR'''R'''' or -NR'''C(O)R'''', where R', R", R''' and R'''' are lndependently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers. Alternatively, C and D may be CHR6(CH2)SCHR7 where S may be from 0 to 2.
Preferred peptide nucleic acids have general formula (III):

.. - ., . ;, ~' ' '' , ~' ' ~' ~ ' '' '., 7 2 ~ 0 ~

L
o,~( C H 2 ) I O~q~( C H 2 ) I

Rh ~ (CH ~ N (CH~ (CH2)k ~ N ~ ~ H-R

(III) wherein:
each L ls independently selected from th2 group consisting of hydrogen, phenyl, heterocycles, e.g. of one, two or three rings, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7 is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60;
each of k, 1 and m is independently zero or an integer from 1 to 5; preferably the sum of k and m is 1 or 2, most preferably 1;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
Particularly preferred are compounds having formula (III) wherein each L is independently selected from the group consisting of the nucleobases thymine (T), adenine (A), : cytosine (C), guanine (G) and uracil (U), in particular thymine, and n is an integer from 1 to 30, in particular from 4 to 20. An example of such a compound is provided in Figure 1, which shows the structural similarity between such compounds and single-stranded DNA.
The peptide nucleic acids of the invention may be synthesized by adaptation of standard peptide synthesis procedures, either in solution or on a solid phase. The synthons used may be specially designed monomer amino acids or their activated derivatives, protected by standard h . . . `- ,. ,., '' V
.,~

-8- 2t0~

protecting groups. The ollgonucleotide analogues also can be synthesized by using the corresponding diaclds and diamines.
Thus, the monomer synthons used to produce compounds for use on the lnvention may be selected from the group conslsting of amino acids, diacids and diamines havlng general formulae:
L

~C~D~F o r E~C~C~E o r F~D~F

(IV) (V) (VI) wherein L, A, B, C and D are as defined above, except that any amino groups therein may be protected by amino protecting groups; E is COOH, CSOH, SOOH, S020H or an activated - derivative thereof; and F is NHR3 or NPgR3, where R3 is as defined above and Pg is an amino protecting group.
Preferred monomer synthons are amino acids having formula (VII):
L

OqJ

HOOC~N ~NH2 (VII) or amino-protected and/or acid terminal activated derivatives thereof, wherein L is selected from the group consisting of hydrogen, phenyl, heterocycles, naturally occurring nucleobases, non-naturally occurring nucleobases, and protected derivatives thereof; and R7 is independently selected from the group consisting of hydrogen and the side , ~ - - ~ . . . .

:'' ',','`'```'''' -9- 2 l 0 ~3 /~

chains of naturally occurring alpha amino aclds. Especlally preferred are such synthons havlng formula (4) whereln R7 is hydrogen and L ls selected from tho group conqisting of the nucleobases thymlne (T), adenine (A), cytoslne (C), guanlne (G) and uracll (U) and protected derlvatlves thereof.
In accordance with the inventlon there is included the use of nucleic acid analogues as hereinbefore defined in the capture, recognition, detection, identification or quantitation of one or more chemical or micro-biological entities. Usually it is envisaged the entity which is detected in the first instance will be a nucleic acid and said entity will be detected via its characteristic sequences of nucleic acid bases by hybridlsation.
Nucleic acid analogues as hereinbefore defined may be used in a method of capturing a nucleic acid comprising contacting under hybridising conditions said nucleic acid with a nucleic acid analogue for use in the invention immobilised to a solid support, which immobilised nucleic acid analogue has a sequence of ligands suitable to hybridise to said nucleic acid or nucleic acid analogue to be captured.
Th~ solid support may take a wide variety of forms as is known in connection with the immobilisation of conventional oligo-nucleotides for use in affinity capture. A solid support may for instance be a plate, a filter, a multi-well plate or a dip stick. It may take the form of individual particles such as beads and such particles may be held in a column through which nucleic acid containing solutions mzy be run to allow the capture of desired species therefrom.
The captured nucleic acid may be recognised, detected, identified or quantitated by a wide variety of methods. Since after washing the captured nucleic acid may be the only nucleic acid remaining in the system, it may be detected by any reagent system suitable for demonstrating the presence of nucleic acid, whether or not specific for the captured sequence. Thus by way of example if the captured nucleic acid is DNA and is captured in single stranded form by a relatively ~;' ~'' ; ,, -lo- '~1O!l,`O j short PNA, overhanging slngle stranded DNA may be dlgested by nuclease and the digestlon products may be detected by conventional means. If the DNA is double ~tranded and the PNA
is once agaln relatlvely short, that part of the DNA whlch remalns ln lts orlginal double stranded form (i.e. which i9 not displaced by the PNA) can be detected by conventlonal DNA
lntercalators that do not blnd to the PNA-DNA duplex.
Antibodles which recognise nuclelc aclds may be used to detect nucleic aclds (RNA, dsDNA or ssDNA) bound to the lmmoblllsed nucleic acid analogue.
In the affinity capture of nucleic acid specles uslng conventional oligonucleotides immobilised to a solld support, it is necessary normally to purify the target nucleic acid.
Nucleases which may be present in the sample are liable to attack the lmmobilised nuclelc acid. Little specific binding is obtained in practice with much non-specific binding.
Furthermore, it is necessary to denature the DNA to single stranded form before the capture can ~ake place.
The nucleic acid analogues of Formula I above are not susceptlble to attac~ by nucleases and typlcally provide higher levels of specific binding by virtue of their higher affinity for nucleic acid of complementary sequence than is obtained using conventional oligonucleotides as the immobilised species. Furthermore, the nucleic acid analogues used in accordance with the invention are typically capable of hybridising to nucleic acids of complementary sequence without those nucleic acids first being denatured into single stranded form. Once the target nucleic acid has been captured, it may be released from the immobilised nucleic acid analogue by subjecting the immobilised nucleic acid analogue and captured nucleic acid to dehybridising conditions such as heat and dimethyl formamide.
By way of example, the immobilised nucleic acid analogue may comprise sequential ligands such as thymine, hybridisable to poly A tails of mRNA to capture the mRNA.

"'' '' ' ', : ' The invention includes an affinity capture column comprising immobilised nucleic acid analogues as described above.
Thus it can be seen that the present invention al80 pertains to the advantageous use of PNA molecules in solid-phase biochemistry (see, e.g., '~soltd-phase Biochemtstry -Analytical and Synthetic Aspects", W. H. Scouten, ed., John Wiley & Sons, New York, 1983), notably solid-phase biosystems, especially bioassays or solid-phase techniques which concern diagnostic detection/quantitation or affinity purification of complementary nucleic acids ( see, e.g., "Affinity Chromatography - A Practical Approach", P. D. G. Dean, W. S.
Johnson and F. A. Middle, eds., IRL Press Ltd., Oxford 1986;
"Nucleic Acid Nybridization - A Practtcal Approach", B. D.
~arnes and S. J. Higgins, IRL Press Ltd., Oxford 1987).
Present day methods for performing such bioassays or purification techniques almost exclusively utilize "normal"
or slightly modified oligonucleotides either physically adsorbed or bound through a substantially permanent covalent anchoring linkage to beaded solid supports such as cellulose, glass beads, including those with controlled porosity (Mizutani, et al., J. Chromatogr., 1986, 356, 202), "Sephadex", "Sepharose", agarose, polyacrylamide, porous particulate alumina, hydroxyalkyl methacrylate gels, diol-bonded silica, porous ceramics, or contiguous materials suchas filter discs of nylon and nitrocellulose. One example employed the chemical synthesis of oligo-dT on cellulose beads for the affinity isolation of poly A tail containing mRNA
(Gilham in "Methods in Enzymology," L. Grossmann and K.
Moldave, eds., vol. 21, part D, page 191, Academic Press, New York and London, 1971). A11 the above-mentioned methods are applicable within the context of the present invention.
However, when possible, covalent linkage is preferred over the physical adsorption of the molecules in question, since the latter approach has the disadvantage that some of the immobilized molecules can be washed out (desorbed) during the .
:~ , -12- 21 on ~1 j hybridization or affinity process. There ls, thu~, llttle control of the exten~ to which a specie~ adsorb~d on the surface of th~ support materlal i9 lost during the varloufl treatments to which the support 15 sub~ected ln the course of the bioassay/puriflcatlon procedure. The severlty of thls problem will, of course, depend to a large extent on the rate at which equilibrium between adsorbed and "free" species is established. In certain cases it may be virtually impossible to perform a quantitative assay with acceptable accuracy and/or reproducibility. Loss of adsorbed species during treatment of the support with body fluids, aqueous reagents or washing media will, in general, be expected to be most pronounced for species of relatively low molecular weight.
In contrast with oligonucleotldes, PNA molecules are easier to attach onto solid supports because they contain strong nucleophilic and/or electrophilic centers. In addition, the direct assembly of oligonucleotides onto solid supports suffers from an extremely low loading of the immobilized molecule, mainly due to the low surface capacity of the materials that allow the successful use of the state-of-the-art phosphoramidite chemistry for the construction of oligo-nucleotides. (Beaucage and Caruthers, Tetrahedron Lett., 1981, 22, 1859; Caruthers, Science, 1985, 232, 281). It also suffers from the fact that by using the alternative phosphlte triester method (Letsinger and Mahadevan, J. Am. Chem. Soc.
1976, 98, 3655), which is suited for solid supports with a high surface/loading capacity, only relatively short oligo-nucleotides can be obtained. As for conventional solid-phase peptide synthesis, however, the latter supports are excellent materials for building up immobilized PNA molecules (the side-chain protecting groups may be removed from the synthesized PNA chain without cleaving the anchoring linkage holding the chain to the solid support). Thus, PNA species benefit from the above-described solid-phase techniques with respect to the much higher (and still sequence-specific) blndlng affinity for complementary nucleic acids and from the additional unique ~; .. .

7~

-13- 2lO~05 sequence-specific recognition of (and strong bindlng to) nucleic acids present in double-stranded structures. They also can be loaded onto solid supports in large amounts, thus further increasing the sensitlvity/capaclty of the solld-phase technique~ Further, certain types of studle concernlng the use of PNA ln solld-phase biochemistry can be approached, facilitated, or greatly accelerated by use of the recently-reported "light-directed, spatially addressable, parallel chemical synthesis" technology (Fodor, et al., Science, 1991, 251, 767), a technique that combines solid-phase chemistry and photolithography to produce thousands of highly diverse, but identifiable, permanently immobilized compounds (such as peptides) in a substantially simultaneous way.
It has been found that PNA's according to Formula I
exhibit a property never before observed which is that such a nucleic acid analogue is capable of hybridising to a conventional nucleic acid presented in double-stranded form and is capable under such conditions of hybridising to the strand which has a sequence complementary to the analogue and o displacing the other strand from the initial nucleic acid duplex. Such recognition can take place to dsDNA sequences 5-60 base pairs long. Sequences between 10 and 20 bases are of interest since this is the range within which unique DNA
sequences of pro}caryotes and eukaryotes are found. Reagents which recognize 17-18 bases are particular interest since this is the length of unique sequences in the human genome.
It has also been observed that when such a hybridisation reaction is conducted in solution, a second strand of the nucleic acid analogue having the same sequence as the first also hybridises ~o the nucleic acid strand of complementary sequence so as form a triple helix structure in which two similar strands of PNA are hybridised to a single strand of conventional nucleic acid. It is believed that the first PNA
strand hybridises by inter-base hydrogen bonding of the usual kind whilst the second strand of PNA is received in the ma~or groove of the initial duplex by Hoogsteen pairing. Where the -14~ 0~)0 j PNA is immobilised to a solid support, hybridisation to double stranded nucleic acid with displacement of one ~trand therefrom is observed but the formatlon of trlple hellx structures may be prevented by the immoblllsatlon of the PNA.
The invention includes a nucleic acld analogue as deflned above lncorporatlng or con~ugated to a detectable label.
Generally, all those methods for labelllng peptides, DNA
and/or RNA whlch are presently known may ln general terms be applied to PNA's also. Thus, methods of labelling will include the use of radio-lsotope labels, enzyme labels, biotin, spin labels, fluorophores, chemiluminence labels, antigen labels or antibody labels.
Labelled PNA's as described above may be used in methods of recognition, detection or quantitation of target nucleic acids comprising hybridising said target to a labelled nucleic acid analogue as defined above of sufficiently complementary sequence to hybridise therewith under hybridising conditions and detecting or quantitating said label of the nucleic acid analogue so hybridised to said target.
Optionally, the target may be immobilised on a substrate prior to the hybridisation.
In such a method, the target may be immobilised to the substrate by the hybridisation of the first region of the target to a capture nucleic acid or nucleic acid analogue having a sequence sufficiently complementary to said flrst region to hybridise therewith and which is itself immobilised to said substrate and the labelled nucleic acid analogue may be hybridised to a second region of the target.
The ability of at least preferred nucleic acid analogues according to the invention to hybridise to a double-stranded target nucleic acid and to displace one strand therefrom has been described above. The invention includes a method for displacing one strand from a nucleic acid duplex comprising hybridising to said duplex a nucleic acid analogue as defined above having an affinity for the other strand of said duplex sufficient to be able to displace said one strand therefrom.

~' ` , ;~

-15- 2ln~0~

The inventlon includes a m~thod of detectlng, identlfying or quantitating a double-stranded targ~t nuclelc acid comprising hybridising thereto a displacing nucleic acid analogue as defined above capable of displaclng one strand from a double-stranded target in which the other strand is of complementary sequence to said displaclng nucleic acid analogue, wherein said displacing nucleic acld analogue is of sufficiently complementary sequence to said other strand of said double-stranded target to hybridise thereto so as to displace said one strand of said target in single stranded ~orm, and detecting or quantitating the presence of said one strand after displacement from said double-stranded target.
The displaced strand may be broken down into fragments and the presence of said fragments may be detected. The displaced strand may preferably be broken down by attack by a nuclease. Thus, one may detect the present of a specific double-stranded target nucleic acid sequence by hybridising thereto a complementary PNA to produce strand displacement so as to produce single-stranded DNA in the reaction mixture and digest the single-stranded DNA by the use of a nuclease to produce nucleotides whose presence can be detected as an indicator that specifically the target double-stranded DNA was present initially.
The invention further includes kits for use in diagnostics incorporating at least one nucleic acid analogue as defined above and preferably comprising at least one such nucleic acid analogue which is labelled, e.g. a labelled PNA, and at least one detection reagent for use in detecting said label.
Generally, the nucleic acid analogues will be provided in solution in a hybridisation buffer. Such a kit will generally also include at least one wash buffer solution.
Where the nucleic acid analogue is indirectly labelled, e.g. by biotin, the kit may include a conjugate between an enzyme label and a material such as avidin able to bind to the label of the nucleic acid analogue.

~-.. ' ' .
. ..
.

-16- 2~Q'~,,O~

Where the nucleic acid analogue i9 el-ther directly or indirectly enzyme labell~d, the kit may comprlse a substrate for the enzyme which is suitable to undergo a monitorable reaction mediated by the en~yme.
The invention will be described in further detail and will be illustrated by reference to the accompanying figures, in which:
Figure 1 shows a naturally occurrlng deoxyribooligo-nucleotide (A) and a peptide nucleic acld (PNA) of the invention (B).
Figure 2 provides examples of naturally occurring and non-naturally occurring nucleobases for DNA recognition and reporter groups.
Figure 3 provides a schematic illustration o~ (a) photocleavage by Acr1-(Taeg)l0-Lys-NH2 (Acr TloLys-NH2); (b) photofootprint by the diazo-linked acridine of Acrl-(Taeg)10-Lys-NH2 and preferred KMnO4-cleavage; and (c) Sl-nuclease enhanced cleavage and (d) micrococcus nuclease c]eavage of Acrl-(Taeg)10-Lys-NH2 binding site.
Figure 4 provides examples of PNA monomer synthons.
Figure 5 shows the Acrl ligand and a PNA, Acr1-(Taeg)10-Lys-NH2.
Figure 6 provides a general scheme for the preparation of monomer synthons.
Figure 7 provides a general scheme for the preparation of the Acr1 ligand.
Figure 8 provides a general scheme for solid-phase PNA
synthesis illustrating the preparation of linear unprotected PNA amides.
Figure 9 shows analytical HPLC chromatograms of: (A) crude H-[Taeg]ls-NH2 after HF-cleavage (before lyophilization); (B)crudeAcr1-[Taeg]15-NH2 after HF-cleavage (before lyophilization); and (C) purified Acr -tTaeg]l5-NH2-Buffer A, 5% CH3CN/95% H20/0.0445% TFA; buffer B, 60%
35 CH3CN/40% H20/0.0390% TFA; linear gradient, 0-100% of B in 30 ~, '`' '" ~ ;

-17- 21~

min; flow rate, 1.2 ml/min; column, Vydac C18 (5 ~m, 0.46 x 25 cm).
Flgure 10 shows analytical ~IPLC chromatograms of: (A) purified H~[Taeg]10-Lys-NH2 and (B) purifled H-[Taeg]5-Caeg-[Taeg]4-Lys-NH2 employing the same conditlons as ln Figure 9.
Figures lla and llb show blnding of AcrT10-Lys to dA1o.
5'-32P-labelled oligonucleotlde (1) (5'-GATCCA1oG) was incubated in the absence or presence of AcrT10-Lys and in the absence or presence of oligonucleotlde (2) (5'-GATCCT1oG) and the samples were analyzed by polyacrylamide gel electrophoresis (PAGE) and autoradiography under "native conditions" (Figure lla) or under "denaturing con~itions"
(Figure llb).
Figures 12a-c show chemical, photochemical and enzymatic probing of dsDNA-AcrT10-Lys-NH2 complex. Complexes between AcrT10-Lys-NH2 and a 32P-end labelled DNA fragment containing a dA1o/dT1o target sequence were probed by affinity photocleavage (Figure 12a, lanes 1-3; Figure 12b, lanes 1-3), photofootprinting (Figure 12a, lanes 5-6), potassium permanganate probing (Figure 12b, lanes 4-6) or probing by staphylococcus nuclease (Figure 12b, lanes 8-10) or by nuclease S1 (Figure 12c). Either the A-strand (Figure 12a) or the T-strand (Figures 12b,c) was probed.
Figure 13 provides a procedure for the synthesis of protected PNA synthons.
Figure 14 provides a procedure for the synthesis of a protected adenine monomer synthon.
Figure 15 provides a procedure for the synthesis of a protected guanine monomer synthon.
Figure 16 provides examples of PNA backbone alterations.
Figure 17 provides a procedure for synthesis of thymine monomer synthons with side chains corresponding to the normal amino acids.
Figures 18a and 18b provide procedures for synthesis of an aminopropyl analogue and a propionyl analogue, respectively, of a thymine monomer synthon.

:

, .
~:' " `1 . -, . - , q .,;., `

-1~- 21 Q'1?,(3 i Figure 19 provides a procedure for synthesls o~ an aminoethyl-~-alanine analogue of thymine monomer synthon.
Figure 20 shows a PAGE autoradlograph demonstrating that PNAs-Tlo, -TgC and -T8C2 blnd to double stranded DNA with hlgh sequence speclficity.
Figure 21 shows a graph based on densitometric scanning of PAGE autoradiographs demonstrating the kinetics of the binding of PNA-Tlo to a double stranded target.
Figure 22 shows a graph based on densitometric scanning of PAGE autoradiographs demonstrating the thermal stabilities of PNAs of varying lengths bound to an Alo/T1o double stranded DNA target.
Figure 23 show an electrophoretic gel staining demonstrating that restriction enzyme activity towards DNA is inhibited when PNA is bound proximal to the restriction enzyme recognition site.
Figure 24 shows a PAGE autoradiograph demonstrating that 125I-labeled PNA-T1o binds to a complementary dAlo oligonucleotide.
Figures 25a to c show the percentage binding achieved at varying temperatures between an immobilised PNA and matching or one base mismatched oligo-DNAs.
Figure 26 is an autoradiograph showing inhibition of transcription by RNA polymerase by T1o PNA on the transcribed strand.
Figure 27 is an autoradiograph of a mixture of labelled plasmid dsDNA's captured on an immobilised complementary to one of them and washed at varying temperatures.
Figure 28 combines an ethidium bromide gel and an autoradiograph thereof illustrating the quantitative determination of plasmid dsDNA by strand displacement by PNA.
In the PNA's of Formula I and monomer synthons used in their production, ligand L is primarily a naturally occurring nucleobase attached at the position found in nature, i.e., position 9 for adenine or guanine, and position l for thymine or cytosine. Alternatively, each of some of the ligands L may ,`~ . ' ' ': , - ,' .
- . ' '';

-19- 21~`,Q j be a non-naturally occurring nucleobase (nucleobase analog), another base-blnding moiety, an aromatlc moiety, (C1-C4)alkanoyl, hydroxy or even hydrogen. Some typieal nucleobase ligands and illus~ratlve synthetic llgands are S shown in Figure 2. Furthermore, L ean be a DNA intercalator, a reporter ligand sueh as, for example, a fluorophor, radio label, spin label, hapten, or a proteln-recognizing ligand such as biotin.
In monomer synthons, L may be equipped with protecting groups. This is illustrated in Figure 4, where pgl is an acid, a base or a hydrogenolytically or photochemically cleavable protecting group such as, for example, t-butoxy-carbonyl ( Boc ), fluorenylmethyloxycarbonyl (Fmoc) or 2-nitrobenzyl (2Nb).
15Linker A can be a wide variety of groups such as -cRlR2CO- -CRlR2CS -, -CRlR2CSe-, -CRlR2CNHR3-, -CRlR2C=CH2 -and -CRlR2C=C(CH3)2-, where Rl, R2 and R3 are as defined above.
Preferably, A is methylenecarbonyl (-CH2C0-). Also, A can be a longer chain moiety such as propanoyl, butanoyl or pentanoyl, or corresponding derivative, wherein 0 is replaced by another value of X or the chain is substituted with RlR2 or is heterogenous, containing Y. Further, A can be a (C2-C6)alkylene chain, a (C2-C6)alkylene chain substituted with RlR2 or can be heterogenous, containing Y. In certain cases, A can just be a single bond.
In the preferred form of the invention, B is a nitrogen atom, thereby presenting the possibility of an achiral backbone. B can also be R3N+, where R3 is as defined above.
30In the preferred form of the invention, C is -CR6R7-, but can also be a two carbon unit, i.e. -CHR6CHR7- or -CR6R7CH2-, where R6 and R7 are as defined above. R6 and R7 also can be a heteroaryl group such as, for example, pyrrolyl, furyl, thionyl, imidazolyl, pyridyl, pyrimidinyl, indolyl, or can be taken together to complete an alicyclic system such as, ~t~ '''~ ~: ~. '',' ~'; , ,.'~ . ", . ,', ' ~

: ,~ ~ "'' '~ ' ' .

~ ' ,: . ... : - , , ~:, .. ' ., " '~ . '' -20- 21~n~

forexample, 1,2-cyclobutanediyl, 1,2-cyclopentanediylor 1,2-cyclohexanediyl.
In the preferred form of the inventlon, E ln the monomer synthon is COOH or an actlvated derlvative thereof, and G in the oligomer ls -CoN~3-. (Preferably in the orientatlon -R3NoC in Formula I). As deflned above, E may also be CSOH, SOOH, S020H or an activated derlvative thereof, whereby G in the oligomer becomes -CSNR3- -SONR3-and -So2NR3-, respectively. The activation may, for example, be achieved using an acid anhydride or an active ester derivative, whereln hydrogen ln the groups represented by E ls replaced by a leaving group suited for generating the growlng backbone.
The amino acids whlch form the backbone may be identical or different. We have found that those based on 2-aminoethyl-glycine are especially well suited to the purpose of theinvention.
In some cases it may be of interest to attach ligands at either terminus (Q, I) to modulate the binding characteristics of the PNAs. Xepresentative ligands include DNA intercalators which will improve dsDNA binding or basic groups, such as lysine or polylysine, which will strengthen the binding of PNA
due to electrostatic interaction. To decrease negatively charged groups such as carboxy and sulfo groups could be used.
The design of the synthons further allows such other moieties to be located on non-terminal positions.
The PNA oligomers may be conjugated to low molecular effector ligands such as ligands having nuclease activity or alkylating activity or reporter ligands (fluorescent, spin labels, radioactive, protein recognition ligands, for example, biotin or haptens). In a further aspect of the invention, the PNAs are conjugated to peptides or protelns, where the pep-tides have signalling activity and the proteins are, for example, enzymes, transcription factors or antibodies. Also, the PNAs can be attached to water-soluble or water-lnsoluble polymers. In another aspect of the invention, the PNAs are conjugated to oligonucleotides or carbohydrates. When , . . . ,~. .
,., ,",,~ ... .. .

~., ~ , ~ -, .

~. .

-21- 21 O~

warranted, a PNA oligomer can be synthesized onto some moiety (e.g., a peptide chain, reporter, intercalator or other type of ligand-containing group) attached to a solld support.
The synthesis of the PNAs for use ln to the lnvention is discussed in detail ln the following, where Flgure 1 illustra-tes one of the preferred PNA examples and compares lts structure to that of a complementary DNA.
Synthesis of PNA Oligomers and Polymers The principle of anchoring molecules onto a solid matrix, which helps in accounting for intermediate products during chemical transformations, is known as Solid-Phase Synthesis or Merrifield Synthesis (see, e.g., Merrifield, J. Am. Chem.
Soc., 1963, 85, 2149 and Science, 1986, 232, 341).
Established methods for the stepwise or fragmentwise solid-phase assembly of amino acids into peptides normally employa beaded matrix of slightly cross-linked styrene-divinylben-zene copolymer, the cross-linked copolymer having been formed by the pearl polymerization of styrene monomer to which has been added a mixture of divinylbenzenes. A level of 1-2%
cross-lin~ing is usually employed. Such a matrix also can be used in solid-phase PNA synthesis in accordance with the present invention (Figure 8).
Concerning the initial functionalization of the solid phase, more than fifty methods have been described in connection with traditional solid-phase peptide synthesis (see, e.g., Barany and Merrifield in "The Peptides" Vol. 2, Academic Press, New York, 1979, pp. 1-284, and Stewart and Young, "Solid Phase Peptide Synthesis", 2nd Ed., Pierce Chemical Company, Illinois, 1984). Reactions for the introduction of chloromethyl functionality (Merrifield resin;
via a chloromethyl methyl ether/SnCl~ reaction), aminomethyl functionality (via an N-hydroxymethylphthalimide reaction;
see, Mitchell, et al., Tetrahedron Lett., 1976, 379~), and benzhydrylamino functionality (Pietta, et al., J. Chem. Soc., 35 1970, 650) are the most widely applied. Regardless of its nature, the purpose of the functlonality is normally to form ~ ' .
~'-~- ' - ., ~'' ' "' .

-2Z~ O~'~O i an anchoring linkage betwesn the copolymer solld support and the C-terminus of the first amino acid to be coupled to the solid support. It is generally convenlent to express the "concentration" of a functional group in terms of mlllimoles S per gram (mmol/g). Other reactive functlonalltleQ which have been lnltlally introduced include 4-methylbenzhydrylamlno and 4-methoxybenzhydrylamino. All of these establlshed methods are in principle useful wlthin the context of the present in-vention. Preferred methods for PNA synthesls employ amlnomet-hyl as the inltial functlonallty, ln that aminomethyl isparticularly advantageous with respect to the incorporation of "spacer" or "handle" groups, owing to the reactivlty of the amino group of the aminomethyl functionality wlth respect to the essentially quantitative formation of amide bonds to a carboxylic acid group at one end of the spacer-forming reagent. A vast number of relevant spacer- or handle-forming bifunctional reagents have been described ( see, Barany, et al., Int. J. Peptide Protein Res., 1987, 30, 705), especially reagents which are reactive towards amino groups such as ~ound in the aminomethyl function. Representatlve blfunctlonal reagents include 4-(haloalkyl)aryl-lower alkanoic acids such as 4-(bromomethyl)phenylacetic acid, Boc-aminoacyl-4-(oxymethyl)aryl-lower alkanoic acids such as Boc-aminoacyl-4-(oxymethyl)phenylacetic acid, N-Boc-p-acylbenzhydrylamines such as N-Boc-p-glutaroylbenzhydrylamine, N-Boc-4'-lower alkyl-p-acylbenzhydrylamines such as N-Boc-4'-methyl-p-glutaroylbenzhydrylamine, N-Boc-4'-lower alkoxy-p-acylbenz-hydrylamines such as N-Boc-4'-methoxy-p-glutaroyl-benzhy-drylamine, and 4-hydroxymethylphenoxyacetic acid. One type of spacer group particularly relevant within the context of the present invention is the phenylacetamidomethyl (Pam) handle (Mitchell and Merrifield, J. Org. Chem., 1976, 41, 2015) which, deriving from the electron withdrawing effect of the 4-phenylacetamidomethyl group, is about 100 times more stable than the classical benzyl ester linkage towards the Boc-amino deprotection reagent trifluoroacetic acid (TFA).

1~,. , ~, ' ' , , ~' ' ' ' . .
~ r.
~ '' ""'' , ' .
' ~

~23- 210~0 i Certainfunctionalities( e.g., benzhydrylamlno,4-methyl-benzhydrylamino and 4-methoxybenzhydrylamlno) whlch may be incorporated for the purpose of cleav~ge of a syntheslzed PNA
chain from the solld support such that the C-termlnal of the 5 PNA chaln is in amide form, requlre no lntroductlon of a spacer group. Any such functlonality may advantageously be employed in the context of the present lnvention.
An alternative strategy concerning the introduction of spacer or handle groups is the so-called "preformed handle"
strategy (see, Tam, et al., Synthesis, 1979, 955-957), whlch offers complete control over coupling of the first amino acid, and excludes the possibility of complications arising from the presence of undesired functional groups not related to the peptide or PNA synthesis. In this strategy, spacer or handle groups, of the same type as described above, are reacted with the first amino acid desired to be bound to the solid support, the amino acid being N-protected and optionally protected at the other side-chains which are not relevant with respect to the growth of the desired PNA chain. Thus, in those cases in which a spacer or handle group is desirable, the first amino acid to be coupled to the solid support can either be coupled to the free reactive end of a spacer group which has been bound to the initially introduced functionality (for example, an aminomethyl group) or can be reacted with the spacer-forming reagent. The space-forming reagent is then reacted with the initially introduced functionality. Other useful anchoring schemes include the "multidetachable" resins (Tam, et al., Tetrahedron Lett., 1979, 4935 and J. Am. Chem. Soc., 1980, 102, 611; Tam, J. Org. Chem., 1985, 50, 5291), which provide more than one mode of release and thereby allow more flexibility in synthetic design.
Suitable choices for N-protection are the tert-butyloxycarbonyl (Boc) group (Carpino, J. Am. Chem. Soc., 1957, 79, 4427; McKay, et al., J. Am. Chem. Soc., 1957, 79, 4686; Anderson, et al., J. Am. Chem. Soc., 1957, 79, 6180) normally in combination with benzyl-based groups for the ,~ .
~ ' ,.

protection of side chains, and the 9-fluorenylmethyloxy-carbonyl (Fmoc) group (Carpino, et al., J. Am. Che~. Soc., 1970, 92, 5748 and J. Org. Chem., 1972, 37, 3404), normally in combinatlon wlth tert-butyl (tBu) for the protection of any side chalns, although a number of other posslbilities exlst whlch are well known ln conventlonal solld-phase peptlde synthesls. Thus, a wlde range of other useful amlno protectlng groups exlst, some of which are Adoc (Hass, et al., J. Am. Chem. Soc., 1966, 88, 1988), Bpoc (Sleber, Helv. Chem.
Acta., 1968, 51, 614), Mcb (Brady, et al., J. Org. Chem., 1977, 42, 143), Blc (Kemp, et al., Tetrahedron, 1975, 4624), the o-nitrophenylsulfenyl (Nps) (Zervas, et al., J. Am. Chem.
Soc., 1963, 85, 3660), and the dithiasuccinoyl (Dts) ~Barany, et al., J. Am. Chem. Soc., 1977, 99, 7363). These amino protecting groups, particularly those based on the widely-used urethane functlonallty, successfully prohlbit racemization (mediated by tautomerization of the readily formed oxazolinone (azlactone) intermediates (Goodman, et al., J. Am. Chem. Soc., 1964, 86, 2918)) during the coupling of most a-amino acids.
In addition to such amino protecting groups,a whole range of otherwise "worthless" nonurethane-type of amino protecting groups are appllcable when assembllng PNA molecules, especially those built from achlral unlts. Thus, not only the above-mentioned amino protecting groups (or those derived from any of these groups) are useful within the context of the present invention, but virtually any amino protecting group which largely fulfils the following requirements: (1) stability to mild acids (not significantly attacked by carboxyl groups); (2) stability to mild bases or nucleophiles (not significantly attacked by the amino group in question);
(3) resistance to acylation (not significantly attacked by activated amino acids). Additionally: (4) the protecting group must be close to quantitatively removable, without serious side reactions, and (5) the optical integrity, if any, of the incoming amino acid should preferably be highly preserved upon coupling. Finally, the choice of side-chain ,, ". ~ . , ~ !

~"

~'~ . ,'., ~ 1 ~ n ~ o j protecting groups, in general, depends on the cholc~ of the amino protectin~ group, since tha protectlon of side-chain functionalitles must wlthstand the conditlons of the repeated amlno deprotection cycles. Thls 19 true whether the overall strategy for chemlcally assembllng PNA molecules relies on, for example, differential acld stability of amlno and slde-chain protectlng groups (such as ls the case for the above-mentioned "Boc-benzyl" approach) or employs an orthogonal, that ls, chemoselective, protection scheme (such as is the case for the above-mentioned "Fmoc-tBu" approach), Following coupling of the first amlno acid, the next stage of solid-phase synthesis is the systematic elaboratlon of the deslred PNA chaln. Thls elaboratlon lnvolves repeated deprotection/coupling cycles. The temporary protecting group, such as a Boc or Fmoc group, on the last-coupled amlno acld i9 quantitatively removed by a suitable treatment, for example, by acidolysis, such as with trifluoroacetic acld, in the case of Boc, or by base treatment, such as wlth piperidine, in the case of Fmoc, so as to llberate the N-terminal amine functlon.
The next desired N-protected amlno acld is then coupled to the N-terminal of the last-coupled amino acid. This coupling of the C-terminal of an amino acid with the N-terminal of the last-coupled amlno acld can be achieved ln several ways. For example, it can be bound by provlding the incoming amino acid in a form with the carboxyl group activated by any of several methods, including the initial formation of an active ester derivative such as a 2,~,5-trichlorophenyl ester (Pless, et al., Helv. Chim. Acta, 1963, 30 46, 1609), a phthalimido ester (Nefkens, et al., J. Am. Chem.
Soc., 1961, 83, 1263), a pentachlorophenyl ester (Kupryszewski, Rocz. Chem., 1961, 35, 595), a pentafluoro-phenyl ester (Kovacs, et al., J. Am. Chem. Soc., 1963, 85, 183), an o-nitrophenyl ester (Bodanzsky, Nature, 1955, 175, 35 685), an imidazole ester (Li, et al., J. Am. Chem. Soc., 1970, 92, 7608), and a3-hydroxy-4-oxo-3,4-dihydroqulnazoline(Dhbt-; ' ~

21~n',~J

OH) ester (Konig, et al., Chem. ~er., 1973, 103, 2024 and 2034), or the inltlal formatlon of an anhydrlde such as a symmetrical anhydride (Wieland, et al., Angew. Chem., I~t. Ed.
Engl ., 1971, 10, 336). Alternatlvely, the carboxyl group of the lncomlng amlno acld can be reacted dlrectly with the N-termlnal of the last-coupled amlno acld wlth the asslstance of a condensation reagent such as, for example, dicyclohexyl-carbodiimide (Sheehan, et al., J. Am. Chem. Soc., 1955, 77, 1067) or derivatives thereof. Benzotriazolyl N-oxytris-dimethylaminophosphonium hexafluorophosphate(BOP), "Castro'sreagent" (see, e.g., ~ivaille, et al., Tetrahedron, 1980, 36, 3413) is recommended when assembllng PNA molecules containing secondary amino groups. Finally, activated PNA monomers analogous to the recently-repor~ed amino acid fluorldes (Carpino, J. Am. Chem. Soc., 1990, 112, 9651) hold con-siderable promise to be used $n PNA synthesis as well.
Following assembly of the desired PNA chain, including protecting groups, the next step will normally be deprotection of the amino acid moieties of the PNA chain and cleavage of the synthesized PNA from the solid support. These processes can take place substantially simultaneously, thereby providing the free PNA molecule in the deslred form. Alternatlvely, in cases in which condensation of two separately synthesized PNA
chains is to be carried out, it ls possible by choosing a suitable spacer group at the start of the synthesis to cleave the desired PNA chains from their respective solid supports (both peptide chains still incorporating their side-chain protecting groups) and finally removing the side-chain protecting groups after, for example, coupling the two side-chain protected peptide chains to form a longer PNA chain.
In the above-mentioned "Boc-benzyl n protection scheme, the final deprotection of side-chains and release of the PNA
molecule from the solid support is most often carried out by the use of strong acids such as anhydrous HF (Sakakibara, et al., ~ull. Chem. Soc. Jpn., 1965, 3~, 4921), boron tris (trifluoroacetate) (Pless, et al., Helv. Chim. Acta, 1973, g6, k ~

-27- Z10 ~ ~ j 1609), and sulfonic acids such as trlfluoromethanesulfonic acid and methanesulfonic acid (Ya~ima, et ~1., J. Chem. Soc., Chem. Comm., 1974, 107). This conventional strong acid (e.g., anhydrous HF) deprotection method, produces very reactive carbocatlons that may lead to alkylatlon and acylation of sensitive residues in the PNA chain. Such side-reactions are only partly avoided by the presence of scavengers such as anisole, phenol, dimethyl sulphide, and mercaptoethanol and, therefore, the sulphide-assisted acidolytlc SN2 deprotectlon method (Tam, et al., J. Am. Chem. Soc., 1983, 105, 6442 and J. Am. Chem. Soc., 1986, 108, 5242), the so-called "low", which removes the precursors of harmful carbocations to form inert sulfonlum salts, is frequently employed in peptide and PNA synthesis, either solely or in combination with "high"
methods. Less frequently, in special cases, other methods used for deprotection and/or final cleavage of the PNA-solid support bond are, for example, such methods as base-catalyzed alcoholysis (Barton, et al., J. Am. Chem. Soc., 1973, 95, 4501), and ammonolysis as well as hydrazlnolysis (Bodanszky, et al., Chem. Ind., 1964 1423), hydrogenolysis (Jones, Tetrahedron Lett. 1977 2853 and Schlatter, et al., Tetrahedron Lett. 1977 2861)), and photolysis (Rich and Gurwara, J. Am.
Chem. Soc., 1975 97, 1575)).
Finally, in contrast with the chemical synthesis of "nor-mal" peptides, stepwise chain building of achiral PNAs such as those based on aminoethylglycyl backbone units can start either from the N-terminus or the C-terminus, because the coupling reactions are free of racemization.
Based on the recognition that most operations are identical in the synthetic cycles of solid-phase peptide synthesis (as is also the case for solid-phase PNA synthesis), a new matrix, PEPS, was recently introduced (Berg, et al., J.
Am. Chem. Soc., 1989, 111, 8024 and International Patent Application W0 90/02749) to facilitate the preparation of large numbers of peptides. This matrix is comprised of a polyethylene (PE) film with pendant long-chain polystyrene ~,',:~ ' ' ' , .
~"' .- .
~ ,'" . ' -2~- 2~

(PS) grafts (molecular welght on the order of lo6). The loading capaclty of the fllm is as hiyh aS that of a beaded matrix, but PEPS ha~ the addltional flexibility ~o sult multiple syntheses slmultaneously. Thus, in a new configuratlon for solid-phase peptide synthesls, the PEPS fllm is fashioned in the form of discrete, labeled sheets, each serving as an individual compartment. During all the identical steps of the synthetic cycles, the sheets are kept together in a slngle reactlon vessel to permlt concurrent preparatlon of a multltude of peptldes at a rate close to that of a slngle peptlde by conventlonal methods. It was reasoned that the PEPS fllm support, comprlslng llnker or spacer groups adapted to the particular chemistry in questlon, should be particularly valuable in the synthesis of multlple PNA
molecules, these being conceptually simple to synthesize since only four different reaction compartments are normally required, one for each of the four "pseudo-nucleotide" units.
Thus, the PEPS film support has been successfully tested in a number of PNA syntheses carried out ln a parallel and substantially simultaneous fashion. The yield and quality of the products obtained from PEPS were comparable to those obtained by using the traditional polystyrene beaded support.
Also, experiments with other geometries of the PEPS polymer such as, for example, non-woven felt, knitted net, sticks or microwellplates have not indicated any limitations of the synthetic efficacy.
Two other methods proposed for the simultaneous synthesis of large numbers of peptides also apply to the preparation of multiple, different PNA molecules. The first of these methods 30 (Geysen, et al., Proc. Natl. Acad. Sci. USA, 1984, 81, 3998) utilizes acrylic acid-grafted polyethylene-rods and 96-microtiter wells to immobilize the growing peptide chains and to perform the compartmentalized synthesis. While highly effective, the method is only applicable on a microgram scale.
The second method (Houghten, Proc. Natl. Acad. Sci. USA, 1985, ~2, 5131) utilizes a "tea ba~" containing traditionally-used " ,s ~' .
~ ,?

29- 2 ~ ~ ~ ,, O i polymer beads. Other relevant proposals for multiple peptlde or PNA synthesls in the context of the present lnventlon include the simultaneous use of two dlfferent supports with different densities (Tregear, in "Chemistry and Blology of Peptides", J. Meienhofer, ed., Ann Arbor Sci. Publ., Ann Arbor, 1972 pp. 175-178), combining of reactlon vessels vla a manifold (Gorman, Anal. Biochem., 1984, 136, 397), multicolumn solld-phase synthesis (e.g. Krchnak, et al., Int.
J. Peptide Prote~n Res., 1989, 33, 209), and Holm and Meldal, in "Proceedings of the 20th European Peptide Symposium", G.
Jung and E. Bayer, eds., Walter de Gruyter & Co., Berlin, 1989 pp. 208-210), and the use of cellulose paper (Eichler, et al., Collect. Czech. Chem. Commun., 1989, 54, 1746).
Whlle the conventional cross-linked styrene/divinylbenzene copolymer matrix and the PEPS support are presently preferred in the context of solid-phase PNA
- synthesis, a non-limiting list of examples of solid supports which may be of relevance are: (l) Particles based upon copolymers of dimethylacrylamide cross-linked with N,N'-bisacryloylethylenediamine, including a known amount of N-tertbutoxycarbonyl-beta-alanyl-N'-acryloyl-hexamethylene-diamine. Several spacer molecules are typically added via the beta alanyl group, followed thereafter by the amino acid residue subunits. Also, the beta alanyl-containing monomer can be replaced with an acryloyl sarcosine monomer during polymerization to form resin beads. The polymerization is followed by reaction of the beads with ethylenediamine to form resin particles that contain primary amines as the covalently linked functionality. The polyacrylamide-based supports are relatively more hydrophilic than are the polystyrene-based supports and are usually used with polar aprotic solvents including dimethylformamide, dimethyl-acetamide, N-methylpyrrolidone and the like (see Atherton, et a7., J. Am.
Chem. Soc., 1975, 97, 6584, Bioorg. Chem. 1979, ~, 351), and J.C.S. Perkin I 538 (1981)); (2) a second group of solid supports is based on silica-containing particles such as .. - , ~ ., .
'~ "'' , . ' , : , :~
~"~

~o- 2 1 ~ ) 0 i porous glass beads and silica gel. One example i8 the reaction product of trlchloro-[3-(4-chloromethyl)-phenyl]propylsilane and porous glass beads (soe Parr and Grohmann, Angew. Chem. Internal. Ed. 1972, 11, 314) sold under the trademark "PORASIL E" by Waters Assoclates, Framlngham, MA, USA. Similarly, a mono ester of 1,4-dlhydroxy-methylbenzene and silica (sold under the trademark "BIOPAK"
by Waters Associates) has been reported to be useful (see Bayer and Jung, Tetrahedron Lett., 1970, 4503); (3) a third general type of useful solid supports can be termed composites in that they contain two ma;or ingredients: a resin and another material that is also substantlally inert to the organic synthesis reaction conditions employed. One exemplary composite (see Scott, et al., J. Chrom. Sc~., 1971, 9, 577) utilized glass particles coated with a hydrophobic, cross-linked styrene polymer containing reactive chloromethyl groups, and was supplied by Northgate Laboratories, Inc., of Hamden, CT, USA. Another exemplary composite contains a core of fluorinated ethylene polymer onto which has been grafted polystyrene (see Kent and Merrifield, Israel J. Chem. 1978, 17, 243) and van Rietschoten in "Peptides 1974", Y. Wolman, Ed., Wiley and Sons, New York, 1975, pp. 113-116); and (4) contiguous solid supports other than PEPS, such as cotton sheets (Lebl and Eichler, Peptide Res. 1989, 2, 232) and hydroxypropylacrylate-coated polypropylene membranes (Daniels, et al., Tetrahedron Lett. 1989, 4345), are suited for PNA
synthesis as well.
Whether manually or automatically operated, solid-phase PNA synthesis in the context of the present invention is normally performed batchwise. However, most of the syntheses may equally well be carried out in the continuous-flow mode, where the support is packed into columns (Bayer, et al., Tetrahedron Lett., 1970, 4503 and Scott, et al., J.
Chromatogr. Sci., 1971, 9, 577). With respect to continuous-flow solid-phase synthesis, the rigid poly(dimethylacrylami-de)-Kieselguhr support (Atherton, et al., J. Chem. Soc. Chem.

~'' '' .
~.i~ . .
~ .
, . ~

-31- 21.0~ 0~i Commun., 1981, 1151) appears to be particularly succes~fu1, but another valuable configuratlon concerns the ono worked out for the standard copoly(styrene-1%-dlvlnylbenzene)~ùpport (Krchnak, et al., Tetrahedron Lett., 1987, 4469).
While the solid-phase technique ls presently preferred in the context of PNA synthesis, other methodologles or combinations thereof, for example, in comblnation with the solid-phase technique, apply as well: (1) the classical solution-phasemethods for peptide synthegls(e. g., Bodanszky, "Principles of Peptide Synthesis", Springer-Verlag, Berlin-New York 1984), either by stepwise assembly or by segment/fragment condensation, are of particular relevance when considering especially large scale productions (gram, kilogram, and even tons) of PNA compounds; (2) the so-called "liquid-phase"
strategy, which utilizes soluble polymeric supports such as linear polystyrene (Shemyakin, et al., Tetrahedron Lett., 1965, 2323) and polyethylene glycol (PEG) (Mutter and Bayer, ,,~ngew. Chem., Int. Ed. Engl., 1974, 13, 88), is useful: (3) random polymerization ( see, e.g., Odian, "Pr~nciples of Polymerization", McGraw-Hill, New York (1970)) yielding mixtures of many molecular weights ("polydisperse") peptide or PNA molecules are particularly relevant for purposes such as screening for antiviral effects; (4) a technique based on the use of polymer-supported amino acid active esters 25 (Fridkin, et al., J. Am. Chem. Soc., 1965, 87, 4646), sometimes referred to as "inverse Merrifield synthesis" or "polymeric reagent synthesis", offers the advantage of isolation and purification of intermediate products, and may thus provide a particularly suitable method for the synthesis of medium-sized, optionally protected, PNA molecules, that can subsequently be used for fragment condensation into larger PNA
molecules; (5) it is envisaged that PNA molecules may be assembled enzymatically by enzymes such as proteases or derivatives thereof with novel specificities (obtained, for example, by artificial means such as protein engineering).
Also, one can envislon the development of "PNA ligases" for r . . .

" ' ~' '~ ' ' "" '~

-32- 2 1 0 ~

the condensation of a number of PNA fragments lnto very large PNA molecules; (6) since antlbodles can be generated to virtually any molecule of lnterest, the recently developed catalytic antibodies (abzymes), discovered slmultaneously by the groups of Lerner (Tramantano, et al., Sc~ence, 1986, 234, 1566) and of Schultz (Pollack, et al., Sclence, 1986, 234, 1570), should also be considered ac potentlal candidates for assembling PNA molecules. Thus, there has been considerable success in producing abzymes catalyzing acyl-transfer reactions (see for example Shokat, et al., Nature, 1989, 338, 269) and references therein). Finally, completely artificial enzymes, very recently pioneered by Stewart's group ~Hahn, et al., Science, 1990, 248, 1544), may be developed to suit PNA
synthesis. The design of generally applicable enzymes, ligases, and catalytic antibodies, capable of mediating specific coupling reactions, should be more readily achieved - for PNA synthesis than for "normal" peptide synthesis since PNA molecules will often be comprised of only four different amino acids tone for each of the four native nucleobases) as compared to the twenty natural by occurring (proteinogenic) amino acids constituting peptides. In conclusion, no single strategy may be wholly suitable for the synthesis of a specific PNA molecule, and therefore, sometimes a combination of methods may work best.
(a) Experimental for the synthesis of monomeric building blocks The monomers preferably are synthesized by the general scheme outlined in Figure 8. This involves preparation of either the methyl or ethyl ester of (Bocaminoethyl)glycine, by a protection/deprotection procedure as described in Examples 21-23. The synthesis of thymine monomer is described in Examples 24-25, and that of the protected cytosine monomer is described in Example 26.
The synthesis of the protected adenine monomer (Figure 14) involved alkylation with ethyl bromoacetate (Example 27) and verification of the position of substitution by X-ray .
'' ~ ,, , ' ~.'' , , ' --33- 21~7'~ i crystallography, as being the wanted 9-posltlon. The N6-amlno group then was protected wlth the benzyloxycarbonyl ~roup by the use of the reagent N-ethyl-benzyloxyc~rbonyli~idazole tetrafluoroborate (Example 28). Simple hydrolysl~ of the product ester (Example 29) gave N6-benzyloxycarbonyl-9-carboxymethyl adenine, which then was used in the standard procedure (Examples 10-11, Figure 8). The adenine monomer has been built into two different PNA-oligomers (Examples 30 and 31).
The synthesis of the protected G-monomer ls outllned ln Figure 15. The starting material, 2-amino-6-chloropurine, was alkylated with bromoacetic acid (Example 32) and the chlorine atom was then substituted with a benzyloxy group (Example 36).
The resulting acid was coupled to the (bocaminoethyl) glyclne methyl ester (Example 33) with agent PyBropTY, and the resulting ester was hydrolysed (Example 23). The O6-benzyl group was removed in the final HF-cleavage step in the synthesis of the PNA-oligomer. Cleavage was verified by finding the expected mass of the final PNA-oligomer, upon incorporation into an PNA-oligomer using dlisopropyl carbodiimide as the condensation agent (Example 52).
The following abbreviations are used in the experimental examples: DMF, N,N-dimethylformamide; DCC, N,N-dicyclohexyl carbodiimide; DCU, N,N-dicyclohexyl urea; THF, tetra-hydrofuran; aeg, N-acetyl (2'-aminoethyl)glycine; pfp, pentafluorophenyl; 8OC, tert-butoxycarbonyl; Z, benzyloxy-carbonyl; NMR, nuclear magnetic resonance; s, singlet; d, doublet; dd, doublet of doublets; t; triplet; q, quartet; m, multiplet; b, broad; ~, chemical shift;
NMR spectra were recorded on either a JEOL FX 90Q
spectrometer, or a Bruker 250 MHz with tetramethylsilane as internal standard. Mass spectrometry was performed on a MassLab VG 12-250 quadropole instrument fitted with a VG FAB
source and probe. Melting points were recorded on 8uchi melting point apparatus and are uncorrected. N,N-Dimethylformamlde was dried over 4 A molecular sieves, . ' '~

' ~"'" ', '~lO~ oO ,j -3~-distilled and stored over 4 A molecular sieves. Pyridlne (HPLC ~uality) was dried and stored over 4 A molecular sleves.
Other solvents used were either the highest quallty obtalnable or were distilled before use. Dioxane was passed through basic alumina prlor to use. Bocanhydrlde, 4-nitrophenol, methyl bromoacetate, benzyloxycarbonyl chloride, pentafluorophenol were all obtalned through Aldrich Chemical Company. Thymine, cytosine, adenlne were all obtained through Sigma.
10Thin layer chromatography (Tlc) was performed uslng the followlng solvent systems: (l) chloroform:triethyl amine:methanol, 7:1:2; (2) methylene chloride:methanol, 9:1;
(3) chloroform:methanol:acetic acid 85:10:5. Spots were visualized by W (254 nm) or/and spraying with a ninhydrin solution (3 g ninhydrin in 1000 ml 1-butanol and 30 ml acetic acid), after heating at 120C for 5 min and, after spraying, heating again.
Extended Backbones Variations of the groups A, C and D (figure 16) are demonstrated by the synthesls of monomeric building blocks and incorporation into PNA-oligomers.
In one example, the C group was a CH(CH3) group. The synthesis of the corresponding monomer is outlined in Figure 17. It involves preparation of Boc-protected l-amino-2,3-propanediol (Example 35), whlch ls cleaved by periodate togive bocaminoacetaldehyde, which is used directly ir.the next reaction. The bocaminoacetaldehyde can be condensed with a variety of amines; in Example 36, alanine ethyl ester was used. In Examples 17-19, the corresponding thymine monomers were prepared. The monomer has been incorporated into an 8-mer by the DCC-coupling protocol (Examples 30 and 31).
In another example, the D-group is a (CH2)3 group. The synthesis of the corresponding monomer ls outlined in figure 18.A and descrlbed in Examples 40 and 46.

z~
~ ' ' :' , '' v., ~ ,,, . .,~, ' ~35- 2109`30i In another example, the A-group ls a (CH2)2C0 group. Th~
synthesis of the correspondin~ thymlne monomer 1~ outlined figur~ 18.B and Examples 42 through 45.
In yet another example, the C-group ls a (CH2)2 group.
The synthesis of the thymine a~d protected cytosine monomor is outlined in Figure 19 and Examples 46 through 51.
Hybridization experiments with a PNA-oligomer containing one unit are described in Example 61, which shows a significant lowering of affinity but a retention of specificity.

tert-Butyl 4-nitrophenyl carbonate Sodium carbonate (29.14 g; 0.275 mol) and 4-nitrophenol (12.75 g; 91.6 mmol) were mixed with dioxane (250 ml). Boc-anhydride (20.0 g; 91.6 mmol) was transferred to the mixture with dioxane (50 ml). The mixture was refluxed for 1 h, cooled to 0C, filtered and concentrated to l/3, and then poured into water (350 ml) at 0C. After stirring for 1/2 h., the product was collected by filtration, washed with water, and then dried over sicapent, in vacuo. Yield 21.3 g (97%).
20 M.p. 73.0-74.5C (litt. 78.5-79.5C). Anal. for C11H13N05 found(calc.) C: 55.20(55.23) H: 5.61(5.48) N: 5.82(5.85).

(N'-Boc-2'-aminoethyl)glycine (2) The title compound was prepared by a modification of the 25 procedure by Heimer, et al. N-(2-Aminoethyl)glycine (1, 3.00 g; 25.4 mmol) was dissolved in water (50 ml), dioxane (50 ml) was added, and the pH was adjusted to 11.2 with 2 N sodium hydroxide. tert-Butyl-4-nitrophenyl carbonate (7.29 g; 30.5 mmol) was dissolved in dioxane (40 ml) and added dropwise over a period of 2 h, during which time the pH was maintained at 11.2 with 2 N sodium hydroxide. The pH was adjusted periodically to 11.2 for three more hours and then the solution was left overnight. The solution was cooled to 0C
and the pH was carefully adjusted to 3.5 with 0.5 M
hydrochloric acid. The aqueous solution was washed with chloroform (3 x 200 ml), the pH adjusted to 9.5 with 2N sodium ~, , . , .
~ , .
~'' ' ,.
:

-36- 21~ 9~0 ~

hydroxide and the solution was evaporated to dryness, i~ vacuo (14 mmH~). The resldue was extracted wlth DMF (25+2xlO ml) and the extracts flltered to remove excess salt. Thls results $n a solution of the tltle compound ln about 60~ yield and greater than 95~ purity by tlc (system 1 and visualised with ninhydrin, Rf-0.3). The solution was used ln the following preparations of Boc-aeg derlvates without further purification.

N-l-Carboxymethylthymine (4) This procedure is different from the literature synthesis, but is easier, gives higher yields, and leaves no unreacted thymine in the product. To a suspension of thymine (3, 40.0 g: 0.317 mol) and potassium carbonate (87.7 g; 0.634 15 mmol) in DMF (900 ml) was added methyl bromoacetate (30.00 ml;
0.317 mmol). The mixture was stirred vigorously overnight under nitrogen. The mixture was filtered and evaporated to dryness, in vacuo. The solld resldue was treated with water (300 ml) and 4 N hydrochloric acld (12 ml), stlrred for 15 min at 0C, filtered, and washed with water (2 x 75 ml). The precipitate was treated with water (120 ml) and 2N sodium hydroxide (60 ml), and was boiled for 10 minutes. The mixture was cooled to 0C, filtered, and the pure tltle compound was precipitated by the addition of 4 N hydrochloric acid (70 ml).
25 Yield after drying, in vacuo over sicapent: 37.1 g (64%). lH-NMR: (90 MHz; DMso-d6): 11.33 ppm (s,lH,NH);
7.49(d,J=0.92Hz,lH,ArH); 4.38 (s,2H,CH2); 1.76 (d,J=0.92Hz,T-CH3) N-l-Carboxymethylthymine pentafluorophenyl ester (5) N-l-Carboxymethylthymine (4, lO.Og; 54.3 mmol) and penta-fluorophenol (10.0 g; 54.3 mmol) were dissolved in DMF (100 ml) and cooled to 5C in ice water. DCC (13.45 g; 65.2 mmol) then was added. When the temperature passed below 5~C, the ice bath was removed and the mlxture was stirred for 3 h at ambient temperature. The precipitated DCU was removed by ~'''~, " ' - '' `' , .
~ ' "" " . , - , - - , , '. ' '' "
~ ~ , , ~,:

--37- 21 0~`3^3 filtration and washed twice with DMF (2 x 10 ml). The combined filtrate was poured into ethQr (1400 ml) and cooled to 0C. Petroleum ether (1400 ml) was added and the mixture was left overnight. The title compound wa~ isolated by filtration and was washed thoroughly with petroleum ether.
Yield: 14.8 g(78%). The product was pure enough to carry out the next reaction, but an analytical sample was obtained by recrystallization from 2-propanol. M.p. 200.5-206C Anal. for C13H7F5N204. Found(calc.) C: 44.79(44.59); H: 2.14(2.01) N:
108.13(8.00). FAB-MS: 443 (M+l+glycerol), 351 (M+1). lH-MMR (90 MHz; DMS0-d6): 11.52 ppm (s,lH,NH); 7.64 (s,lH,Ar_); 4.99 (s,2H,CH2); 1.76 (s,3H,CH3).

1-(Boc-aeg)thymine (6) 15To the DMF-solution from above was added triethyl amine (7.08 ml; 50.8 mmol) followed by N-l-carboxymethylthymine pentafluGrophenyl ester (5, 4.45 g; 12.7 mmol). The resultant solution was stirred for 1 h. The solution was cooled to 0C
and treated with cation exchange material ("Dowex 50W X-8", 40 g) for 20 min. The cation exchange material was removed by filtration, washed with dichloromethane (2 x 15 ml), and dichloromethane (150 ml) was added. The resulting solution was washed with saturated sodium chloride, dried over magnesium sulfate, and evaporated to dryness, in vacuo, first by a water aspirator and then by an oil pump. The residue was shaken with water (50 ml) and evaporated to dryness. This procedure was repeated once. The residue then was dissolved in methanol (75 ml) and poured into ether (600 ml) and petroleum ether (1.4 L). After stirring overnight, the white solid was isolated by filtration and was washed with petroleum ether. Drying over sicapent, in vacuo, gave 3.50 g (71.7%).
M.p. 142-147C. Anal. for C16H24N407. Found(calc.) C:
49.59(50.00) H: 6.34(6.29) N: 14.58(14.58). lH-NMR (250 MHz, DMS0-d6): Due to the limited rotation around the secondary amide bond several of the signals were doubled in the ratio 2:1,(indicated in the list by m~. for ma~or and mi. for , : ; ` '''~ ' ' .,, 2 l 0 ~ '~) 0 ~
minor). 12.73 ppm (b,lH, -C02H); 11.27 ppm (9, m~., imide);
11.25 ppm (s, mi., imide); 7.30 ppm (9, m~., ArH); 7.26 ppm (s, mi., ArH); 6.92 ppm (unres. t, mJ., BocNH) 6.73 ppm (unres. t; mi., BocNH); 4.64 ppm (s, m~., T-CH2-CO-); 4.47 ppm (s, mi., T-CH2-CO-); 4.19 ppm (s, mi., CONRCH2C02H); 3.97 ppm (s, m~., CONRCH2C02H); 3.41-2.89 ppm (unres. m, -CH2CH2- and water); 1.75 ppm (s,3H, T-CH3); 1.38 ppm (8, 9H, t-Bu). 13C-NMR: 170.68 ppm (CO); 170.34 (CO); 167.47 (CO); 167.08 (CO);
164.29 (CO); 150.9 (C5''); 141.92 (C6''); 108.04 (C2'); 77.95 and 77.68 (Thy-CH2CO); 48.96, 47.45 and 46.70 (-CH2CH2- and NCH2C02H); 37.98 (Thy-CH3); 28.07 (t-Bu). FAB-MS: 407 (M+Na+);
385 (M+H+).

1-(Boc-aeg)thymine pentafluorophenyl ester (7, Boc-~aeg.OPfp) l-(Boc-aeg)thymine (6) (2.00 g; 5.20 mmol) was dissolved in DMF (5 ml) and methylene chloride (15 ml) was added.
Pentafluorophenol (1.05 g; 5.72 mmol) was added and the solution was cooled to 0C in an ice bath. DDC then was added (1.29 g; 6.24 mmol) and the ice bath was removed after 2 min.
After 3 h with stirring at ambient temperature, the precipitated DCU was removed by filtration and washed with methylene chloride. The combined filtrate was washed twice with aqueous sodium hydrogen carbonate and once with saturated sodium chloride, dried over magnesium sulfate, and evaporated to dryness, in vacuo. The solid residue was dissolved in dioxane (150 ml) and poured into water (200 ml) at 0C. The title compound was isolated by filtration, washed with water, and dried over sicapent, in vacuo. Yield: 2.20 g (77~). An analytical sample was obtained by recrystallisation from 2-30 propanol. M.p. 174-175.5C. Analysis for C22H23N407F5, found(calc.): C: 48.22(48.01); H: 4.64(4.21); N: 9.67(10.18).
lH-NMR (250 MHz, CDC13):Due to the limited rotation around the secondary amide bond several of the signals were doubled in the ratio 6:1 (indicated in the list by m;. for major and mi.
35 for minor). 7.01 ppm (s, mi., ArH); 6.99 ppm ~s, mJ., ArH);
5.27 ppm (unres. t, BocN_); 4.67 ppm (s, mJ., T-CH2-CO-); 4.60 . ,. ,~ .
;.

2lO9'~0':j ppm (s, mi., T-CH2-CO-); 4.45 ppm (s, m~., CONRCH2C02PfP);
4.42 ppm (s, mi., CONRCH2C02Pfp); 3.64 ppm (t,2H,~ocNHCH2CH2-); 3.87 ppm ("q",2H,BocNHCH2CH2-); 1.44( 8, 9H,t-~u). FAB-MS:
551 (10; M+l); 495 (10; M+1-tBu); 451 (80; -~oc).

N~-senzyloxycarbonyl cytosine (9) Over a perlod of about 1 h, benzyloxycarbonyl chlorlde (52 ml; 0.36 mol) was added dropwlse to a suspenslon of cytosine (8, 20.0 g;O.18 mol) ln dry pyrldlne (1000 ml) at 0C
under nltrogen in oven-dried equipment. The solutlon then was stirred overnlght, after which the pyrldine suspenslon was evaporated to dryness, in vacuo. Water (200 ml) and 4 N
hydrochloric acid were added to reach pH -1. The resulting white precipitate was filtered off, washed with water and partially drled by air suction. The still-wet precipitate was boiled with absolute ethanol (500 ml) for 10 min, cooled to 0C, filtered, washed thoroughly with ether, and dried, in vacuo. Yield 24.7 g (54~). M.p.>250C. Anal. for C12HllN303. Found(calc.); C: 58.59(58.77); H: 4.55(4.52); N:
17.17(17.13). No NMR spectra were recorded slnce lt was not possible to get the product dissolved.

N4-Benzyloxycarbonyl-Nl-carboxymethyl cytosine (10) In a three necked round bottomed flask equipped with mechanical stirring and nitrogen coverage was placed methyl bromacetate (7.82 ml;82.6 mmol) and a suspension of N4-benzyloxycarbonyl-cytosine (9, 21.0 g;82.6 mmol) and potassium carbonate (11.4 g;82.6 mmol) in dry DMF (900 ml). The mixture was stirred vigorously overnight, filtered, and evaporated to dryness, in vacuo. Water (300 ml) and 4 N
hydrochloric acid (10 ml) were added, the mixture was stirred for 15 minutes at 0C, filtered, and washed with water (2 x 75 ml). The isolated precipitate was treated with water (120 ml), 2N sodium hydroxide (60 ml), stirred for 30 min, filtered, cooled to 0C, and 4 N hydrochloric acid (35 ml) was added. The title compound was isolated by filtration, washed ,~ ' . , .
.

' ` ~ ' ~

~40- ~lO'`~O j thoroughly with water, recrystallized from methanol (1000 ml) and washed thoroughly with ether. This afforded 7.70 g (31%) of pure compound. The mother liquor from the recrystal-lization was reduced to a volume of 200 ml and cooled to 0C.
This afforded an additional 2.30 g of a materlal that was pure by tlc but had a reddish colour. M.p. 266-274C. Anal. for C14H13N305. Found(calc.); C: 55.41(55.45); H: 4.23(4.32); N:
14.04(13.86). lH-NMR (90 MHz; DMS0-d6): 8.02 ppm (d,J=7.32Hz,lH,H-6);7.39(s,5H,Ph);7.01(d,J-7.32Hz,lH,H-5);
5.19 (s,2H,PhCH2-); 4.52 (s,2H).

N4-Benzyloxycarbonyl-Nl-carboxymethyl-cytosine penta-fluorophenyl ester (11) N4-Benzyloxycarbonyl-N1-carboxymethyl-cytosine(10,4.00 g; 13.2 mmol) and pentafluorophenol (2.67 g; 14.5 mmol) were mixed with DMF (70 ml), cooled to 0C with ice-water, and DCC
(3.27 g; 15.8 mmol) was added. The ice bath was removed after 3 min and the mixture was stirred for 3 h at room temperature.
The precipitated DCU was removed by filtration, washed with DMF, and the filtrate was evaporated to dryness, in vacuo (0.2 mmHg). The solid residue was treated with methylene chloride (250 ml), stirred vigorously for 15 min, filtered, washed twice with diluted sodium hydrogen carbonate and once with saturated sodium chloride, dried over magnesium sulfate, and evaporated to dryness, in vacuo. The solid residue was recrystallized from 2-propanol (150 ml) and the crystals were washed thoroughly with ether. Yield 3.40 g (55~). M.p. 241-245C. Anal. for C20H12N3F505. Found(calc.); C: 51.56(51.18);
H: 2.77(2.58); N: 9.24(8.95).1H-NMR (90 MHz; CDC13): 7.66 ppm (d,J=7.63Hz,lH,H-6);7.37(s,5H,Ph);7.31(d,J=7.63Hz,lH,H-5);
5.21 (s,2H,PhCH2-); 4.97 (s,2H,NCH2-). FAB-MS: 470 (M+1) N4-Benzyloxycarbonyl-l-Boc-aeg-cytosine (12) To a solution of (N-Boc-2-aminoethyl)glycine (2) in DMF, prepared as described above, was added triethyl amine (7.00 ml; 50.8 mmol) and N4-ben~yloxycarbonyl-Nl-carboxymethyl-~' '' ., ~': ', , , ' '' ~' - ' .

cytosine pentafluorophenyl ester (11, 2.70 g; S.75 mmol).
After stirring the solution for 1 h at room temperat~lre, methylene chloride (150 ml), s~turated sodium chlorld~ (250 ml), and 4 N hydrochloric acid to pH -1 were added. The organic layer was separated and washed twice with saturated sodium chloride, dried over magneslum sulfate, and evaporated to dryness, in vacuo, first wlth a water aspirator and then with an oil pump. The olly resldue was treated wlth water (25 ml~ and was agaln evaporated to dryness, in vacuo. This procedure then was repeated. The olly resldue (2.80 g) was then dlssolved ln methylene chloride (100 ml), petroleum ether (250 ml) was added, and the mixture was stirred overnlght.
The title compound was isolated by filtration and washed with petroleum ether. Tlc (system 1) indlcated substantlal quantities of pentafluorophenol, but no attempt was made to remove i$. Yield: 1.72 g (59%). M.p. 156C(decomp.). lH-NMR
(250 MHz, CDC13): Due to the limited rotation around the secondary amide bond several of the signals were doubled in the ratio 2:1,(indicated in the list by m~. for major and mi.
for minor). 7.88 ppm (dd,lH,H-6); 7.39 (m,5H,Ph); 7.00 (dd,lH,H-5); 6.92 (b,lH,BocNH); 6.74 (b,lH,ZNH)-?; 5.19 (s,2H,Ph-CH3); 4.81 ppm (s, m;., Cyt-CH2-C0-); 4.62 ppm (s, mi., Cyt-CH2-C0-); 4.23 (s, mi., CONRCH2C02H); 3.98 ppm (s, m;., CONRCH2C02H); 3.42-3.02 (unres. m, -CH2CH2- and water);1.37 (s,9H,tBu). FAB-MS: 504 (M+l); 448 (M+l-tBu).

N4-Benzyloxycarbonyl-1-Boc-aeg-cytosine pentafluorophenyl ester (13) N4-Benzyloxycarbonyl-l-Boc-aeg-cytosine(12,1.50g;2.98 mmol) and pentafluorophenol (548 mg; 2.98 mmol) was dissolved in DMF (10 ml) Methylene chloride (10 ml) was added, the reaction mixture was cooled to O~C in an ice bath, and D~C
(676 mg; 3.28 mmol) was added. The ice bath was removed after 3 min and the mixture was stirred for 3 h at ambient temperature. The precipitate was isolated by filtration and washed once with methylene chloride. The precipitate was ~ f .~"~
, .. . . .
,' :::
,.~:

:

-~2- 21~9,0~

dissolved in boiling dioxane (150 ml) and the solution was cooled to 15C, whereby DCU prec~pitated. The DCU was removed by filtration and the resultlng flltrate Wa8 poured lnto wator (250 ml) at 0C. The title compound was isolated by filtration, was washed with water, and dried over slcapent, in vacuo. Yield 1.30 g (65%). Analysls for C29H28N508F5.
Found(calc.); C: 52.63(52.02); H: 4.41(4.22) N: 10.55(10.46).
lH-NMR (250 MHz; DMS0-d6): showed essentlally the spectrum of the above acid, most probably due to hydrolysis of the ester.
FAB-MS: 670 (M~l); 614 (M~l-t3u) 4-Chlorocarboxy-9-chloroacridine 4-Carboxyacridone (6.25 g; 26.1 mmol), thionyl chloride (25 ml), and 4 drops af DMF were heated gently under a flow of nitrogen until all solid material had dissolved. The solution then was refluxed for 40 min. The solution was cooled and excess thionyl chloride was removed in vacuo. The last traces of thionyl chloride were removed by coevaporation with dry benzene (dried over Na-Pb) twice. The remaining yellow powder was used directly in the next reaction.

4-(5-Methoxycarbonylpentylamidocarbonyl)-9-chloroacridine Methyl 6-aminohexanoate hydrochloride (4.70 g; 25.9 mmol) was dissolved in methylene chloride (90 ml), cooled to 0C, triethyl amine (15 ml) was added, and the resulting solution then was immediately added to the acid chloride from above.
The round bottomed flask containing the acid chloride was cooled to 0C in an ice bath. The mixture was stirred vigorously for 30 min at 0C and 3 h at room temperature. The resulting mixture was filtered to remove the remaining solids, which were washed with methylene chloride (20 ml). The red-brown methylene chloride filtrate was subsequently washed twice with saturated sodium hydrogen carbonate, once with saturated sodium chloride, dried over magnesium sulfate, and evaporated to dryness, ln vacuo. To the resulting oily substance was added dry benzene (35 ml) and ligroin (60-80C, ~' , ~, ~, '' '' ' ,' , ,, , , - , : '' ' ' ~
,,P';.~ : .

-43- '' l O ~ J 3 dried over Na-Pb). The mixtur~ was heated to reflux.
Actlvated carbon and celite were added and mlxture was refluxed for 3 min. After filtratlon, the tltle compound crystallised upon coollng with magnetlc stirrlng. It was isolated by filtration and washed with petroleum ether. The product was stored over solid potassium hydroxide. Yield 5.0 g (50%)-4-(5-Methoxycarbonylpentyl)amidocarbonyl-9-16'-(4''-nitro-benzamido)hexylamino]-aminoacridine 4-(5-Methoxycarbonylpentylamidocarbonyl)-9-chloroacrldine (1.30 g; 3.38 mmol) and phenol (5 g) were heated to 80C for min under a flow of nltrogen, after which 6-(4'-nitrobenzamldo)-1-hexylamine (897 mg; 3.38 mmol) was added.
The temperature raised to 120~C for 2 h. The reaction mixture was cooled and methylene chloride t80 ml) was added. The resulting solution was washed three times with 2N sodlum hydroxide (60 ml portions) and once wlth water, dried over magnesium sulfate, and evaporated to dryness, in vacuo. The resulting red oil (1.8 g) was dissolved in methylene chloride (40 ml), cooled to 0C. Ether (120 ml) was added and the resultant solution was stirred overnlght. This results in a mixture of solid material and an oil. The solld was lsolated by filtration. The solid and the oil were re-dlssolved in methylene chloride (80 ml) and added dropwise to cold ether (150 ml). After 20 minutes of stirring, the title compound was isolated by filtration in the form of orange crystals.
The product was washed with ether and dried in vacuo over potassium hydroxide. Yield 1.60 g (77~). M.p. 145-147C.

4-(s-r~boxypentyl)amidocarbonyl-9-t6~-(4~-nitrobenzamido)-hexylamino]-aminoacridine 4-(5-Methoxycarbonylpentyl)amidocarbonyl-9-[6'-(4''-nitrobenzamido)hexylamino]aminoacridine (503 mg; 0.82 mmol) was dissolved in DMF (30 ml), and 2 N sodium hydroxide (30 ml) was added. After stlrring for 15 mln, 2 N hydrochloric acid 44~ 0 ~ O j (35 ml) and water (50 ml) were added at 0C. After stlrring for 30 min, the solution was decanted, leavlng an olly substance whlch was dissolved in bolling methanol (150 ml), filtered and concentrated to 1/3 volume. To the methanol solutlon were added ether (125 ml) and 5-6 drops of HC1 ln ethanol. The solution was decanted after 1 h of stlrring at 0C. The oily substance was redissolved in methanol (25 ml) and precipitated with ether (150 ml). The title compound was isolated as yellow crystals after stirrlng overnight. Yield 417 mg (80%). M.p. 173C (decomp.).

(a) 4-(5-pentafluorophenyloxycarbonylpentyl)-amidocarbonyl-9-t6'-(4''-nitrobenzamido)-hexylamino]-aminoacridine(Acr1Opfp) The acid from above (300 mg; 0.480 mmol) was dissolved in DMF (2 ml) and methylene chloride (8 ml) was added.
Pentafluorophenol (97 mg; 0.53 mmol), transferred with 2 x 2 ml of the methylene chloride, was added. The resulting solution was cooled to ODC after which DCC (124 mg; 0.60 mmol) was subseguently added. The ice bath was removed after 5 minutes and the mixture was left with stirring overnight. The precipitated DCU was removed by centrifugation and the centrifugate was evaporated to dryness, in vacuo, first by a water aspirator and then by an oil pump. The residue was dissolved in methylene chloride (20 ml), filtered, and evapo-rated to dryness, in vacuo. The residue was again dissolved in methylene chloride and petroleum ether (150 ml). A 1 ml portion of 5M HCl in ether was added. The solvent was removed by decanting after 30 min of stirring at O~C. The residual oily substance was dissolved in methylene chloride (100 ml).
Petroleum ether (150 ml) was added and the mixture was left with stirring overnight. The next day the yellow precipitated crystalline material was isolated by filtration and was washed with copious amounts of petroleum ether. Yield, after drying, 300 mg (78~). M.p. 97.5~C (decomp.) All samples showed ~ .
. ' .
,"'.. -. ~ -, I '; ' '' ',. '' ' , '' .
~' . : , ' ' , '. . , .. . ..

21'~0~
satisfactory elemental analysl~, lH- and 13C-NMR and mass spectra.
(b) Experimental for the synthes~s of PNA compounds, cf~ Figure 8 Materials: Boc-Lys (ClZ), benzhydrylamlne-copoly(styrene-1~-divinylbenzene) resin (BHA resin), and p-methylbenz-hydrylamine-copoly(styrene-l~-divinylbenzene) resin (MBHA
resin) were purchased from Peninsula Laboratorles. Other reagents and solvents were: Biograde trifluoroacetic acid from Halocarbon Products; diisopropylethylamine (99~; was not further distilled) and N-acetylimidazole (98~) from Aldrich;
H20 was distilled twice; anhydrous HF from Union Carbide;
synthesis grade N,N-dimethylformamide and analytical grade methylene chloride (was not further distilled) from Merck;
HPLC grade acetonitrile from Lab-Scan; purum grade anisole, N,N'-dicyclohexylcarbodiimide, and puriss. grade 2,2,2-trifluoroethanol from Fluka.
(b) General Methods and Remarks Except where otherwise stated, the following applies.
The PNA compounds were synthezised by the stepwise solid-phase approach (Merrifield, J. Am. Chem. Soc., 1963, ~5, 2149) employing conventional peptide chemistry utilizing the TFA-labile tert-butyloxycarbonyl (Boc) group for "temporary" N-protection (Merrifield, J. Am. Chem. Soc., 1964, 86, 304) and the more acid-stable benzyloxycarbonyl (Z) and 2-chlorobenzyloxycarbonyl (ClZ) groups for "permanent" side chain protection. To obtain C-terminal amides, the PNAs were assembled onto the HF-labile BHA or MBHA resins (the MBHA
resin has increased susceptibility to the final HF cleavage relative to the unsubstituted BHA resin (Matsueda, et al ., Peptides, 1981, 2, 45). All reactions (except HF reactions) were carried out in manually operated standard solid-phase reaction vessels fitted with a coarse glass frit (Merrifield, et al., Biochemistry, 1982, 21, 5020). The quantitative ninhydrin reaction (Kaiser test), originally developed by Merrifield and co-workers (Sarin, et al ., Anal . Biochem., -~6- 21 ~ 30~

1981, 117, 147) for peptide~ containing "normal" amino acid~, was successfully applied (see Table I - III) using the "normally" employed effective extinction coefficlent ~ - 15000 M~lcm~l for all residues to determine the completeness of the individual couplings as well as to measure the number of growing peptide chalns. The theoretical substitution Sn_1 upon coupling of residue number n (assuming both complete deprotection and coupling as well as neither chain termination nor loss of PNA chains during the synthetic cycle) is calculated from the equation:
Sn = Sn_l x (1 + (Sn_l x ~MW x 10-3 mmol/mol))-l where ~MW is the gain in molecular weight ([oMW] = g/mol) and Sn_l is the theoretical substitutlon upon coupling of the preceding residue n-l (ts] - mmol/g). The estimated value (%) on the extent of an individual coupling is calculated relative to the measured substitution (unless S was not determined) and include correction for the number of remaining free amino groups following the previous cycle~ HF reactions were carried out in a Diaflon HF apparatus from Toho Kasei (Osaka, Japan). Vydac C18 (5 ym, 0.46 x 25 cm and 5 um, 1.0 x 25 cm) reverse-phase columns, respectively were used for analytical and semi-preparative HPLC on an SP8000 instrument. Buffer A
was 5 vol % acetonitrile in water containing 445 yl trifluoroacetic acid per litre, and buffer B was 60 vol %
acetonitrile in water containing 390 ,ul trifluoroacetic acid per litre. The linear gradient was 0-100% of buffer B in 30 min, flow rates 1.2 ml/min (analytical) and 5 ml/min (semi-preparative). The eluents were monitored at 215 nm (analytical) and 230 nm (semi-preparative). Molecular weights of the PNAs were determined by 252Cf plasma desorption time-of-flight mass spectrometry from the mean of the most abundant isotopes.

,, ' ' ", , ' -~
: :

210~0 ;i Solid-Phase S~nthesis of Acrl-[Taeg]15-NH2 and 8horter Derivatives (a) Stepwise Assembly of Boc- [Taeg] 15-BHA Resln The synthesls was lnitiated on 100 mg of preswollen and neutralized BHA resin (determined by the quantitative ninhydrln reactlon to contaln 0.57 mmol NH2/g) employlng single couplings ("~ynthetic Protocol 1") using 3.2 equivalents of BocTaeg-OPfp in about 33% DMF/CH2Cl2. The individual coupling reactions were carried out by shaking for at least 12 h in a manually operated 6 ml standard solid-phase reaction vessel and unreacted amino groups were blocked by acetylation at selected stages of the synthesis. The progress of chain elongation was monitored at several stages by the quantitative ninhydrin reaction (see Table I). Portions of protected Boc-[Taeg]5-BHA, Boc-[Taeg]10-BHA, and Boc-[Taeg]l5-BHA resins were taken out after assembling 5, 10, and 15 residues, respectively.

'~
, `'~ ' ' ,,;.'`
' , ., :

2 1~ ~0 -i ~ - - -- - - -Synthetic ResidueSubsti~u~lon Af~er Remaining Free Amlno Estimaled Step CoupledDeprolectionGroups A~ler Extent o~
__ __ (mmol/g) ~mol/g) Coupllng _ Measd Theore~ol SingleAce~ylalion(%) Coupling I
I ~0~ 0.57 ¦ 1 BocTaeg ND 0.50 130 <99.7 ¦ 2 BocTaeg ND 0.44 1.43 <99.9 _ _ 3 BocTaeg 0.29 0.39 3.33 99.3 I
¦ 4 BocTaeg 0.27 0.35 13.30 96.3 ¦ 5 BocTaeg 0.26 0.32 8.33 >99.9 ¦ 6 BocTaeg ND 0.30 7.78 >99.9 7 BocaTeg ND 0.28 13.81 7.22 ~97.8 I
¦ 8 BocTaeg ND 0.26 14.00 <99.9 ¦ 9 BocTaeg ND 0.24 30.33 93.2 ~ 10 BocT~eg - 0.16 0.23 11.67 2.67 >99.9 15 - 11 BocTaeg ND 0.21 4.58 >99.9 12 BocTaeg ND 0.20 5.87 <99.4 13 BocTaeg ND 0.19 1.67 >99.9 14 BocTaeg ND 0.18 14.02 <93.1 BocTaeg 0.07 0.17 4.20 3.33 >99.9 (b) Synthesis of Acr1-[Taeg]l5-BHA Resin IFollowing deprotection of the residual ~oc-[Taeg]l5-BHA
jresin (estimated dry weight is about 30 mg; -0.002 mmol growing chains), the H-[Taeg]l5-BHA resin was reacted wlth about 50 equivalents (80 mg; 0.11 mmol) of Acrl-OPfp in 1 ml 11~,';:

l ~

¦ ~' _49_ 210~0i of about 66% DMF/C}l2C12 (~.e., a 0.11 M solution of the penta~luorophenylester) in a 3 ml solid-pha~e reactlon v~ssel.
AS judged by a qualitative ninhydrin reaction, coupllng of the acridine moiety was close to quantitative.
(c) Cleavage, Purlf~cation, and Identlflcatlon of H-[Taeg~s~NH2 A portion of protected Boc-[Taeg]5-~HA resin was treated with 50% trifluoroacetic acid in methylene chloride to remove the N-terminal Boc group (which i9 a precursor o the potentially harmful tert-butyl catlon) prior to the HF
cleavage. Following neutralization and washing (performed in a way similar to those of steps 2 4 in "Synthetic Protocol 1"), and drying for 2 h in vacuum, the resulting 67.1 mg (dry weight) of H-[Taeg]5-BHA resin was cleaved with 5 ml of 15 HF:anisole (9:1, v/v) stirring at 0C for 60 min. After removal of HF, the residue was stirred with dry diethyl ether (4 x 15 ml, 15 min each) to remove anisole, filtered under gravity through a fritted glass funnel, and dried. The PNA
was then extracted into a 60 ml (4 x 15 ml, stirring 15 min each) 10~, aqueous acetic acid solution. Aliquots of this solution were analyzed by analytical reverse-phase HPLC to establish the purity of the crude PNA. The main peak at 13.0 min accounted for about 93% of the total absorbance. The remaining solution was frozen and lyophilized to afford about 25 22.9 mg of crude material. Finally, 19.0 mg of the crude product was purified from five batches, each containing 3.8 mg in 1 ml of H20. The main peak was collected by use of a semi-preparative reverse-phase column. Acetonitrile was removed on a speed vac and the residual solution was frozen 30 (dry ice) and subsequently lyophilized to give 13.1 mg of >99%
pure H-tTaeg]5-NH2. The PNA molecule readily dissolved in water and had the correct molecular weight based on mass spectral determination. For (M+H)+ the calculated m/z value was 1349.3 and the measured m/z value was 1347.8.

'' ' ' ' ' '. ' ~; . .
~" - ' ' '' ' '' . "` ~", ',: n ' ~' ' . ' y _50~ 9 ,~) 0 ~j (d) Cleavage, Pur~fication, and Identlflcatlon of H-[Taeg~lo-NH2 A portion of protected Boc-[Taeg]10-BHA resln wa~ treated as described in sectlon (c) to yleld 11.0 mg of crude materlal upon HF cleavage of 1~.9 mg dry H-[Taeg]10-BHA resln. The main peak at 15.5 min accounted for about 53~ of the total absorbance. About 1 mg of the crude product was purlfled repeatedly (for reasons described below) to give approxlmately 0.1 mg of at least 80~ but presumably >99% pure H-[Taeg]10-NH2. A rather broad tail eluting after the target peak andaccounting for about 20% of the total absorbance could not be removed (only slightly reduced) upon the repeated purification. Judged by the mass spectrum, which only confirms the presence of the correct molecular weight H-[Taeg]10-NH2, the tail phenomonen is ascribed to more or less well-defined aggregational/conformational states of thetarget - molecule. Therefore, the crude product is likely to contain more than the above-mentioned 53% of the target molecule. H-[Taeg]10-NH2 is readily dissolved in water. For (M+H)+ the 20 calculated m/z value was 2679.6 and the measured m/z value was 2681.5.
(e) Cleavage, Purificatlon, and Identification of H-[Taeg]15-NH2 A portion of protected soc-[Taeg]l5-BHA resin was treated as described in section (c) to yield 3.2 mg of crude material upon HF cleavage of 13.9 mg dry H-[Taeg]l5-BHA resin. The main peak at 22.6 min was located in a broad bulge accounting for about 60% of the total absorbance (Fig. 12a). Again (see the preceding section), this bulge is ascribed to aggregational/conformational states of the target molecule H-[Taeg]l5-NH2 since mass spectral analysis of the collected "bulge" did not significantly reveal the presence of other molecules. All of the crude product was purified collecting the "bulge" to give approximately 2.8 mg material. For (M+Na)+
35 the calculated m/z value was 4033.9 and the measured m/z value was 4032.9.

r ~

. ' ~ ' .
.
~ .

-51- 2109'~0~j (f) Cleavage, Purification, and Identification of Acr1-tTaeg]15-NH2-A portion of protected Acr1-[Taeg~15-~HA resin wa~
treated aæ described ln sectlon (b) to yleld 14.3 mg of crude material upon HF cleavage of 29.7 mg dry Acr1-[Taeg]15-BHA
resin. Taken together, the main peak at 23.7 min and a "dimer" (see below) at 29.2 min accounted for about 40% of the total absorbance (Fig. 12b). The crude product was purified repeatedly to give approximately 1 mg of presumably ~99% pure Acrl-[Taeg]15-NH2 "contaminated" with self-aggregated molecules eluting at 27.4 min, 29.2 min, and finally as a huge broad bulge eluting with 100% buffer B (Fig. 12c). This interpretation is in agreement with the observation that those peaks grow upon standing (for hours) in aqueous acetic acid solution, and finally precipitate out quantltatively. For (M+H)+ the calculated m/z value was 4593.6 and the measured m/z value was 4588.7.
(g) Synthet$c Protocol 1 (1) Boc-deprotection with TFA/CH2C12 (1:1, v/v), 3 ml, 3 x 1 min and 1 x 30 min; (2) washing with CH2C12, 3 ml, 6 x 1 min; (3) neutralization with DIEA/CH2C12 (1: 19, v/v), 3 ml, 3 x 2 min; (4) washing with CH2C12, 3 ml, 6 x 1 min, and drain for 1 min; (5) 2-5 mg sample of PNA-resin may be taken out and dried thoroughly for a quantitative ninhydrin analysis to determine the substitution; (6) addition of 3.2 equiv. (0.18 mmol; 100 mg) BocTaeg-OPfp dissolved in 1 ml CH2C12 followed by addition of 0.5 ml DMF (final concentration of pentafluorophenylester -0.12 M); the coupling reaction was allowed to proceed for a total of 12-24 h shaking at room temperature; (7) washing with DMF, 3 ml, l x 2 min; (8) washing with CH2Cl2, 3 ml, 4 x l min; (9) neutralization with DIEA/CH2C12 (1: l9, v/v), 3 ml, 2 x 2 min; (10) washing with CH2C12, 3 ml, 6 x 1 min; (11) 2-5 mg sample of protected PNA-resin is taken out for a rapid qualitative ninhydrin test and further 2-5 mg is dried thoroughly for a quantitative ninhydrin analysis to determine the extent of coupling (after . .

. ~ , ., ' .
r,r, -52- 2 1On'30~

cycles 7, 10, and 15 unreacted amlno groups we~e blocked by acetylation with N-acetylimidazol in methylene chlorlde).
EXaMPLE 18 Solid-Phase Synthesi~ of Acr1-tTaeg~l5-Lys-NH2 and Shorter Derivatives (a) Stepwise Assembly of Boc-tTaeg~15-Lys(ClZ)-BHA Resin The synthesls was initiated by a quantitative loading (standard DCC in situ coupling in neat CH2C12) of Boc-Lys(ClZ) onto 100 mg of preswollen and neutralized BHA resin (0.57 mmol NH2/g). Further extension of the protected PNA chain employed single couplings ("Synthetic Protocol 2") for cycles 1 to 5 and cycles 10 to 15 using 3.2 equivalents of BocTaeg-OPfp in about 33% DMF/CH2Cl2. Cycles 5 to 10 employed an extra straight DCC (i.e., ~n situ) coupling of the free acid BocTaeg-OH in about 33% DMF/CH2C12. All coupling reactions were carried out by shaking for at least 12 h in a manually operated 6 ml standard solid-phase reaction vessel. Unreacted amino groups were blocked by acetylation at the same stages of the synthesis, as was done in Example 17. Portions of protected Boc-[Taeg]5-Lys(ClZ)-BHA andBoc-[Taeg]10-Lys(ClZ)-BHA resins were taken out after assembling 5 and 10 PNA
residues, respectively. As ~udged by the analytical HPLC
chromatogram of the crude cleavage product from the Boc-[Taeg]10-Lys(ClZ)-BHA resin (see section (e)), an additional "free acid" coupling of PNA residues 5 to 10 gave no significant improvement of the synthetic yield as compared to the throughout single-coupled residues in Example 17.
(b) Synthesis of Acrl-[Taeg]10-Lys(ClZ)-BHA Resin Following deprotection of a portion of Boc-[Taeg]10-Lys(ClZ)-BHA resin (estimated dry weight is about 90 mg;
~ 0.01 mmol growing chains), the H-tTaeg]15-BHA resln was reacted with about 20 equivalents (141 mg; 0.19 mmol) of Acr1-OPfp in 1 ml of about 66~ DMF/CH2C12 in a 3 ml solid-phase reaction vessel. As ~udged by a qualitative ninhydrin reaction, coupling of the acrldine molety was close to quantitative.

,:
'x, " ',. ' ' "
,~" ~ .

, ..... .
>,' ::
: : .
~: .
. ..... .

-53- 2 l0~0j (c) Synthesis of Acrl-[Taeg]l5-Lys(ClZ)-~HA Resin Following deprotection of the resldual ~oc-[Taeg]15-Lys(ClZ)-BHA resin (estimated dry weight about 70 mg; ~ 0.005 mmol growing chains), the H-[Taeg]l5-Lys(ClZ)-~HA resin was reacted with about 25 equlvalQnts (91 mg; 0.12 mmol) of Acrl-OPfp in 1 ml of about 66% DMF/CH2CI2 in a 3 ml solid-phase reaction vessel. As ~udged by a qualitative ninhydrin reaction, coupling of the acridine moiety was close to quantitative.
(d) Cleavage, Purification, and Identificatlon of H-tTaeg] 5~LYS~NH2 A portion of protected Boc-[Taeg]5-Lys(ClZ)-BHA resin was treated as described in Example 17c to yield 8.9 mg of crude material upon HF cleavage of 19.0 mg dry H-tTaeg]5-Lys(ClZ)-BHA resin. The main peak at 12.2 min (eluted at 14.2 min if injected from an aqueous solution instead of the 10% aqueous acetic acid solution) accounted for about 90% of the total absorbance. About 2.2 mg of the crude product was purified to give approximately 1.5 m~ of 99% pure H-[Taeg]5-Lys-NH2.
j 20 (e) Cleavage, Purification, and Identification of H-[Taeg]lO-Lys-NH2 I A portion of protected Boc-[Taeg]10-Lys(ClZ)-BHA resin ¦ was treated as described in Example 17c to yield 1.7 mg of crude material upon HF cleavage of 7.0 mg dry H-[Taeg]l0-Lys(ClZ)-BHA resin. The main peak at 15.1 min (eluted at 17.0 min if in~ected from an aqueous solution instead of the 10%
3 aqueous acetic acid solution) accounted for about 50% of the total absorbance. About 1.2 mg of the crude product was purified to give approximately 0.2 mg of >95% pure H-[Taeg]10-¦ 30 Lys-NH2. Figure 13a. For (M+H)+ the calculated m/z value was 2807.8 and the measured m/z value was 2808.2.
(f) Cleavage, Purification, and Identification of Acrl-[Taeg]lo-Lys-NH2 99.1 mg protected Acrl-[Taeg]10-Lys(ClZ)-BHA resin (dry weight) was cleaved as described in Example 17c to yield 42.2 mg of crude material. The main peak at 25.3 min (eluted at ,~ . ''''" ' ' :
~ w~

,.
.
. ., '~ 'l O ~ ', (J 'j -5~-23.5 min if inJected from an aqueous solution instead of the 10% aqueous acetic acid solution) accounted for ahout 45~ of the total absorbance. An 8.87 mg portlon of the crude product was purified to give approximately 5.3 mg of ~97~ pure H-[Taeg]l0-Lys-NH2. For (M+H)+ the calculated m/z value was 2850.8 and the measured m/z value was 2849.8.
(g) Cleavage and Purification of Acr1-tTaeg~15-Lys-NH2 A 78.7 mg portion of protected Acrl-[Taeg]l5-Lys(ClZ)-BHA
resin (dry weight) was cleaved as descrlbed in Example I
section (c) to yield 34.8 mg of crude materlal. The main peak at 23.5 min (about the same elution time if in~ected from an aqueous solution instead of the 10~ aqueous acetic acid solution) and a "dimer" at 28.2 min accounted for about 35~
of the total absorbance. About 4.5 mg of the crude product was purified to give approximately 1.6 mg of presumably >95~
pure H-[Taeg]l0-Lys-NH2. This compound could not be free of the "dimer" peak, which grew upon standing in aqueous acetic acid solution.
(h) Synthetic Protocol 2 (1) Boc-deprotection with TFA/CH2C12 (1:1, v/v), 3 ml, 3 x 1 min and 1 x 30 min; (2) washing with CH2C12, 3 ml, 6 x 1 min; (3) neutralization with DIEA/CH2C12 (1: 19, v/v), 3 ml, 3 x 2 min; (4) washing with CH2C12, 3 ml, 6 x 1 min, and drain for 1 min; (5) 2-5 mg sample of PNA-resin can be taken out and dried thoroughly:Eor a qualitative ninhydrin analysis; (6) for cycles 1 to 5 and cycles 10 to 15 the coupling reaction was carried out by addition of 3.2 equiv. (0.18 mmol; 100 mg) BocTaeg-OPfp dissolved in 1 ml CH2C12 followed by addition of 0.5 ml DMF (final concentration of pentafluorophenylester -0.12 M); the coupling reaction was allowed to proceed for a total of 12-24 h with shaking; cycles 5 to 10 employed an additional 0.12 M DCC coupling of 0.12 M BocTaeg-OH in 1.5 ml DMF/CH2C12 (1:2, v/v); (7) washing with DMF, 3 ml, 1 x 2 min;
(8) washing with CH2C12, 3 ml, 4 x 1 min; (9) neutralization with DIEA/CH2C12 (1: 19, v/v), 3 ml, 2 x 2 min; (10) washing with CH2C12, 3 ml, 6 x 1 min; (11) 2-5 mg sample of protected r.' ' ' ', '~' ' -' " '~ ' " " '' , .. - . ~

~i~ , ' , ';"' ' ..
-- ' -~
.~, ~55~ '~10~) 'OJ

PNA-resin is taken out for a qualltative nlnhydrln test ~after cycles 7, 10, and 15 unreacted amlno ~roups were block~d by acetylation wlth N-acetylimidazol in methylene chlorlde).

S Improved Solid-Phase Synthesis of N-~Taeg]10-Lys-NH2 The protected PNA was assembled onto an MBHA resin, uslng approximately half the loading of the BHA resin used in the previous examples. Furthermore, all cycles except one was followed by acetylatlon of uncoupled amlno groups. The following describes the synthesis in full detail:
(a) Preparation of Boc-Lys(ClZ)-NH-CH(p-C~3-C5H4)-C6H4 Resin (MBHA Resin) with an Initial Substitution of O.3 mmol/g The desired substitution of Boc-Lys(ClZ)-MBHA resin was 0.25 - 0.30 mmol/g. In order to get this value, 1.5 mmol of Boc-Lys(ClZ) was coupled to 5.0 g of neutralized and preswollen MBHA resin (determined by the quantitative ninhydrin reaction to contain 0.6~ mmol NH2/g) using a single "in situ" coupling (1.5 mmol of DCC) in 60 ml of CH2C12. The reaction was carried out by shaking for 3 h in a manually operated, 225 ml, standard, solid-phase reaction vessel.
Unreacted amino groups were then blocked by acetylation with a mixture of acetic anhydride/pyridine/CH2C12 (1:1:2, v/v/v) for 18 h. A quantitative ninhydrin reaction on the neutralized resin showed that only 0.00093 mmol/g free amine remained (see Table I), i.e. 0.15~ of the original amino groups. The degree of substitution was estimated by deprotection and ninhydrin analysis, and was found to be 0.32 mmol/g for the neutralized H-Lys(ClZ)-MBHA resin. This compares well with the maximum value of 0.28 mmol/g for a quantitative coupling of 0.30 mmol Boc-Lys(ClZ)/g resin (see Table II).
(b) Stepwise Assembly of Boc-tTaeg]3-Lys(ClZ)-MBHA
Resin The entire batch of H-Lys(ClZ)-MBHA resin prepared in section (a) was used directly (in the same reaction vessel) . .~

,~
~ '. '' .~ ~.

-56- 2 1 0 ~ i to assemble Boc-[Taeg]3-Lys(ClZ)-M~HA resln by slngle couplings ("Synthetic Protocol 3") utillzlng 2.5 equlvalents of BocTaeg-OPfp in neat CH2C12. The quantltative ninhydrln reaction was applied throughout the synthesls (see Table II).
(c~ Stepwise Assembly of 80c-~Taeg]8-Lys(ClZ)-MBHA
Resin About 4.5 g of wet Boc-[Taeg]3-Lys(ClZ)-MBHA resin (~0.36 mmol growing chains; taken out of totally - 19 g wet resin prepared in section (b)) was placed in a 55 ml SPPS reaction vessel. Boc-tTaeg]8-Lys(ClZ)-MBHA resin was assembled by single couplings ("Synthetic Protocol 4") utilizing 2.5 equivalents of BocTaeg-OPfp in about 30~ DMF/CH2Cl2. The progress of the synthesis was monitored at all stages by the quantitative ninhydrin reaction (see Table II).
(d) Stepwise Assembly of Boc-[Taeg]10-Lys(ClZ)-MBHA
Resin About 1 g of wet Boc-[Taeg]8-Lys(ClZ)-MBHA resin (-0.09 mmol growing chains; taken out of totally -4 g wet resin prepared in section (c)) was placed in a 20 ml SPPS reaction vessel. Boc-[Taeg]10-Lys(ClZ)-MBHA resin was assembled by the single-coupling protocol employed in the preceding section utilizing 2.5 equivalents of BocTaeg-OPfp in about 30 DMF/CH2Cl2. The reaction volume was 3 ml (vigorous shaking).
The synthesis was monitored by the quantitative ninhydrin reaction (see Table II).

" 21 0~ 3()~

~ ..., . _ ~
SyntheticResidu0Substitulion AflerRemaining Free Amino Eslimaled Step CoupledD~protec~ion Group~ A~er E~nent o~
(mmol/~ ~mol/~) Couplin~
Moasd Thoolo~ Sin~lo Acetyialion (%) ¦ "~ BocLys(ClZ) 0.32 0.28 0.93 S ¦ 1 BocTaeg 0.23 0.26 0.97 0.54 >99.9 ¦ 2 BocTaeg 0.21 0.24 0.92 0.4G 99.8 ¦ ~ BocTaeg 0.19 0.23 1.00 0.57 7 ¦ 4 BocTaeg 0.18 0.21 1.85 g9.3 ¦ 5 80cTaeg 0.17 0.20 2.01 0.19 99.9 1 0 6 BocTao~ 0.15 0.19 1.69 0.10 99.0 7 BocaTeg 0 11 0.18 1.11 0.66 99.1 l 8 BocTaeg 0.12 0.17 1.82 0.44 99.0 ¦
9 BocTaeg 0.10 0.17 5.63 0.56 94.8 10~ BocTae~ 0.11 O 10 1.54 0.67 (e) Synthesis of Ac-[Taeg~10-Lys(ClZ)-MBHA Resin Following deprotection of a portion of Boc-[Taeg]10-Lys(ClZ)-MBHA resin (estimated dry weight is about 45 mg), the resin was nex~ acetylated quantitatively with a 2 ml mixture of acetic anhydride/pyridine/CH2Cl2 (1:1:2, v/v/v) for 2 h in a 3 ml solid-phase reaction vessel.
(f) Cleavage, Purification, and Identification of H-tTaeg~ lo~LYS~NH2 A portion of protected Boc-tTaeg]10-Lys(ClZ)-BHA resin was treated as described in Example 17c to yield about 24 mg of crude material upon HF cleavage of 76 mg dry H-tTaeg]5-Lys(ClZ)-BHA reqin. The main peak at 15.2 min (which includes . ., - . ~ , ~ - , ...

.... .
,~,. ~: . . . .
, --_5~_ 210 ~`3~ j impurities such as deletion peptide9 and varlous byproduc~s) accounted for about 78% of the total absorbanc~. The maln peak also accounted for about 88% of the "main pesk plus deletion peaks" absorbance, which is in good agree~ent wlth the overall estimated coupling yleld of 90.1% obtalned by summarizing the individual coupling yields ln Table II. A 7.2 mg portion of the crude product was purlfled from two batches by use of a semi-preparative reverse-phase column, (collecting the main peak in a beaker cooled with dry ice/2-propanol).
Each contained 3.6 mg in 1 ml of H20. The frozen solution was lyophilized directly (without prior removal of acetonitrlle on a speed vac) to give 4.2 mg of 82% pure H-[Taeg]10-Lys-NH2.
(g) Cleavage, Purification, and Identification of Ac-~Taeg]lo-Lys-NH2 A 400.0 mg portion of protected Ac-tTaeg]lO-Lys(clz)-BHA
resin (dry weight) was cleaved as described in Example 17c, except for the TFA treatment to yield 11.9 mg of crude material. The main peak at 15.8 min accounted for about 75%
of the total absorbance. A 4.8 mg portlon of the crude product was purified to give approximately 3.5 mg of >95% pure Ac-~Taeg]10-Lys-NH2. For (M+H)+ the calculated m/z value =
2849.8 and the measured m/z value = 2848.8.
(h) Synthe~tic Protocol 3.
(l) Boc-deprotection with TFA/CH2Cl2 (1:1, v/v), 100 ml, 3 x 1 min and 1 ~c 30 min; (2) washing wlth CH2C12, 100 ml, 6 x l min; (3) neutralization with DIEA/CH2Cl2 (1: 19, v/v), 100 ml, 3 x 2 min; (4) washing with CH2C12, lOOml, 6 x 1 min, and drain for 1 min; (5) 2-5 mg sample of PNA-resin is taken out and dried thoroughly for a quantitative ninhydrin analysis to determine the substitution; (6) addition of 2.5 equiv. (3.75 mmol; 2.064 g) BocTaeg-OPfp dissolved in 35 ml CH2C12 (final concentration of pentafluorophenylester -0.1 M); the coupling reaction was allowed to proceed for a total of 20-24 h with shaking; (7) washing with DMF, 100 ml, 1 x 2 min (to remove precipitate of BocTaeg-OH); (8) washing with CH2Cl2, 100 ml, 4 x 1 min; (9) neutralization with DIEA/CH2Cl2 (l: 19, v/v), .', ~, .,- .
: ... ; ' '' ! . , ~, ; , . .:
.' " ' ~
~ "-_59_ 210~l30j 100 ml, 2 ~ 2 min; (10) washing wlth CH2C12, 100 ml, 6 x 1 min; (11) 2-5 mg sample of protected PNA-resln ls taken out for a rapid qualitative ninhydrin test and a further 2-5 mg is dried thoroughly for a quantitatlve ninhydrin analysis to determine the extent of coupling; (12) blocking of unreacted amino groups by acetylation with a 100 ml mixture of acetic anhydride / pyridine / CH2C12 (1:1:2, v/v/v) for 2 h; (13) washing with CH2Cl2, 100 ml, 6 x 1 min; (14) 2 x 2-5 mg samples of protected PNA-resin are taken out, neutralized with 10 DIEA/CH2Cl2 (1: 19, v/v) and washed with CH2C12 for qualitative and quantitative ninhydrin analyses.
(i) Synthetic Protocol 4.
(1) ~oc-deprotection with TFA/CH2C12 (1:1, v/v), 25 ml, 3 x 1 min and 1 x 30 min; (2) washing with CH2Cl2, 25 ml, 6 15 x 1 min; (3) neutralization with DIEA/CH2Cl2 (1: 19, v/v), 25 ml, 3 x 2 min; (4) washing with CH2C12, 25 ml, 6 x 1 min, and drain for 1 min; (5) 2-5 mg sample of PNA-resin is taken out and dried thoroughly for a quantitative ninhydrin analysis to determine the substitution; (6) addition of 2.5 equiv. (0.92 20 mmol; 0.506 g) BocTaeg-OPfp dissolved in 6 ml CH2Cl2 followed by addition of 3 ml DMF (final concentration of pentafluorophenylester ~0.1 M); the coupling reaction was allowed to proceed for a total of 20-24 hrs with shaking; (7) washing with DMF, 25 ml, 1 x 2 min; (8) washing wlth CH2Cl2, 25 25 ml, 4 x 1 min; (9) neutralization with DIEA/CH2Cl2 (l: 19, v/v), 25 ml, 2 x 2 min; (10) washing with CH2C12, 25 ml, 6 x 1 min; (11) 2-5 mg sample of protected PNA-resin is taken out for a rapid qualitative ninhydrin test and a further 2-5 mg is dried thoroughly for a quantitative ninhydrin analysis to determine the extent of coupling; (12) blocking of unreacted amino groups by acetylation with a 25 ml mixture of acetic anhydride/pyridine/CH2Cl2 (1:1:2, v/v/v) for 2 h (except after the first cycle); (13) washing with CH2C12, 25 ml, 6 x 1 min;
(1~) 2 x 2-5 mg samples of protected PNA-resin are taken out, 35 neutralized with DIEA/CH2Cl2 (1: 19, v/v) and washed with CH2Cl2 for qualitative and quantitati~e ninhydrin analyses.

~ . ....
'' ~, '~, , -60- 2 1 0 ~

Solid-Phase Synthesis of H-[Taeg]5-Caeg-[Taeg]q-Lys-N~2 (a) Stepwi-qe AsQembly of Eoc-~Taeg]5-Caeg-~Taeg]4-Lys(Clz)-Ms~A Res~n About 2.5 g of wet Boc-[Taeg]3-Lys(ClZ)-MBHA resln ~~ 1/6 of the total remalnlng about 16 g wet resln; -0.75 g dry resin -0.15 mmol growing chains) was placed ln a 6 ml SPPS reaction vessel. Boc-[Taeg]5-Caeg-[Taeg]4-Lys(ClZ)-MBHA resin was assembled by double coupling of all Taeg-residues utilizing the usual 2.5 equlvalents of BocTaeg-OPfp ln 2.5 ml about 30%
DMF/CH2C12, except that the first residue was single-coupled.
Incorporation of the C(Z)aeg-residue was accomplished by coupling with 2.0 equivalents of BocC(Z)aeg-OPfp in TFE/CH2C12 (1:2, v/v). The progress of the synthesis was monitored at all stages by the quantitative ninhydrin reaction (see Table III ) .

¦Synthetic ResidueSubsUtution An-rRemainlng Free Arnino -:stimat d Step CoupledDeprotectlonGrou~ Aner txtent or (mmoUg) ~,umoUg) . Coupling Measd. Theoret. 1st 2nd Acetyi-Coupl Coupl ation l I
3 0.19 0.23 1.00 0.57 ¦ 4 BocTa~g 0.17 0.21 4.88 97.3 97.3 BocC(Z)aeg 011 0 20 70 Z0 27.Z~ 1 33 78.4 (46) 6 BocTaeg o.1 0 0.1 a Z4.7~1 ~1.55 Z.40 Z5.~75) BocTaeg O Og ~ 0.18 b.55 1.b1 O.Z0 99.9 (93) 8 BocTaeg O.Ob 0.17 5.53 0 30o 4s99.0 (91) 9 BocTaeg 0 07 0.16 ~ Z~i 3 M Q31 94.8 (86) ec~T~og 0.07 0.15 5.32 1.480.6098.8 (93) - - ~ . . .
,,~,~, ~-, :~ ' '.'' ' '' ' ''.. , ''' ~',,"' '' '`' ' ,',~ ",;, '`

~' .

-61- ~ 0()~0 j (b) Cleavage, Purification, and Identification of H-[Taeg]5-Cae~-[Taeg]4-Lys-NH2 AportionofprotectedBoc-[Taeg~5-Caeg-[Taeg¦4-Lys(ClZ)-BHA resin was treated as described in Example I sectlon (c) to yield about 14.4 mg of crude material upon HF cleavage of 66.9 mg dry ~-[Taeg]5-Cae~-[Taeg]4-Lys(ClZ)-BHA resin. The main peak at 14.5 min accounted for >50% of the total absor-bance. A 100.0 mg portion of the crude product was purified (8 batches; each dissolved in 1 ml H2O) to give approximately 9.1 mg of 96~ pure H-[Taeg]5-Caeg-[Taeg]4-Lys-NH2 (Figure 13b). For (M+H)+ the calculated m/z value = 2793,~ and the measured m/z value = 2790,6.

N-8enzyloxycarbonyl-N-'(bocaminoethyl)glycine.
Aminoethyl glycine (52.86 g; O.447 mol) was dissolved in water (900 ml) and dioxane (900 ml) was added. The pH was adjusted to 11.2 with 2N NaOH. While the pH was kept at 11.2, tert-butyl-p-nitrophenyl carbonate (128.4 g; 0.537 mol) was dissolved in dioxane (720 ml) and added dropwise over the course of 2 hours. The pH was kept at 11.2 for at least three more hours and then left with stirring overnight. The yellow solution was cooled to 0C and the pH was adJusted to 3.5 with 2 N HCl. The mixture was washed with chloroform (4xlOO ml), and the pH of the aqueous phase was readJusted to 9.5 with 2 N NaOH at 0C. Benzyloxycarbonyl chloride (73.5 ml; 0.515 mol) was added over half an hour, while the pH was kept at 9.5 with 2 N NaOH. The pH was adjusted frequently over the next 4 hours, and the solution was left with stirring overnight.
On the following day the solution was washed with ether (3x600 ml) and the pH of the solution was afterwards adJusted to 1.5 with 2 N HCl at 0C. The title compound was isolated by extraction with ethyl acetate (5x1000 ml). The ethyl acetate solution was dried over magnesium sulfate and evaporated to dryness, in vacuo. This afforded 138 g, which was dissolved in ether (300 ml) and precipitated by the addition of petroleum ether (1800 ml). Yield 124.7 g (79%). M.p. 64.5-85 t ~
~..
~ . .
~ ..

, .

-62- '~ 10~') i C. Anal. for C17H24N206 found(calc.) c: 5~.40(57.94); H:
7.02(6.86); N: 7.94(7.95). 1H-NMR (250 MHz, CDCl3) 7.33 &
7.32 (5H, Ph); 5.15 & 5.12 (2H, PhCH2); 4.03 6 4.01 (2H, NCH2C02H); 3.46 (b, 2H, BocNHCH2CH2); 3.28 (b, 2H, BocNHCH2CH2); 1.43 & 1.40 (9H, tBu). HP~C (260 nm) 20.71 mln.
(80.2~) and 21.57 min. (19.8%). The UV-spectra (200 nm - 300 nm) are identical, lndicating that the minor peak consists of Bis-Z-AEG.

N'-Boc-aminoethyl glycine ethyl ester.
N-Benzyloxycarbonyl-N'-(bocaminoethyl)glyclne (60.0 g;
0.170 mol) and N,N-dimethyl-4-aminopyridine (6.00 g) were dissolved in absolute ethanol (500 ml), and cooled to 0C
before the addition of DCC (42.2 g; 0.204 mol). The ice bath was removed after 5 minutes and stirring was continued for 2 more hours. The precipitated DCU (32.5 g dried) was removed by filtration and washed with ether (3xlO0 ml). The combined filtrate was washed successively with diluted potassium hydrogen sulfate (2x400 ml), diluted sodium hydrogencarbonate (2x400 ml) and saturated sodium chloride (lx400 ml). The organic phase was filtered, then dried over magnesium sulfate, and evaporated to dryness, in vacuo, which yielded 66.1 g of an oily substance which contained some DCU.
The oil was dissolved in absolute ethanol (600 ml) and was added 10% pa:Lladium on carbon (6.6 g) was added. The solution was hydrogenated at atmospheric pressure, where the reservoir was filled with 2 N sodium hydroxide. After 4 hours, 3.3 L was consumed out of the theoretical 4.2 L. The reaction mixture was filtered through celite and evaporated to dryness, in vacuo, affording 39.5 g (94%) of an oily substance. A 13 g portion of the oily substance was purified by silica gel (600 g SiO2) chromatography. After elution with 300 ml 20% petroleum ether in methylene chloride, the title compound was eluted with 1700 ml of 5% methanol in methylene chloride. The solvent was removed from the fractions with satisfactory purity, ~n vacuo and the yield was 8.49 g.

5y.,~. ... .
~,~ : ,; ' '' ' ..
~" .

'~1' ~, -63- 2 lO~'`)O~j Alternatively 10 g of the crude material wa8 purlfled by Kugel Rohr distillation. 1H-NMR (250 MHz, CD30D); 4.77 (b. Y, NH);
4.18 (q, 2H, MeCH2-); 3.38 (s, 2H, NCH2C02Et); 3.16 (t, 2H, BocNHCH2CH2); 2.68 (t, 2H, BocNHCH2CH2): 1.43 (s, 9H, tBu) and 1.26 (t, 3H, CH3) 13C-NMR 171.~ (COEt); 156.6 (CO); 78.3 ((CH3)3_); S9.9 (CH2); 49.0 (CH2); 48.1 (CH2); 39.0 (CH2);
26.9 (CH2) and 12.6 (CH3).

N '-soc-aminoethyl glycine methyl eqter.
The above procedure was used, with methanol belng substituted for ethanol. The final product was purlfied by column purification.

1-(soc-aeg)thymine ethyl ester.
N'-80c-aminoethyl glycine ethyl ester (13.5 g; 54.8 mmol), DhbtOH (9.84 g; 60.3 mmol) and l-carboxymethyl thymlne (11.1 g; 60.3 mmol) were dissolved ln DMF (210 ml).
Methylene chloride (210 ml) then was added. The solution was cooled to 0C in an ethanol/ice bath and DCC (13.6 g; 65.8 mmol) was added. The lce bath was removed after 1 hour and stirring was continued for another 2 hours at ambient temperature. The precipitated DCU was removed by filtration and washed twice with methylene chloride (2 x 75 ml). To the combined filtrate was added more methylene chloride (650 ml).
The solution was washed successively with diluted sodium hydrogen carbonate (3 x 500 ml), diluted potassium hydrogen sulfate (2 x 500 ml), and saturated sodium chloride (1 x 500 ml). Some precipitate was removed from the organic phase by filtration, The organic phase was dried over magnesium sulfate and evaporated to dryness, in vacuo. The oily residue was dissolved in methylene chloride (150 ml), filtered, and the title compound was precipitated by the addition of petroleum ether (350 ml) at 0C. The methylene chloride/petroleum ether procedure was repeated once. This afforded 16.0 g (71%) of a material which was more than 99%
pure by HPLC.

, ~ . , ` - ~
6~- 2 ~0~g0 1-tBoc-aeg)thymine.
The materlal from above was suspended in THF (194 ml, gives a 0.2 M solution), and 1 M aqueous llthium hydroxlde (116 ml) was added. The mixture was stlrred for 45 mlnutes at ambient temperature and then flltered to remove resldual DCU. Water (40 ml) was added to the solutlon whlch was then washed with methylene chlorlde (300 ml). Addltlonal water (3C
ml) was added, and the alkallne solutlon was washed once more wlth methylene chloride (150 ml). The aqueous solu~lon was cooled to 0C and the pH was adjusted to 2 by the dropwise addition of 1 N HCl (approx. 110 ml). The title compound was extracted with ethyl acetate (9 x 200 ml), the combined extracts were dried over magnesium sulfate and were evaporated to dryness, in vacuo. The residue was evaporated once from methanol, which after drying overnight afforded a colourless glassy solid. Yield 9.57 g (64 ~). HPLC > 98% RT-14.8 min . for C16H24N4O7OO.25 H2O Found (calc-) C:
49.29(49.42); H: 6.52(6.35); N: 14.11(14.41). Due to the limited rotation around the secondary amide, several of the signals were doubled in the ratio 2:1 (indicated in the list by m~. for ma~or and mi. for minor). lH-NMR (250 MHz, DMSO-d6): 12.75 (b.s., lH, C02H); 11.28 (s, "lH", m~., imide NH);
11.26 (s, "lH", mi., imide NH); 7.30 (s, "lH", m~., T H-6);
7.26 (s, "lH", mi., T H-6); 6.92 (b.t., "lH", m~., BocNH);
6.73 (b.t., "lH", mi., BocNH); 4.64 (s, "2H", m;., CH2CON);
4.46 (s, "2H", mj., CH2CON); 4.19 (s, "2H", mi., CH2CO2H);
3.97 (s, "2H", m;., CH2CO2H); 3.63-3.01 (unresolved m, includes water, CH2CH2); 1.75 (s, 3H, CH3) and 1.38 (s, 9H, tBu).

N4-Benzyloxycarbonyl-l-(Boc-aeg)cytosine.
¦ N'-Boc-aminoethyl glycine ethyl ester (5.00 g; 20.3 mmol), DhbtOH (3.64 g; 22.3 mmol) and N4-benzyloxycarbonyl-1-¦ 35 carboxymethyl cytosine (6.77 g; 22.3 mmol) were suspended in DMF (100 ml). Methylene chloride (100 ml) then was added. The ~ ""~, ,~ .r .~ ~ ; ~ . .~ " . . .* ~Y . ~ ~ .X ~ ~ ~ . . " ~ r 2~0~
solution was cooled to 0C and DCC ( 5 . 03 g: 24.4 mmol) was added. The ice bath was rem~ved after 2 h and stlrrlng wa~
continued for another hour at ambient tempera-ture. The reaction mixture then was evaporated to dryness, ln vacuo.
The residue was suspended ln ether (100 ml) and stirred vi-gorously for 30 min. The solid material was isolated by filtration and the ether wash procedure was repeated twice.
The material was then stirred vigorously for 15 min with dilute sodium hydrogencarbonate (approx. 4% solution, 100 ml), filtered and washed with water. Thig procedure was then repeated once, which after drying left 17.0 g of yellowish solid material. The solid was then boiled with dio~ane (200 ml) and filtered while hot. After cooling, water (200 ml) was added. The precipitated material was isolated by filtration, washed with water, and dried. According to HPLC (observing at 260 nm) this material has a purity higher than 99%, besides the DCU. The ester was then suspended in THF (100 ml), cooled to 0C, and 1 N LiOH (61 ml) was added. After stirring for 15 minutes, the mixture was filtered and the filtrate was washed with methylene chloride (2 x 150 ml). The alkaline solution then was cooled to 0C and the pH was adjusted to 2.0 with 1 N HCl. The title compound was isolated by filtration and was washed once with water, leaving 11.3 g of a white powder after drying. The material was suspended in methylene chloride (300 ml) and petroleum ether (300 ml) was added.
Filtration and wash afforded 7.1 g (69%) after drying. HPLC
showed a purity of 99% RT= 19.5 min, and a minor impurity at 12.6 min (approx. 1~) most likely the Z-de protected monomer.
Anal- for C23H29N5o8 found(calc-) C: 54-16(54-87); H:
5.76(5.81) and N: 13.65(13.91). lH-NMR (250 MHz, DMSO-d6).
10.78 (b.s, lH, CO2H); 7.88 (2 overlapping dublets, lH, Cyt H-5); 7.41-7.32 (m, 5H, Ph); 7.01 (2 overlapping doublets, lH, Cyt H-6); 6.94 & 6.78 (unres. triplets, lH, BocNH); 5.19 (s, 2H, PhCH2); 4.81 & 4.62 (s, 2H, CH2CON); 4.17 & 3.98 (s, 2H, CH2CO2H); 3.42-3.03 (m, includes water, CH2CH2) and 1.38 &
1.37 (s, 9H, tBu). 13C-NMR. 150.88; 128.52; 128.18; 127.96:

.,,,~, ,, . ' :~

:
.

-66- 2 103 ,~j 93.90; 66.53; 49.58 and 28.22. IR: Frequency ln cm~1 (lnten-sity). 3423 (26.4), 3035 (53.2), 2978(41.4), 1736~17.3), 1658(3.8), 1563(23.0), 1501(6.8) and 1456 (26.4).

9-Carboxymethyl adenine ethyl ester.
Adenine (10.0 g, 74 mmol) and potasslum carbonate (10.29 g, 74.0 mmol) were suspended in DMF and ethyl bromoacetate (8.24 ml, 74 mmol) was added. The suspension was stirred for 2.5 h under nitrogen at room temperature and then filtered, The solid residue was washed three times with DMF (10 ml).
The combined filtrate was evaporated to dryness, ln vacuo.
The yellow-orange solid material was poured into water (200 ml) and 4 N HCl was added to pH 6. After stirring at 0C for 10 min, the solid was filtered off, washed with water, and recrystallized from 96% ethanol (150 ml). The title compound was isolated by filtration and washed thoroughly with ether.
Yield 3.4 g (20%). M.p. 215.5-220C. Anal. for CgHllN502 found(calc.): C: 48.86(48.65); H: 5.01(4.91); N: 31.66(31.42).
lH-MMR (250 MHz; DMSO-d6): (s, 2H, H-2 & H-8), 7.25 (b. s., 2H, NH2), 5.06 (s, 2H, NCH2), 4.17 (q, 2H, J=7.11 Hz, OCH2) and 1.21 (t, 3H, J=7.13 Hz, NCH2). 13C-NMR. 152.70, 141.30, 61.41, 43.97 and 14.07. FAB-MS. 222 (MH+). IR: Frequency in cm~l (intensity). 3855 (54.3), 3274(10.4), 3246(14.0), 3117(5.3), 2989(22.3), 2940(33.9), 2876(43.4), 2753(49.0), 2346(56.1), 2106(57.1), 1899(55.7), 1762(14.2), 17g2(14.2), 1742(1.0), 1671(1.8), 1644(10.9), 1606(0.6), 1582(7.1), 1522(43.8), 1477(7.2), 1445(35.8) and 1422(8.6). The position of alkylation was verified by X-ray crystallography on crystals, which were obtained by recrystallization from 96 ethanol.

N6 Benzyloxycarbonyl-9-carboxymethyl adenine ethyl ester.
9-Carboxymethyladenine ethyl ester ~3.40 g, 15.4 mmol) was dissolved in dry DMF (50 ml) by gentle heating, cooled to 20C, and added to a solution of N-ethyl- ben-zyloxycarbonylimidazole tetrafluoroborate (62 mmol) in t ' - !i~
--67- 2LO~`,O ) methylene chlorlde (50 ml) over a period of 15 mln wlth lce-cooling. Some precipitation was observed. The lce bath wa~
removed and the solution was stirred overnlght. The reaction mixture was treated with saturated sodium hydrogen carbonate (100 ml). After stirring for 10 mln, the phase~ were separated and the organic phase was wa~hed successively with one volume of water, dilute potassium hydrogen sulfate (twice), and with saturated sodium chloride. The solution was dried over magnesium sulfate and evaporated to dryness, in vacuo, which afforded ll g of an oily material. The material was dissolved in methylene chloride (25 ml), cooled to 0C, and precipitated with petroleumeum ether (50 ml). This procedure was repeated once to give 3.45 g (63~) of the title compound. M.p. 132-3soC- Analysis for C17H17N54 found (calc.): C: 56.95(57.46); H: 4.71(4.82); N: 19.35(19.71). lH-NMR (250 MHz; CDCl3): 8.77 (s, lH, H-2 or H-8); 7.99 (s, lH, H-2 or H-8); 7.45-7.26 (m, 5H, Ph); 5.31 (s, 2H, N-CH2); 4.96 (s, 2H, Ph-CH2); 4.27 (q, 2H, J=7.15 Hz, CH2CH3) and 1.30 (t, 3H, J=7.15 Hz, CH2CH3). 13C-NMR: 153.09; 143.11; 128.66;
67.84; 62.51; 44.24 and 14.09. FA~-MS: 356 (MH+) and 312 (MH+-C02). IR: frequency in cm~l (intensity). 3423 (52.1);
3182 (52.8); 3115(52.1); 3031(47.9); 2981(38.6); 1747(1.1);
1617(4.8); 15.87(8.4); 1552(25.2); 1511(45.2); 1492(37.9);
1465(14.0) and 1413(37.3).

N6~Benzyloxycarbonyl-9-carboxymethyl adenine.
N6-Benzyloxycarbonyl-9-carboxymethyladenine ethyl ester (3.20 g; 9.01 mmol) was mixed with methanol (50 ml) cooled to 0C. Sodium Hydroxide Solution (50 ml; 2N) was added, whereby the material quickly dissolved. After 30 min at 0C, the alkaline solution was washed with methylene chloride (2x50ml).
The aqueous solution was brought to pH 1.0 with 4 N HCl at ODC, whereby the title compound precipitated. The yield after filtration, washing with water, and drying was 3.08 g (104~).
The product contained salt and elemental analysis reflected that- Anal- for C15H13N504 found(calc.): C: 46.32(55.05); H

,'~':' ~ ' , '~ : ~` '' ''' ' F ~
.
.

' -~3n-'~10~,0 'i 4.24(4.00); N: 18.10(21.40) and C/N: 2.57(~.56). 1H-NMR(250 MHz; DMSO-d6): 8.70 (s, 2H, H-2 and ~l-8); 7.50-7.35 (m, 5H, Ph); 5.27 (5, 2H, N-C~2); and 5.15 (s, 2~l, Ph-CH2). 13C-NMR.
168.77, 152.54, 151.36, 148.75, 145.13, 128.51, 128.17,127.98, 66.76 and 44.67.IR (KBr) 3484(18.3); 3109(15.9); 3087(15.0);
2966(17.1); 2927(19.9); 2383(53.8); 1960(62.7); 1739(2.5);
1688(5.2); 1655(0.9); 1594(11.7); 1560(12.3); 1530(26.3);
1499(30.5); 1475(10.4); 1455(14.0); 1429(24.5)andl411(23.6).
FAB-MS: 328 (MH+) and 284 (MH+-C02). HPLC (215 nm, 260 nm) in system 1: 15.18 min, minor impurities all less than 2~.

N6-Benzyloxycarbonyl-1-(Boc-aeg)adenine ethyl ester.
N'-Boc-aminoethyl glycine ethyl ester (2.00 g; 8.12 mmol), DhbtOH (1.46 g; 8.93 mmol) and N6-benzyloxycarbonyl-9-carboxymethyl adenine (2.92 g; 8.93 mmol) were dissolved in DMF ( 15 ml). Methylene chloride (15 ml) then was added. The solution was cooled to 0C in an ethanol/ice bath. DCC (2.01 g; 9.74 mmol) was added. The ice bath was removed after 2.5 h and stirring was continued for another 1.5 hour at ambient temperature. The precipitated DCU was removed by filtration and washed once with DMF ( 15 ml), and twice with methylene chloride (2 x 15 ml). To the combined filtrate was added more methylene chloride (100 ml). The solution was washed successively with dilute sodium hydrogen carbonate (2 x 100 ml), dilute potassium hydrogen sulfate (2 x 100 ml), and saturated sodium chloride (1 x 100 ml). The organic phase was evaporated to dryness, in vacuo, which afforded 3.28 g (73~) of a yellowish oily substance. HPLC of the raw product showed a purity of only 66~ with several impurities, both more and less polar than the main peak. The oil was dissolved in absolute ethanol (50 ml) and activated carbon was added.
After stirring for 5 minutes, the solution was filtered. The filtrate was mixed with water (30 ml) and was left with stirring overnight. The next day, the white precipitate was removed by filtration, washed with water, and dried, affording 1.16 g (26~) of a material with a purity hi~her than sa~ by ~. '~", .

,~," , ,, ~1~n ~o~
HPLC. Addition of water to the mother llquor af~orded another 0.53 g with a purity of approx. 95~. Anal. for C26H33N707H20 found(calc.) C: 55.01(54.44; ~: 6.85(6.15) and N:
16.47(17.09). lH-NMR (250 MHz, CDC13) 8.74 (s, lH, Ade H-2);
8.18 (b. s, lH, ZNH); 8.10 & 8.04 (9, lH, H-8); 7.~6-7.34 (m, 5H, Ph); 5.63 (unres. t, lH, BocNH); 5.30 (s, 2H, PhCH2); 5.16 & 5.00 (s, 2H, CH2CON); 4.29 & 4.06 (s, 2H, CH2C02H); 4.20 (q, 2H, OCH2CH3); 3.67-3.29 (m, 4H, C_2C_2); 1.42 (s, 9H, tBu) and 1.27 (t, 3H, OCH2C_3). The spectrum shows traces of ethanol and DCU.

N6-Benzyloxycarbonyl-l-(Boc-aeg)adenine.
N6-Benzyloxycarbonyl-l-(Boc-aeg)adenine ethyl ester (1.48 g; 2.66 mmol) was suspended in THF (13 ml) and the mixture was cooled to 0C. Lithium hydroxide (8 ml; 1 N) was added.
After 15 min of stirring, the reaction mixture was filtered, extra water (25 ml) was added, and the solution was washed with methylene chloride (2 x 25 ml). The pH of the aqueous solution was adjusted to pH 2.0 with 1 N HCl. The precipitate was isolated by filtration, washed with water, and dried, and dried affording 0.82 g (58~). The product reprecipitated twice w~th methylene chloride/petroleum ether, 0.77 g (55~) after dryin~. M.p. 119C (decomp.) Anal. for C24H29N707H20 I found(calc.) C: 53.32(52.84); H: 5.71(5.73); N: 17.68(17.97).
¦ 25 FAB-MS. 528.5 (MH+). lH-NMR (250 MHz, DMSO-d6). 12.75 (very b, lH, CO2H); 10.65 (b. s, lH, ZNH); 8.59 (d, lH, J= 2.14 Hz, Ade H-2); 8.31 (s, lH, Ade H-8); 7.49-7.31 (m, 5H, Ph); 7.03 fi 6.75 (unresol. t, lH, BocNH); 5.33 ~ 5.16 (s, 2H, CH2CON);
5.22 (s, 2H, PhCH2); 4.34-3.99 (s, 2H, CH2CO2H); 3.54-3.03 30 (m's, includes water, CH2CH2) and 1.39 ~ 1.37 (s, 9H, tBu).
13C-NMR. 170.4; 166.6; 152.3; 151.5; 149.5; 145.2; 128.5;
128.0; 127.9; 66.32; 47.63; 47.03; 43.87 and 28.24.

2-Amino-6-chloro-9-carboxymethylpurine.
~o a suspension of 2-amino-6-chloropurine (5.02 g; 29.6 mmol) and potassium carbonate (12.91 g; 93.5 m~.ol) ln DMF (50 . ., ., ~,~,, , .,,. ~ j,; ' ~"

-70- 2109,0~

ml) was added bromoacetic acld (4.70 g; 22.8 mmol). The mixture was stirred vigorously for ~0 h. under nitrogen.
Water (150 ml) was added and the solution was filter~d through Celite to give a clear yellow ~olution. The solutlon was acidified to a pH of 3 with 4 N hydrochloric acid. The precipitate was filtered and dried, ln vaCuo, over sicapent.
Yield (3.02 g; 44.8%). 1H-NMR(DMS0-d6): d - 4.88 ppm (s,2H);
6.95 (s,2H); 8.10 (s,lH).
EXaMPLE 33 2-Amino-6-benzyloxy-9-carboxymethylpurine.
Sodium (2.0 g; 87.0 mmol) was dissolved in benzyl alcohol (20 ml) and heated to 130C for 2 h. After cooling to 0C, a solution of 2-amino-6-chloro-9-carboxymethylpurine (4.05 g;
18.0 mmol) in DMF (85 ml) was slowly added, and the resulting suspension stirred overnight at 20C. Sodium hydroxide solution (lN, 100 ml) was added and the clear solution was washed with ethyl acetate (3 x 100 ml). The water phase then was acidified to a pH of 3 with 4 N hydrochloric acid. The precipitate was taken up in ethyl acetate (200 ml), and the water phase was extracted with ethyl acetate (2 x 100 ml).
The combined organic phases were washed with saturated sodium chloride solution (2 x 75 ml), dried with anhydrous sodium sul~ate, and taken to dryness by evaporation, tn vacuo. The residue was recrystallized from ethanol (300 ml). Yield after drying, in vacou, over sicapent: 2.76 g (52~). M.p. 159-65C.
Anal. (calc., found) C(56.18; 55.97), H(4.38; 4.32), N(23.4;
23.10). lH-NMR (DMSO-d6): 4.82 ppm.(s,2H); 5.51 (s,2H); 6.45 (s,2H); 7.45 (m,5H); 7.82 (s,lH).

N-([2-Amino-6-benzyloxy-purine-9-yl]-acetyl)-N-(2-Boc-aminoethyl)-glycine tBocGaeg-OH monomer].
2-Amino-6-benzyloxy-9-carboxymethyl-purine(0.50g;1.67 mmol), methyl-N(2-[tert-butoxycarbonylamino]ethyl)-glycinate ~0.65 g; 2.80 mmol), diisopropylethyl amine (0.54 g; 4.19 mmol), and bromo-tris-pyrrolidino-phosphonium-hexafluoro-pho~phate (PyBroP~) (0.798 g; 1.71 mmol) were stirred in DMF

, . . .
, . .
, i,., -71- 2 1O~n~

(2 ml) for 4 h. The clear solution was poured Lnto an lce-cooled solution of sodium hydrogen carbonate ~1 N; 40 ml) and extracted with ethyl acetate (3 X 40 ml). The organic layer was washed with potassium hydrogen sulfate solutlon (1 N; 2 X 40 ml), sodlùm hydrogen carbonate (1 N; 1 X 40 ml) and saturated sodlum chlorlde solutlon (60 ml). After drying with anhydrous sodium sulfate and evaporation, ~n vacuo, the solid residue was recrystallized from ethyl acetate/hexane (20 ml (2:1)) to give the methyl ester in 63% yleld (MS-FAB 514 10 ( M+l ) . Hydrolysis was accomplished by dlssolvlng the ester in ethanol/water (30 ml (1:2)) containing conc. sodium hydroxide (1 ml). After stirring for 2 h, the sol~tion was filtered and acidified to a pH of 3, by the addition of 4 N
hydrochloric acid. The title compound was obtained by filtration. Yield: 370 m~ (72% for the hydrolysis). Purity by HPLC was more than 99%. Due to the limited rotation around the secondary amide several of the signals were doubled in the ratio 2:1 (indicated in the list by m;. for major and mi. for minor). lH-NMR(250, MHz, DMSO-d6): d - 1.4 ppm. (s,9H); 3.2 (m,2H); 3.6 (m,2H); 4.1 (s, m~., CONRCH2COOH); 4.4 (s, mi., CONRCH2COOH); 5.0 (s, mi., Gua-CH2C0-); 5.2 (s, m~., Gua-Ca2C0); 5.6 (s,2H); 6.5 (s,2H); 6.9 (m, mi., BocNH); 7.1 (m, m~., BocNH); 7.5 (m.,3H); 7.8 (s,lH); 12,8 (s;lH). 13C-MMR.
170.95; 170.52; 167.29; 166.85; 160.03; 159.78; 155.84;
154.87; 140.63; 136.76; 128.49; 128.10; 113.04; 78.19; 77.86;
66.95; 49.22; 47.70; 46.94; 45.96; 43.62; 43.31 and 28.25.

3-Boc-amino-1,2-propanediol.
3-Amino-1,2-propanediol (40.00 g, 0.440 mol, 1.0 eq.) was dissolved in water (1000 ml) and cooled to 0C. Di-tert-butyl dicarbonate (115.0 g, 0.526 mol, 1.2 eq.) was added in one portion. The reaction mixture was heated to room temperature on a water bath during stirring. The pH was maintained at 10.5 with a solution of sodium hydroxide (17.56 g, 0.440 mol, 1.0 eq.) in water (120 ml). When the addition of aqueous sodium hydroxide was completed, the reaction mixture was '~' ., ''' . ' ,~'',, ~.
,. . .

-7~-2,10~1,0~
stirred overnight at room temperature. Subsequently, ethyl acetate (750 ml) was added to the reaction mixture, followed by cooling to 0C. The pH was adJusted to 2.S with 4 N
sulphuric acid with vigorous stlrring. The phases were separated and the water phase was washed wlth additlonal ethyl acetate (6x350 ml). The volume of the organlc phase was reduced to 900 ml by evaporation under reduced pressure. The organic phase then was washed with a saturated aqueous solution of potassium hydrogen sulfate diluted to twice its volume (lxlOOO ml) and with saturated aqueous sodium chloride (lx500 ml). The organic phase was dried (MgS04) and evaporated under reduced pressure to yield 50.12 g (60%) of the title compound. The product could be solidif~ed by evaporation from methylene chloride and subsequent freezing.
lH-NMR (CDC13/TMS): d ~ 1.43 (s, 9H, Me3C), 3.25 (m, 2H, CH2), 3.57 (m, 2H, CH2), 3.73 (m, lH, CH). 13C-NMR (CDC13/TMS): d = 28.2 (Me3C), 42.6 (CH2), 63.5, 71.1 (CH20H, CHOH), 79.5 (Me3C), 157.0 (C=O).

2-(Boc-amino)ethyl-L-alanine methyl ester.
3-Boc-amino-1,2-propanediol (20.76 g, 0.109 mol, 1 eq.) was suspended in water (150 ml). Potassium m-periodate (24.97 g, 0.109 mol, 1 eq.) was added and the reaction mixture was stirred for 2 h at room temperature under nitrogen. The reaction mixture was filtered and the water phase extracted with chloroform (6x250 ml) The organic phase was dried (MgS04) and evaporated to afford an almost quantitative yield of Boc-aminoacetaldehyde as a colourless oil, which was used without further purification in the following procedure.
Palladium-on-carbon (10%, 0.8 g) was added to MeOH (250 ml) under nitrogen with cooling (0C) and vigorous stirring.
Anhydrous sodium acetate (4.49 g, 54.7 mmol, 2 eqv) and L-alanine methyl ester, hydrochloride (3.82 g, 27.4 mmol, l eqv) were added. Boc-aminoacetaldehyde (4.79 g, 30.1 mmol, 1.1 eqv) was dissolved in MeOH (150 ml) and added to the reaction mixture. The reaction mixture was hydrogenated at atmospheric ''' :'~' ' , ' , , ~, ' , .

~ ~ O ~ /; O ~1 pressure and room temperatu~e until hydrogen uptake had ceased. The reaction mixture was filtered through cellte, which was washed with additlonal MeC:~. The MeOH was removed under reduced pressure. The residue was suspended ln water 5 (150 ml) and pH ad~usted to 8.0 by dropwlse addition of 0.5 N NaOH with vigorous stirring. The water phase was extracted with methylene chloride (4x250 ml). The organic phase was dried (MgS04), filtered through celite, and evaporated under reduced pressure to yield 6.36 g (94~) of the title compound as a clear, slightly yellow oil. MS (FA~-MS): m/z (~) - 247 (100, M+l, 191 (90), 147 (1~ H-NMR (250 MHz, CDCl~). 1.18 (d, J=7.0 Hz, 3H, Me), 1.36 (s, 9H, Me3C), 1.89 (b, lH, NH), 2.51 (m, lH, CH2), 2.66 (m, lH, CH2), 3.10 (m, 2H, CH2), 3.27 (q, J=7.0 Hz, lH, CH), 3.64 (s, 3H, OMe), 5.06 (b, lH, carbamate NH). 13C-NMR. d = 18.8 (Me), 28.2 (Me3C), 40.1, 47.0 (CH2), 51.6 (OMe), 56.0 (CH), 155.8 (carbamate CsO), 175.8 (ester C=O).

N-(Boc-aminoethyl)-N-(l-thyminylacetyl)-L-alanine methyl ester.
To a solution of Boc-aminoethyl-(L)-alanine methyl ester (1.23 g, 5.0 mmol) in DMF (10 ml) was added Dhbt-OH (0,90 g, 5.52 mmol) and l-thyminylacetic acid (1.01 g, 5.48 mmol).
When the l-thyminylacetic acid was dissolved, dichloromethane (10 ml) was added and the solution was cooled on an ice bath.
After the reaction mixture had reached 0C, DCC (1.24 g, 6.01 mmol) was added. Within 5 min after the addition, a precipitate of DCU was seen. After a further 5 min, the ice bath was removed. Two hours later, TLC analysis showed the reaction to be finlshed. The mlxture was filtered and the precipitate washed with dichloromethane (100ml). The resulting solution was extracted twice with 5% sodium hydrogen carbonate (150 ml) and twice with saturated potassium hydrogen sulfate (25 ml) in water (100 ml). After a final extraction with saturated sodium chloride (150 ml), the solutlon was dried with magnesium sulfate and evaporated to glve a whlte ~: .
~ .

-74- 2~ 0~j foam. The foam was purified by column chromatography on silica gel using dichloromethane with a methanol gr~dient as eluent. This yielded a pure compound (>99% by HPLC) (1.08 g, 52.4%). FAB-MS: 413 (M+1) and 431 (M~1 + water). lH-NMR
(CDC13): 4.52 (s, 2 H, CH 2); 3,73 (s, 3 H, OMe); 3.2-3.6 (m, 4 H, ethyl CH2's); 1.90 (s, 3 H, Me ln T); 1.49 (d, 3 H, Me in Ala, J=7.3 Hz); 1.44 (s, 9 H, Boc).

N-(Boc-aminoethyl)-N-(l-thyminylacetyl)- L- alanine.
The methyl ester of the title compound (2.07 g, 5.02 mmol) was dissolved in methanol (100 ml), and cooled on an ice bath. 2 M sodium hydroxide (100 ml) was added. After stirring for 10 min, the pH of the mixture was ad~usted to 3 with 4 M hydrogen chloride. The solution was subsequently extracted with ethyl acetate (3 x 100 ml). The combined organic extracts were dried over magnesium sulfate. After evaporation, the resulting foam was dissolved in ethyl acetate (400 ml) and a few ml of methanol to dissolve the solid material. Petroleum ether then was added until precipitation started. After standing overnight at -20C, the precipitate was removed by filtration. This gave 1.01 g (50.5~) o~ pure compound (>99~ by HPLC). The compound can be recrystallized from 2-propanol. FAB-MS: 399 (M+l). 1H-NMR (DMSO-d6): 11.35 (s, 1 H, COO); 7.42 (s, 1 H, H 6); 4.69 (9, 2 H, CH'2); 1.83 (s, 3 H, Me in T); 1.50-1.40 (m, 12 H, Me in Ala + Boc).

(a) N-(Boc-aminoethyl)--N-(1-thyminylacetyl)-D-alanine methyl ester.
To a solution of Boc-aminoethyl alanine methyl ester (2.48 g, 10.1 mmol) in DMF (20 ml) was added Dhbt-OH (1.80 g, 11.0 mmol) and thyminylacetic acid (2.14 g, 11.6 mmol). After dissolution of the l-thyminylacetic acid, methylene chloride (20 ml) was added and the solution cooled on an ice bath.
When the reaction mixture had reached 0C, DCC (2.88 g, 14.0 mmol) was added. Wlthin 5 min after the addition a precipitate of DCU was seen. After 35 min the ice bath was }-: . "' ' '`'' :':
~,~ ~ , ' '' .

~75- 2 1 ~ 5 removed. The reaction mixture was filt~red 3.5 h later and the precipltat~ washed wlth methylene chlorlde (200 ml). The resulting solution was extracted twice wlth 5% sodium hydrogen carbonate (200 ml) and twic~ with saturated potassium hydrogen sulfate in water (100 ml). After a flnal extractlon wlth saturated sodlum chlorlde (250 ml), the solutlon was drled with magneslum sulfate and evaporated to glve an oil. The oil was purified by short column silica gel chromatography using methylene chloride with a methanol gradlent as eluent. This yielded a compound which was 96% pure according to HPLC (1.05 g, 25.3%) after preclpitatlon with petroleum ether. FAB-MS:
413 (M+l). lH-NMR (CDC13): 5.64 ( t, 1 H, BocNH, J=~.89 Hz);
4.56 (d, 2 H, CH 2); 4.35 (q, 1 H, CH ln Ala, J-7.25 Hz);
3.74 (s, 3 H, OMe); 3.64-3.27 (m, 4 H, ethyl H s); 1.90 (s, 3 H, Me in T); 1.52-1.44 (t, 12 H, Boc+Me ln Ala).
(b) N-(Boc-aminoethyl)-N-(1-thyminylacetyl)-D-alanine The methyl ester of the title compound (1.57 g, 3.81 mmol) was dissolved in methanol (100 ml) and cooled on an ice bath. Sodium hydroxide (100 ml; 2 M) was added. After stirring for 10 min the pH of the mixture was ad~usted to 3 with 4 M hydrogen chloride. The solution then was extracted with ethyl aceta~e (3 x 100 ml). The combined organic extracts were dried over magnesium sulfate. After evapora-tion, the oil was dissolved in ethyl acetate (200 ml).
Petroleum ether was added (to a total volume of 600 ml) until precipitation started. After standing overnight at -20C, the precipitate was removed by filtration. This afforded 1.02 g (67.3%) of the title compound, which was 94% pure according to HPLC. FAB-MS: 399 (M+l). lH-NMR: 11.34 (s, 1 H, COOH);
7.42 (s, 1 H, H 6); 4.69 (s, 2 H, CH 2); 4.40 (q, l H, CH in Ala, J=7.20 Hz); 1.83 (s, 3 H, Me in T); 1.52-1.40 (m, 12 H, Boc + Me in Ala).

: , .
' ,. -. ,"' -t6~ 2 l O ~

N- (~ ' -Boc-3'-aminopropyl)-N-~(l-thymlnyl)acetyl~glyclne methyl ester.
N-(N'-~oc-3'-amlnopropyl)glycine methyl ester ~2.84 g, 0.0115 mol) was dlssolved ln DMF (35 ml), follow~d by additlon of DhbtOH (2.07 g, 0.0127 mol) and l-thyminylacetlc acld (2.34 g, 0.0127 mol). Methylene chlorlde (35 ml) was added and the mixture cooled to 0C on an lce bath. After additlon of DCC
(2.85 g, 0.0138 mol), the mixture was stirred at 0C for 2 h, followed by 1 h at room temperature. The precipitated DCU was removed by fil~ration, washed with methylene chloride (25 ml), and a further amount of methylene chloride (150 ml) was added to the filtrate. The organic phase was extracted with sodium hydrogen carbonate (1 volume saturated diluted with 1 volume water, 6 x 250 ml), potassium sulfate (1 volume saturated diluted with 4 volumes water, 3 x 250 ml), and saturated aqueous sodium chloride (1 x 250 ml), dried over magnesium sulfate, and evaporated to dryness, in vacuo. The solid residue was suspended in methylene chloride (35 ml) and stirred for lh. The precipitated DCU was removed by filtration and washed with methylene chloride (25 ml). The filtrate was evaporated to dryness, in vacuo, and the residue purified by column chromatography on silica gel, eluting with a mixture of methanol and methylene chloride (gradient from 3-7% methanol in methylene chloride). This afforded the title compound as a white solid (3.05 g, 64%). M.p.. 76-79C
(decomp.). Anal. for C18H28N407, found (calc.) C: 52.03 (52.42) H: 6.90 (6.84) N: 13.21 (13.58). The compound showed satisfactory lH and 13C-NMR spectra.

N-(N'-Boc-3'-aminopropyl)-N-t(l-thyminyl)acetyl]glycine.
N-(N'-Boc-3'-aminopropyl)-N-[(l-thyminyl)acetyl]glycine methyl ester (3.02 g, 0.00732 mol) was dissolved in methanol (25 ml) and stirred for 1.5 h with 2 M sodium hydroxide (25 ml). The methanol was removed by evaporation, in vacuo, and pH ad~usted to 2 with 4 M hydrochloric acid at O~C. The ,-~ . . -.
.. ~ -:., - .
., .~
.-'~ - ' . ' -2 1 0 ~ 5~
product was isolated as white crystals by filtratlon, washed with water (3 x 10 ml), and drled over slcapent, ln vacuo.
Yield 2-19 g (75%). Anal- for C17H26N407~ H20, found ( C: 49.95 (49.03) H: 6.47 (6.29) N: 13.43 (13.45). The 5 compound showed satisfactory lH and 13C-NMR spectra.

3-(1-Thyminyl)-propanoic acid methyl ester.
Thymine (14.0 g, 0.11 mol) was suspended in methanol.
Methyl acrylate (39.6 ml, 0.44 mol) was added, along wlth catalytic amounts of sodium hydroxlde. The solutlon was refluxed in the dark for 45 h, evaporated to dryness, in vacuo, and the residue dissolved in methanol (8 ml) with heating. After cooling on an ice bath, the product was precipitated by addition of ether (20 ml), lsolated by filtration, washed with ether (3 x 15 ml), and dried over sicapent, in vacuo. Yield 11.23 g (48%). M.p. 112-119C.
Anal. for CgH12N204, found (calc.) C: 51.14 (50.94) H: 5.78 (5.70) N: 11.52 (13.20). The compound showed satlsfactory lH
and 13C-NMR spectra.

3-(1-Thyminyl)-propanoic acid.
3-(1-Thymlnyl)-propanoic acld methyl ester (1.0 g, 0.0047 mol) was suspended in 2 M sodium hydroxide (15 ml), boiled for 10 min. The pH was adjusted to 0.3 wlth conc. hydrochloric acld. The solution was extracted with ethyl acetate (10 x 25 ml). The organic phase was extracted with saturated aqueous sodium chloride, dried over magnesium sulfate, and evaporated to dryness, in vacuo, to give the title compound as a white solid (0.66 g, 71%). M.p. 118-121C. Anal. for CBHloN204, 30 found (calc.) C: 48.38 (48.49) H: 5.09 (5.09) N: 13.93 (14.14). The compound showed satisfactory lH and 13C-NMR
spectra.

,', ' ' '`''' '''' ., '''' '' '" ' ~ "
,., ;

- ~- 2 1 ~ 9 '~

N-(N'-Boc-aminoethyl)-N-[(l-thyminyl)propanoyl]~lyclne ethyl ester.
N-(N'-Boc-aminoethyl)glycine ethyl ester (1.0 ~, 0.00~1 mol) was dissolved in DMF (12 ml). DhbtOH (0.73 g, 0.0045 mol) and 3-(1-thyminyl)-propanoic acid (0.89 g, 0.0045 mol) were added. Methylene chloride (12 ml) then was added and the mixture was cooled to 0C on an ice bath. After addition of DCC (1.01 g, 0.0049 mol), the mixture was stirred at 0C for 2 h, followed by 1 h at room temperature. The precipitated DCU was removed by filtration, washed with methylene chloride (25 ml), and a further amount of methylene chlorid~ (50 ml) was added to the filtrate. The organic phase was extracted with sodium hydrogen carbonate (1 volume saturated diluted with 1 volume water, 6 x 100 ml), potassium sulfate (1 volume saturated diluted with 4 volumes water, 3 x 100 ml), and saturated aqueous sodium chloride (1 x 100 ml), dried over magnesium sulfate, and evaporated to dryness, in vacuo. The solid residue was suspended in methylene chloride (15 ml), and stirred for lh. The precipitated DCU was removed by filtration and washed with methylene chloride. The filtrate was evaporated to dryness, in vacuo, and the residue purified by column chromatography on silica gel, eluting with a mixture of methanol and methylene chloride (gradient from 1 to 6~
methanol in methylene chloride). This afforded the title compound as a white solid (1.02 g, 59%). Anal. for ClgH30N407, found (calc.) C: 53.15 (53.51) H: 6.90 (7.09) N:
12.76 (13.13). The compound showed satisfactory lH and 13C-NMR spectra.

N-(N'-Boc-aminoethyl)-N-t(1-thyminyl)propanoyl]glycine .
N-(N'-Boc-aminoethyl)-N-t(l-thyminyl)propanoyl]glycine ethyl ester (0.83 g, 0.00195 mol) was dissolved in me-thanol (25 ml). Sodium hydroxide (25 ml; 2 M) was added. The solution was stirred for 1 h. The methanol was removed by evaporation, in vacuo, and the pH ad~usted to 2 with 4 M

.,' ' ,.
": ~ :
,' ~, "' ''' s,i ~ ' .... . .

-79- 2109~0~J

hydrochloric acid at 0C. The product was isolated by filtration, washed with ether (3 x IS ml), and dried over sicapent, ln vacuo. Yleld 0.769 ~, 99~). M.p. 213C (de-comp.).

Mono-Boc-ethylenediamine (2).
tert-Butyl-4-nltrophenyl carbonate (1) (10.0 g; 0.0418 mol) dissolved in DMF (50 ml) was added dropwise over a period of 30 min to a solution of ethylenediamlne (27.9 ml; 0.418 mol) and DMF (50 ml) and stirred overnight. The mixture was evaporated to dryness, in vacuo, and the resulting oil dissolved in water (250 ml). After cooling to 0C, pH was adjusted to 3.5 with 4 M hydrochlorlc acid. The solution then was filtered and extracted with chloroform (3x250 ml). The 15 pH was ad~usted to 12 at 0C with 2 M sodium hydroxlde, and the aqueous solution extracted with methylene chloride (3x300 ml). After treatment with sat. aqueous sodium chloride (250 ml), the methylene chloride solution was dried over magnesium sulfate. After filtration, the solution was evaporated to dryness, in vacuo, resulting in 4.22 g (63%) of the product (oil). 1H-NMR (90 MHz; CDC13): ~1.44 (s, 9H); 2.87 (t, 2H):
3.1 (q, 2H); 5.62 (s, broad).

(N-Boc-aminoethyl)-~-alanine methyl ester, HCl.
Mono-Boc-ethylenediamine (2) (16.28 g; 0.102mol) was dissolved in acetonitrile (400 ml) and methyl acrylate (91.50 ml; 1.02 mol) was transferred to the mixture with acetonitrile (200 ml). The solution was refluxed overnight under nitrogen in the dark to avoid polymerization of methyl acrylate. After evaporation to dryness, in vacuo, a mixture of water and ether (200 + 200 ml) was added, and the solution was filtered and vigorously stirred. The aqueous phase was extracted one more time with ether and then freeze dried to yield a yellow solid.
Recrystallization from ethyl acetate yielded 13.09 g (46~) of 35 the title compound. M.p. 138-140C. Anal. for C11H23N204Cl, found (calc.) C: 46.49 (46.72) H: 8.38 (8.20) N: 9.83 ~9.91) ~',.: ' ' , . , ' ,. . ...

2 1 ~ ~ ~ O, Cl: 12.45 (12.54). lH-NMR (90 MHz; DMS0-d6): ~ 1.39 (s, 9H);
2.9 (m, 8H); 3.64 (s, 3H).
EXAMP~E 48 N-~(1-Thyminyl)acetyl]-N'-Boc-am~noethyl-~-alanlne methyl ester.

(N-Boc-amino-ethyl)-~-alanlne methyl ester, HCl (3) (2.0 g; 0.0071 mol) and l-thyminylacetic acid pentafluorophenyl ester (5) (2.828 g; 0.00812 mol) were dlssolved in DMF (50 ml). Triethyl amine (1.12 ml; 0.00812 mol) was added and the mixture stirred overnight. After addition of methylene chloride (200 ml) the organic phase was extracted with aqueous sodium hydrogen carbonate (3x250 ml), half-sat. aqueous potassium hydrogen sulfat~ (3x250 ml), and sat. aqueous sodium chloride (250 ml) and dried over magnesium sulfate.
Filtration and evaporation to dryness, in vaCuo, resulted in 2.9 g (99%) yield (oil). lH-NMR (250 MHz; CDCl3): due to limited rotation around the secondary amide several of the signals were doubled; ~ 1.43 (s, 9H); 1.88 (s, 3H); 2.63 (t, lH); 2.74 (t, lH); 3.25-3.55 (4xt, 8H); 3.65 (2xt, 2H); 3.66 (s, 1.5); 3.72 (s, 1.5); 4.61 (s, lH); 4.72 (s, 2H); 5.59 (s, 0.5H); 5.96 (s, 0.5H); 7.11 (s, lH); 10.33 (s, lH).

N-~(l-Thyminyl)acetyl]-N'-Boc-aminoethyl-~-alanine.
N-[(l-Thymi~yl)acetyl]-N'-Boc-aminoethyl-~-alaninemethyl ester (3.0 g; 0.0073 mol) was dissolved in 2 M sodium hydroxide (30 ml), the pH ad~usted to 2 at 0C with 4 M
hydrochloric acid, and the solution stirred for 2 h. The precipitate was isolated by filtration, washed three times with cold water, and dried over sicapent, in vacuo. Yield 2.23 g (77%). M.p. 170-176C. Anal. for C17H26N407, H20, found (calc.) C: 49.49 (49.03) H: 6.31 (6.78) N: 13.84 (13.45). lH-NMR (90 MHz; DMSO-d6): ~ 1.38 (s, 9H); 1.76 (s, 3H); 2.44 and 3.29 (m, 8H); 4.55 (s, 2H); 7.3 (s, lH); 11.23 (s, lH). FAB-MS: 399 (M+l).

~; ~ , f - , ~

~ ' ' ' ", ~i; - . ," , -81- '~ L09~ j N~ [N4~ cytosyl)acetyl]-N'-~oc-amino~thyl-~-alanlne methyl ester.
(N-Boc-amino-ethyl)-~-alanine methyl ester, HCl (3) (2.0 5 g: 0.0071 mol) and 1-(N-4-Z)-cytosylacetlc acld pentafluorophenyl ester (5) (3.319 g; 0.0071 mol) were dissolved in DMF (50 ml). Triethyl amine (0.99 ml; 0.0071 mol) was added and the mixture stirred overnlght. After addition of methylene chloride (200 ml), the organic phase was extracted with aqueous sodium hydrogen carbonate (3x250 ml), half-sat. aqueous potassium hydrogen sulfate (3x250 ml), and sat. aqueous sodium chloride (250 ml), and dried over magnesium sulfate. Filtration and evaporation to dryness, ~n vacuo, resulted in 3.36 g of solld compound which was 15 recrystallized from methanol. Yield 2.42 g (64%). M.p. 158-161C- Anal- for C25H33N58, found (calc.) C: 55.19 (56.49) H: 6.19 (6.26) N: 12.86 (13.18). lH-NMR (250 MHz; CDC13): due to limited rotation around the secondary amide several of the signals were doubled; ~ 1.43 (s, 9H); 2.57 (t, lH); 3.60-3.23 20 (m's, 6H); 3.60 (s, 1,5H); 3.66 (s, 1.5H); 4~80 (s, lH); 4.88 (s, lH); 5.20 (s, 2H); 7.80-7.25 (m's, 7H). FAB-MS: 532 (M+l).

N-[(l-(N4-Z)-cytosyl)acetyl]-N'-Boc-aminoethyl-~-alanine.
N-[(l--(N-4-Z)-cytosyl)acetyl]-N'-Boc-aminoethyl-~-alanine methyl ester (0.621 g; 0.0012 mol) was dissolved in 2 M sod~um hydroxide (8.5 ml) and stirred for 2h.
Subsequently, pH was adjusted to 2 at 0C with 4 M
hydrochloric acid and the solution stirred for 2 h. The precipitate was isolated by filtration, washed three times with cold water, and dried over sicapent, ln vacuo. Yield 0.326 g (54%). The white solid was recrystallized from 2-propanol and washed with petroleum ether. Mp.163'C (decomp.).
Anal. for C24H31N508, found (calc.) C: 49.49 (49.03) H: 6-31 35 (6.78) N: 13.84 (13.45). lH-NMR (250 MHz; CDCl3): due to limited rotation around the secondary amide several of the ..
- ' , "-.
;"
.~ .

-82- 2~ 09~0~j signals were doubled; ~ 1.40 (s, 9~); 2.57 (t, lH); 2.65 (t, lH); 3.60-3.32 (m's, 6H); 4.85 (s, lH); 4.98 (9, lH); 5.21 (s, 2H); 5.71 (s, lH, broad): 7.99-7.25 (m's, 7H). FA~-MS: 518 (M+l).

Example of a PNA-oligomer with a guanine residue (a) Solid-Phase Synthesis of H-[Taeg]5-[Gaeg]-[Taeg]4-Lys-NH2 The protected PNA was assembled onto a Boc-Lys(ClZ) modified MBHA resin with a substitution of approximately 0.15 mmol/g (determined by quantitative Ninhydrin reaction).
Capping o~ uncoupled amino groups was only carried O'lt before the incorporation of the BocGaeg-OH monomer.
(b) Stepwise Assembly of H-[Taeg]5-[Gaeg~-tTaeg]4-Ly~-NH2 (synthetic protocol) Synthesis was initiated on 102 mg (dry weight) of preswollen (overnight in DCM) and neutralized Boc-Lys(ClZ)-MBHA resin. The steps performed were as follows: (1) Boc-deprotection with TFA/DCM (1:1, v/v), 1 x 2 min and 1 x 1/2 h, 3 ml; (2) washing with DCM, 4 x 20 sec, 3 ml; washing with DMF, 2 x 20 sec, 3 ml; washing with DCM, 2 x 20 sec, 3 ml, and drain for 30 sec; (3) neutralization with DIEA/DCM (1:19 v/v), 2 x 3 min, 3 ml; (4) washing with DCM, 4 x 20 sec, 3 ml, and drain for 1 min.; (5) addition of 4 equiv. diisopropyl carbodiimide (0.06 mmol; 9.7 ~l) and 4 equiv. (O.06 mmol; 24 mg) BocTaeg-OH or (O.06 mmol; 30 mg) BocGaeg-OH dissolved in 0.6 ml DCM/DMF (1:1, v/v) (final concentration of monomer 0.1 M), the coupling reaction was allowed to proceed for 1/2 h shaking at room temperature; (6) suction was applied for 20 seconds (7) washing with DMF, 2 x 20 sec and l x 2 min, 3 ml; washing with DCM 4 x 20 sec, 3 ml;
(8) neutralization with DIEA/DCM (1:19 v/v), 2 x 3 min, 3 ml;
(9) washing with DCM 4 x 20 sec, 3 ml, and drain for l min.;
(10) qualitative Kaiser test; (11) blocking of unreacted amino groups by acetylation with Ac2O/pyridine/DCM (1:1:2, v/v), 1 x 1/2 h, 3 ml; and (12) washing with DCM, 4 x 20 sec, 2 x 2 -: , .. , , ,, , ' . ....
.~' , ... .
:.'' '' , :

-83- 2109~0~i min and 2 x 20 sec, 3 ml. Steps 1-12 were repeated untll the desired sequence was obtained. All qualltatlve Kalser tests were negatlve ~straw-yellow colour with no coloratlon of the beads) indicating near 100~ coupling yleld. The PNA-ollgomer was cleaved and purified by the normal procedure. FAB-MS:
2832.11 [M +l] (calc. 2832.15) Solid-Phase Synthesis of H-Taeg-Aaeg-tTaeg]8-Lys-NH2.
(a) Stepwise Assembly of Boc-Taeg-A(Z)aeg-[Taeg]8-Lys(ClZ)-MBHA Resin.
About 0.3 g of wet Boc-[Taeg]8-Lys(ClZ)-MBHA resin was placed in a 3 ml SPPS reaction vessel. Boc-Taeg-A(Z)aeg-~Taeg]8-Lys(ClZ)-MBHA resin was assembled by ~n situ DCC
coupling (single) of the A(Z)aeg residue utilizing 0.19 M of 15 BocA(Z)aeg-OH together with 0.15 M DCC in 2.5 ml 50%
DMF/CH2Cl2 and a single coupling with 0.15 M BocTaeg-OPfp in neat CH2Cl2 ("Synthetic Protocol 5"). The synthesis was monitored by the quantitative ninhydrin reaction, which showed about 50% incorporation of A(Z)aeg and about 96% incorporation of Taeg.
(b) Cleavage, Purification, and Identification oE H-Taeg-Aaeg-~Taeg]8-Lys-NH2.
The protected Boc-Taeg-A(Z)aeg-[Taeg]8-Lys(ClZ)-BAH resin was treated as described in Example 40c to yield about 15.6 mg of crude material upon HF cleavage of 53.1 mg dry H-Taeg-A(Z)aeg-[Taeg]8-Lys(ClZ)-BHA resin. The main peak at 14.4 min accounted for less than 50% of the total absorbance. A 0.5 mg portion of the crude product was purified to give approximately 0.1 mg of H-Taeg-Aaeg-[Taeg]8-Lys-NH2. For (MH+)+ the calculated m/z value was 2816.16 and the measured m/z value was 2816.28.
(c) Synthetic Protocol 5 (1) Boc-deprotection with TFA/CH2Cl2 (1:1, v/v), 2.5 ml, 3 x 1 min and 1 x 30 min; (2) washing with CH2Cl2, 2.5 ml, 6 x 1 min; (3) neutralization with DIEA/CH2Cl2 (1: l9, v/v), 2.5 ml, 3 x 2 min; (4) washing with CH2Cl2, 2.5 ml, 6 x 1 min, and ~' ,.
~::

, .. ' , ' .
, ,,`

-84- 2109~0 j drain for 1 min; (5) 2-5 mg sample of PNA-resln 19 taken out and dried thoroughly for a quantltatlve nlnhydrln analysls to determlne the substltutlon: (6) addltlon of 0.47 mmol (0.25 g) BocA(Z)aeg-OH dlssolved ln 1.25 ml DMF followed by addltlon of 0.47 mmol (0.1 g) DCC ~n 1.25 ml CH2C12 or 0.36 mmol (0.20 g) BocTaeg-OPfp ln 2.5 ml CH2C12; the coupllng reactlon was allowed to proceed for a total of 20-24 hrs shaklng; (7) washing with DMF, 2.5 ml, 1 x 2 min; (8) washing with CH2C12, 2.5 ml, ~ x 1 min; (9) neutrallzation with DIEA/CH2C12 (1: 19, v/v), 2.5 ml, 2 x 2 min; (10) washing wlth CH2C12, 2.5 ml, 6 x 1 mln; (11) 2-5 mg sample of protected PNA-resln is taken out and dried thoroughly for a quantitative ninhydrin analysis to determine the extent of coupling; (12) blocking of unreacted amino groups by acetylation with a 25 ml mixture of acetic anhydride/pyridine/CH2Cl2 (1:1:2, v/v/v) for 2 h (except after the last cycle); and (13) washing with CH2Cl2, 2.5 ml, 6 x 1 min; (14) 2 x 2-5 mg samples of protected PNA-resin are taken out, neutralized with DIEA/CH2C12 (1: 19, v/v) and washed with CH2Cl2 for ninhydrin analyses.

Solid-Phase Synthesis of H-tTaeg~2-Aaeg-~Taeg]5-Lys-NH2.
(a) Stepwise Assembly of 80c-[Taeg]2-A(Z)aeg-[Taeg]5-Lys(ClZ)-MBHA Resin.
About 0.5 g of wet Boc-tTaeg]5-Lys(ClZ)-MBHA resin was placed in a 5 ml SPPS reaction vessel. Boc-tTaeg]2-A(Z)aeg-tTaeg]5-Lys(ClZ)-MBHA resin was assembled by in situ DCC
coupling of both the A( Z )aeg and the Taeg residues utilising 0.15 M to 0.2 M of protected PNA monomer (free acid) together with an equivalent amount of DCC in 2 ml neat CH2Cl2 ("Synthetic Protocol 6"). The synthesis was monitored by the quantitative ninhydrin reaction which showed a total of about 82% incorporation of A(Z)aeg after coupling three times (the first coupling gave about 50~ incorporation; a fourth HOBt-mediated coupling in 50% DMF/CH2Cl2 did not increase the total coupling yield significantly) and quantitative incorporation (single couplings) of the Taeg residues.

~'~ ,,, .. '' - ' ' ,.' ,"'; ~'' .' ' ' ;, ,' . .. .

-`` 2109~'0 ) (b) Cleavage, Purification, and Identification of H-~Taeg]2-Aaeg-~Taeg]5-L~-NH2.
The protected Boc-[Taeg]2-A(Z)aeg-~Taeg]5-Lys(ClZ)-~HA
resin was treated as described in Example 40c to yleld about 16.2 mg of crude material upon HF cleavage of 102.5 mg dry ~-[Taeg]2-A(Z)aeg-tTaeg]5-Lys(ClZ)-BHA resln. A small portlon of the crude product was purlfled. For (MH+)+, the calculated m/z value was 2050.85 and the measured m/z value was 2050.90 (c) Synthetic Protocol 6 (1) Boc-deprotection wlth TFA/CH2C12 (1:1, v/v), 2 ml, 3 x 1 min and 1 x 30 min; (2) washing with CH2C12, 2 ml, 6 x 1 min; (3) neutralizatlon wlth DIEA/CH2C12 (1: 19, v/v), 2 ml, 3 x 2 min; (4) washing with CH2C12, 2 ml, 6 x 1 min, and drain for 1 min; (5) 2-5 mg sample of PNA-resin was taken out and dried thoroughly for a quantitative ninhydrin analysis to determine the substitution; (6) addition of 0.44 mmol (0.23 g) BocA(Z)aeg-OH dissolved in 1.5 ml CH2C12 followed by addition of 0.44 mmol (0.09 g) DCC in 0.5 ml CH2C12 or 0.33 mmol (0.13 g) BocTaeg-OH in 1.5 ml CH2C12 followed by addition of 0.33 mmol (0.07 g) DCC in 0.5 ml CH2C12;; the coupling reaction was allowed to proceed for a total of 20-24 hrs with shaking; (7) washing with DMF, 2 ml, 1 x 2 min; (8) washing with CH2C12, 2 ml, 4 x 1 min; (9) neutralization with DIEA/CH2C12 (1: 19, v/v), 2 ml, 2 x 2 min; (10) washing with ¦ 25 CH2C12, 2 ml, 6 x 1 min; (11) 2-5 mg sample of protected PNA-resin is taken out and dried thoroughly for a quantitative ninhydrin analysis to determine the extent of coupling; (12) blocking of unreacted amino groups by acetylation with a 25 ml mixture of acetic anhydride/pyridine/CH2C12 (1:1:2, v/v/v) for 2 h (except after the last cycle); (13) washing with CH2C12, 2 ml, 6 x 1 min; and (14) 2 x 2-5 mg samples of protected PNA-resin were taken out, neutralized with DIEA/CH2C12 (1: 19, v/v) and washed with CH2C12 for ninhydrin analyses.

An example with a "no base" substitution.

~ .
.

-16- 2~ 30 ~ o C H ~0 N~\/ ~ , /N.
H H
I . ~ . L~H

PNA DNA Tm H-Tlo-LysNH2 (dA)10 73C

H-T4(Ac)T5-LysNH2 (dA)lo 49C

H-T4(Ac)T5-LysNH2 (dA)4(dG)(dA)5 37C

H-T4(Ac)Ts-LysNH2 (dA)4(dC)(dA)5 41C
H-T4(AC)Ts-LysNH2 (dA)4(dT)(dA)5 41C

H-T4(AC)Ts-LysNH2 (dA)5(dG)(dA)4 36C

H-T4(Ac)Ts-LysNH2 (dA)5(dC)(dA)4 40C
H-T4(Ac)T5-LysNH2 (dA)5(dT)(dA)4 40C

Thus it can be seen that compared with H-Tlo~LysNH2, replacement of one thymine ligand by H results in a drop of Tm to 48C from 73C. The effect of also lntroducing a single base mismatch is also shown.

. ~ .
i~
, -87- 210~ 0 i Certain biochemical/biological properties of PNA
oligomers are illustrated by the followlng experiments.
1. Sequence discrimination at the dsDNA level (Example 63, Figure 20).
Using the Sl-nuclease problng technique, the dls-crimination of binding of the T1o, T5CT4 (TgC) & T2CT2CT4 (T8C2) PNA to the recognition sequences A1o, A5GA4 (AgG) ~
A2GA2GA4 (A8G2) cloned into the ~amHI, SalI or PStI site of the plasmid pUCl9 was analyzed. The results (Figure 20) show that the three PNAs bind to their respective recognition sequences with the following relative efficiencies: PNA - Tlo:
Alo > AgG A8G2, PNA -TgC AgG ~ Alo ~ A8G2~ PNA 8 2 A8G2 ' AgG >> Alo. Thus at 37C one mismatch out of ten gives reduced efficiency (5-10 times estimated) whereas two mismatches are not accepted.
2. Displacement of a single strand DNA from a ds-DNA by hybridisation of PNAS Tlo/TgC/T8C2 (Figure 20) - Example 63.
3. Kinetics of PNA-Tlo - dsDNA strand d~splacement complex formation (Example 64, Figure 21).
Complex formation was probed by Sl-nuclease at various times following mixing of PNA and 32P-end labelled dsDNA
fragment (Figure 21).
4. Stability of PNA-dsDNA complex (Example 65, Figure 22) Complexes between PNA-Tn and 32P-dsDNA (Alo/Tlo) target were formed (60 min, 37C). The complexes were then incubated at the desired temperature in the presence of excess oligo-dAlo for 10 min, cooled to RT and probed with KMnO4. The results (Figure 22) show that the thermal stability of the PNA-dsDNA complexes mirror that of the PNA oligonucleotide complexes in terms of "Tm".
5. Inhibition of restriction enzyme cleavage by PNA (Example 64, Figure 23) The plasmid construct, pT10, contains a dAlo/dT1o tract cloned into the BamHI site ln pUCl9. Thus, cleavage of pT10 with BamHI and PvuII results in two small DNA fragments of 211 and 111 bp, respectlvely. In the presence of PNA-Tlo, a 336 ~., ~., ,f,i: - , ~'', :.

-88- ~l 0~

bp fragment is obtained corresponding to cleavage only by PvuII (Figure 23). Thus cleavage by BamHI ls inhlbitsd by PNA
bound proximal to the restriction enzyme site. The results also show that the PNA-dsDNA complex can be formed ln 100%
yield. Similar results were obtained using the pT8C2 plasmid and PNA-T8C2.
6. Binding of 125I-labeled PNA to oligonucleotides (Example 63, Figure 24) A Tyr-PNA-T10-Lys-NH2 was labeled with 125I using Nal25I
and chloramine-T and purified by HPLC. The 125I-PNA-Tlo was shown to bind to oligo-dA10 by PAGE and autoradiography (Figure 24). The binding could be competed by exce~s denatured calf thymus DNA.
Reverting to point (1) above, the sequence-specific recognition of dsDNA i9 illustrated by the binding of a PNA, consisting of 10 thymine substituted 2-aminoethylglycyl units, which C-terminates in a lysine amide and N-terminates in a complex 9-aminoacridine ligand (9-Acrl-(Taeg)10-Lys-NH2, Figures lla and b) to a dA10/dTlO target sequence. The target 20 is contained in a 248 bp 32P-end-labelled DNA-fragment.
Strand displacement was ascertained by the following type of experiments:
1) The 9-Acrl ligand (Figure 5), which is equipped with a 4-nitrobenzamido group to ensure cleavage of DNA upon irradiation, is expected only to cleave DNA in close proximlty to its binding site. Upon irradiation of the PNA with the above 248 bp DNA fragment, selective cleavage at the dA1o/dTlo sequence is observed (Figure 3a).
2) In a so-called photofootprinting assay, where a synthetic diazo-linked acridine under irradiation cleaves DNA
upon interaction with DNA (except where the DNA is protected by said binding substance).
Such an experiment was performed with the above 248 bp dsDNA fragment, which showed clear protection against pho-tocleavage of the PNA binding site (Figure 3b).

~:

~~9- 21-09~0 j 3) In a slmilar type of experlment, the DNA-cleavlng enzyme micrococcus nuclease, which i9 also hlnd~red in lts action by most DNA-blndlng reagents, showed lncreased cleavag~
at the T10-target (Figure 3c).
4) In yet another type of experiment, the well-known hlgh susceptibility of single strand thymine ligands (as opposed to double strand thymine ligands) towards potassium permanganate oxidation was employed. Oxidatlon of the 248 bp in the presence of the reagent showed only oxidation of the T10-strand of the target (Figure 3b).
5) In a similar type of demonstration, the single strand specificity of Sl nuclease clearly showed that only the Tlo~
strand of the target was attacked (Figure 3d).
The very efficient binding of (Taeg)10, (Taeg)10-Lys-NH2 and Acrl-(Taeg)10-Lys-NH2 (Figure 5) to the corresponding dAlo was furthermore illustrated in two ways:
1. As shown in Example 56 below PNA-oligonucleotide complexes will migrate slower than the single stranded oligonucleotide upon electrophoresis in polyacrylamide gels.
Consequently, such experiments were performed with Acrl-(Taeg)10-Lys-NH2 and 32P-end-labelled dAlo. This showed retarded migration under conditions where a normal dAlo/dTlo duplex is stable, as well as under conditions where such a duplex is unstable (denaturing gel). A control experiment was 25 performed with a mixture of Acrl-(Taeg)10-Lys-NH2 and 32P-end-labelled dTlo which showed no retardation under the above conditions.
2. Upon formation of DNA duplexes (dsDNA) from single strand DNA, the extinction coefficient decreases (hypo-chromicity). Thus, the denaturing of DNA can be followed by measuring changes in the absorbance, for example, as a function of Tm~ the temperature where 50% of a duplex has disappeared to give single strands.

:~. , ,,.. ~ , ..
,...

, ' S~
,~'' ' ' , .

~90- 2~ ~9~0'i Duplexes were formed from the slngle-stranded ollgo-deoxyribonucleotides and the PNAs listed below. Typically 0.3OD260 of the T-rich strand was hybridlzed wlth 1 equlvalent of the other strand by heating to 90 C for 5 mln, coollng to room temperature and kept for 30 min and flnally stored ln a refrigerator at 5 C for at least 30 mln. The buffers used were all 10 mM in phosphate and 1 mM in EDTA. The low salt buffer contained no sodium chloride, whereas the medium salt buffer contalned 140 mM NaCl and the hlgh salt buffer 500 mM
NaCl. The pH of all the buffers was 7.2. The meltlng temperature of the hybrids were determlned on a Gllford Response apparatus. The followlng extinction coefficients were used A: 15.4 ml/,umol-cm; T: 8.8; G: 11.7 and C: 7.3 for both normal oligonucleotldes and PNA. The meltlng curves were recorded in steps of 0.5 C/mln. The Tm were determlned from the maximum of the 1st derlvative of the plot of A260 vs temperature.

List of oligodeoxyribonucleotides:
1. 5'-AAA-AAA-AA
2. 5'-AAA-AAA-AAA-A
3. 5'-TTT-TTT-TTT-T
4. 5'-AAA-AAG-AAA-A
5. 5'-AAG-AAG-AAA-A
6. 5'-AAA-AGA-AAA-A
7. 5'-AAA-AGA-AGA-A
8. 5'-TTT-TCT-TTT-T
9. 5'-TTT-TCT-TCT-T
10. 5'-TTT-TTC-TTT-T
11. 5'-TTT-TTC-TTC-T
12. 5'-TTC-TTC-TTT-T
13. 5'-TTT-TTT-TTT-TTT-TTT
14. 5'-AAA-AAA-AAA-AAA-AAA

~';.' ~ "~" , ' ' -91- 21.~9~,0~

List of PNAs a. TTT-TTT-TTT-T-Lys-NH2 b. TTT-TTT-TT-Lys-NH2 c. TTT-TTC-TTT-T-Lys-NH2 d. TTC-TTC-TTT-T-Lys-NH2 e. Acr-TTT-TTT-TTT-T-Lys-NH2 f. Ac-TTT-TTT-TTT-T-Lys-NH2 _ . .... _ ~ ,.,. , Oligo/PNA Low Salt M~dium Salt High Salt 10 1+b 56.0 51.5 50.0 2+a 73.0 72.5 73.0 2+c 41.5 and 52.0~
, 2+e 84.5 86 0 -90 15 4+a 60.0 59.0 61.5 4+c 74.5 72.0 72.5 ~ O ~

20 E~ 55 7+~ 43.5 7+12 23.0 :' ' 13+14 39.0 * - Two distinct melting temperatures are seen, indicating local melting before complete denaturation .,. - , ~, .

--- 21 a~,o^i The hybrid formed between RNA-A (poly rA) and PNA-Tlo~
Lys-NH2 melts at such high temperature that it cannot be measured (>90 C). But specific hybridlzatlon ls demonstrated by the large drop ln A260 by mlxing with RNA-A but not G,C and U. The experiment ls done by mlxlng 1 ml of a solutlon of the PNA and 1 ml of a solution the RNA, each with A260 ~ 0.6, and then measuring the absorbance at 260 nm. Thereafter the sample is heated to 90 C for 5 min, cooled to room temperature and kept at this temperature for 30 minutes and finally stored at 5C for 30 min.

Before After After ¦
Mixing Mixing Mianidng Heating RNA-APNA-TlnlYS-NH7 O.600 O.389 O.360 ¦RNA-UPNA-Tlo-lys-NH7 O.600 O.538 O.528 ~ PNA-Tln-lys-NH~ O.G~0 0 5-0 0.5l7 I . . 1 n .~ ... ... . . .

From the above measurements the following conclusions can be made. There ls base stacking, since a melting curve is observed. The PNA-DNA hybrid is more stable than a normal DNA-DNA hybrid, and the PNA-RNA is even more stable.
Mismatches cause significant drops in the Tm-value, whether -the mispaired base is in the DNA or in the PNA-strand. The Tm-value is only slightly dependent on ionic strength, as opposed to normal oligonucleotides.

Binding of Acrl-(Taeg)10-Lys-NH2 to dAlo (Figure lla) Acrl-(Taeg)10-Lys (100 ng) was lncubated for 15 min at room temperature with 50 cps 5'-t32P]-end-labelled oligonucleotide [d(GATCCAloG)] in 20,ul TE buffer (10 mM Tris-~' },- ~
:' ,,, ,, ,,,,", ,,' ,~, ., , -93- 210~ ,0j HCl, 1 mM EDTA, pH 7.4). The sample was cooled in lce (15 min) and analyzed by gel electrophorQsls ln polyacrylamlde ( PAGE ) . To 10 ,Ul of the sample was added 2 ~1 50% glycerol, S,ul TBE (TBE ~ 90 mM Tris-borate, 1 mM EDTA, pH 8.3), and the sample was analysed by PAGE ( 15% acrylamide, 0.5%
bisacrylamide) in TBE buffer at 4C. A 10 ,ul portion of the sample was lyophilized and redissolved in lO,ul 80% formamide, 1 TBE, heated to 90C (5 min), and analyzed by urea/PAGE (lS~
acrylamide, 0.5~ bisacrylamide, 7 M urea) in TBE. [32p]_ containing DNA bands were visualized by autoradiography using intensifying screens and Agfa Curix RPI X-ray films exposed at -80C for 2 h.
Oligonucleotides were synthesized on a Biosearch 7500 DNA
synthesi~er, labelled with y[32P]-ATP(Amersham~ 5000 Ci/mmol) and polynucleotide kinase, and purified by PAGE using standard techniques (Maniatis et al. (1986): A laboratory manual, Cold Spring Harbor Laboratories).
In Figure lla and in Figure llb, the 5'-32P-labelled oligonucleotide 1 is 5'-GATCCA1oG. This was incubated ln the absence (lanes 1 and 4) or presence of Acr-T10-Lys-NH2 (in lanes 2 and 5, 25 pmol; lanes 3 and 6, 75 pmol) and also in the absence (lanes 1 to 3) or presence (lanes 4 to 6) of "oligo-2" which was 5'-GATCCT1oG. 5'-32P-labelled oligo 2 was incubated in the absence (lane 7) or presence of the same PNA
(lane 8, 25 pmol; lane 9, 75 pmol) and analysed by PAGE as described above in detail.
The results in Figure lla show retardation of the ssDNA
as it is hybridised by PNA (lanes 1 to 3) and the ability of PNA to compete with a DNA oligonucleotide, for labelled complementary oligonucleotide (lanes 4 to 6). The intensity of the band attributable to dsDNA grows faster as the PNA
concentration is raised and is replaced by a band representing the slower moving PNA-DNA hybride. Lanes 7 to 9 show that the PNA has no effect on the T1o oligo DNA with which it is non-complementary.

,~

~'~ '' -' ''' ''' ''' '. .
, , .
' ~94~ 21 ~7~~;j In Figure llb, which was run under DNA denaturing conditions the PNA-DNA duplexes remain undenatured.

Formation of strand displacement complex A dAlo-dTlo target sequence contalned wlthln a plasmld DNA sequence was constructed by cloning of two ollgonu-cleotides (d(GATCCAloG) ~ d(GATCCTloG)) lnto the ~amHI
restriction enzyme site of pUCl9 uslng the Escherlcla coll JM101 strain by standard technlques (Manlatis et al., 1986).
The desired plasmld (deslgnated pT10) was lsolated from one of the resulting clones and purlfied by the alkallne extraction procedure and CsCl centrifugatlon (Manlatis et al., 1986). A 3'-~32P]-end-labelled DNA fragment of 248 bp containing the dAlo/dTlo target sequence was obtained by cleaving the pTlO DNA with restrlction enzymes EcoRI and PvuII, labelling of the cleaved DNA with at32P]-dATP (4000 Ci/mmol, Amersham) using the Klenow fragment of E. coli DNA
polymerase (Boehringer Mannheim), and purifying the 248 bp DNA
fragment by PAGE (5~ acrylamide, 0.06~ bisacrylamide, TBE
buffer). This DNA fragment was obtained wlth t32P]-end-labelling at the 5'-end by treating the EcoRI-cleaved pTlO
plasmid with bacterial alkaline phosphatase (Boehringer Mannheim), purifying the plasmid DNA by gel electrophoresis in low melting temperature agarose, and labelling with y[32p]
ATP and polynucleotide kinase. Following treatment wlth PvuII, the 248 bp DNA fragment was purified as above.
The complex between Acrl-(Taeg)10-Lys-NH2 and the 248 bp DNA fragment was formed by incubating 50 ng of Acrl-(Taeg)10-Lys-NH2 with 500 cps 32P-labelled 248 bp fragment and 0.5 ,ug 30 calf thymus DNA in 100 ,ul 25 mM Tris-HCl, 1 mM MgC12, 0.1 mM
CaC12, pH 7.4 for 60 min at 37C as described further below.

Probing of strand displacement complex with:
(a) Staphylococcus nuclease (Figure 12b lanes 8 to 10) The strand displacement complex was formed as described above. The complex was treated with Staphylococcus nuclease ~ , ~ ,; , ,, , !

~10~,Q~

(Boehringer Mannheim) at 750 U/ml for 5 mln at 20~C and the reaction was stopped by additlon of EDTA to 25 mM. The DNA
was precipitated with 2 vols. of ethanol, 2~ potasslum acetate redissolved in 80% formamide, TBE, heated to 90~C (5 min), and analyzed by high resolution PAGE (10% acrylamide, 0.3 bisacrylamide, 7 M urea) and autoradiography. Lane 8 contains ze~o PNA, lane 9 40 pmol and lane 10 120 pmol. As the PNA is included, we see the emergence of footprint indicating increasing susceptability to digestion by Staphlococcus nuclease and hence increasing displacement of ssDNA from dsDNA.
(b) Affinity photocleavage (Figure 12a ~ 12b; lanes 1 to 3 in each case) The complex was formed in TE buffer. A sample contained in an Eppendorf tube was irradiated from above at 300 nm (Philips TL 20 W/12 fluorescent light tube, 24 Jm~ 2s~l) for 30 min. The DNA was precipitated as above, taken up in 1 M
piperidine, and heated to 90C for 20 min. Following lyophilization, the DNA was analysed by PAGE as above. Once again, in each case lane 1 contains no PNA, and lanes 2 and 3 contain 40 pmol and 120 pmol of PNA respectively. The DNA
strand bound to PNA (the Alo strand) cleaves at the location of the acridine ester (lanes 1 to 3 of Figure 12a) producing a new band (arrowed) whilst the strand displaced by PNA (the Tlo strand) cleaves randomly producing a footprint.
(c) Potassium permanganate (Figure 12b lanes 4 to 6) The complex was formed in 100 ~1 TE and 5 ,ul 20 mM KMnO4 was added. After 15 s at 20~C, the reaction was stopped by addition of 50 ~1 1.5 M sodium acetate, pH 7.0, 1 M 2-mercaptoethanol. The DNA was precipitated, treated withpiperidine and analyzed, as above. The same PNA
concentrations are used in lanes 4 to 6 as in lanes 1 to 3.
Once again, one can see the emergence of a footprint showing cleavage of displaced ssDNA by permanganate.

~' ~!, ~.' , . .
~ , ' ' .
~' ' 'i .
~; , --96- 2~a~

(d) Photofootprinting (Figure 12a lane~ 5 to 6) The complex was formed in 100 ~1 TE and diazo-linked acridine (0.1 ~g/,ul) (DHA, Niel~en et al. (1988) Nucl. Acids Res. 16, 3877-88) was added. The sample was lrradlated at 365 nm (Philips TL 20 W/09N, 22 Jm~2s~l) for 30 min and treated as described for "affinity photocleavage". In the presence of PNA, (lane 6) the DNA is protected and bands corresponding to cleavage in the protected region disappear.
(e) S1-nuclease (Figure 12c lane~ 1 to 3) The complex was formed in 50 mM sodium acetate, 200 mM
NaCl, 0.5~ glycerol, 1 mM ZnCl2, pH 4.5 and treated with nuclease Sl (Boehringer Mannheim) at 0.5 U/ml for 5 min at 20C. The reaction was stopped and treated further as described under "Staphylococcus nuclease". The quantity of 15 PNA used was zero (lanes 1 to 3) or 120 pmol (lanes 4 to 6) lane 7 shows size standards. Once again, cleavage of the T1o DNA strand displaced by PNA is seen.

Sensitivity of hYbridisation to (1) orientation (2) pH and (3) se~uence mismatch The PNA-oligomer H-T4C2TCTC-LysNH2 was prepared by Synthetic Protocol 6, purified by reverse phase HPLC, and identified by FAB-mass spectrometry; found(calc.) 2746.8 (2447.15~. Hybridization experiments wlth this sequence resolve the issue of orientation, since it is truly asymmetrical. Such experiments also resolve the issues of pH-dependency of the Tm, and the stoichiometry of complexes formed.
Hybridization experiments with the PNA-oligomer H-T4C2TCTC-LysNH2 were performed as follows:

-97- 21 ~0~

Row H~bridized with p~l Tm 1 5'-(dA)4(dG)2(dA)(dG)(dA)(dG) 7.2 55.5 2:1 2 5'-(dA)4(dG)2(dA)(dG)(dA)(dG) 9 0 26.0 2:1 3 5'-(dA)4(dG)2(dA)(dG)(dA)(dG) 5.0 88.5 2:1 4 5'-(dG)(dA)(dG)(dA)(dG)2(dA)4 7.2 38.0 2:1 5 5'-(dG)(dA)(dG)(dA)(dG)2(dA)4 9.0 31.5 6 5'-(dG)(dA)(dG)(dA)(dG)2(dA)4 5.0 52.5 61.0 7 5'-(dA)4(dG)(dT)(dA)(dG)(dA)(dG) 7.2 39.0 8 5'-(dA)4(dG)(dT)(dA)(dG)(dA)(dG) 9.0 <20 9 5'-(dA)4(dG)(dT)(dA)(dG)(dA)(dG) 5.0 51.5 lO 5'-(dA)4(dG)2(dT)(dG)(dA)(dG) 7.2 31.5 11 5'-(dA)4(dG)2(dT)(dG)(dA)(dG) 5.0 50.5 12 5'-(dG)(dA)(dG)(dA)(dT)(dG)(dA)4 7.2 24.5 13 5'-(dG)(dA)(dG)(dA)(dT)(dG)(dA)4 9.0 <20 14 5'-(dG)(dA)(dG)(dA)(dT)(dG)(dA)4 5.0 57.0 15 5'-(dG)(dA)(dG)(dT)(dG)2(dA)4 7.2 25.0 16 5'-(dG)(dA)(dG)(dT)(dG)2(dA)4 5.0 39.5 52.0 = stoichiometry determined by W-mixing curves - = not determined These results show that a truly mixed sequence gave rise to well defined melting curves. The PNA-oligomers can actually bind in both orientations (compare row 1 and 4), although there is preference for the N-terminal/5'-orientation. Introducing a single mismatch opposite eitherT or C caused a lowering of Tm by more than 16C at pH 7.2;
at pH 5.0 the Tm-value was lowered more than 27C. This shows that there is a very high degree a sequence-selectivity.
As indicated above, there is a very strong pH-dependency for the Tm-value, indicating that Hoogsteen basepairing is important for the formation of hybrids. Therefore, lt is not .. - . .

-98- 2l 09~';j surprising that the stoichiometry was found to be 2:1.
The lack of symmetry ln the sequence and the very large lowering of Tm when mismatches are pr~sent show that the Watson-Crick strand and the Hoogsteen strand are parallel when bound to complementary DNA. Thls 19 true for both of the orientations, ~.e., 5'/N-termlnal and 3'/N-terminal.

Sequence discrimination in hYbridisation The results of hybridization experiments with H-T5GT4-LysNH2 to the deoxyoligonucleotides shown below were asfollows:

Row Deoxyoligonucleotide Tm 1 5'-(dA)5(dA)(dA)4-3' 55.0 2 5'-(dA)5(dG)(dA)4-3' 47.0 3 5'-(dA)5(dC)(dA)4-3' 56.5 4 5'-(dA)5(dT)(dA)4-3' 46.5 5'-(dA)4(dG)(dA)5-3' 48.5 6 5'-(dA)4(dC)(dA)5-3' 55.5 7 5'-(dA)4(dT)(dA)5-3' 47.0 As shown by comparing rows 1, 3, and 6 with rows 2, 4, 5, and 7, G can in this mode discriminate between C/A and G/T
in the DNA-strand, ~.e., sequence discrimination is observed.
The complex in row 3 was furthermore determined to be 2 PNA:
1 DNA complex by W-mixing curves.

"

, . '"

9 9 2 1 ~ , O ) Sequence _specificity in hybridisation us~nq a modified backbone Hybridization data for a PNA-oligomer wlth a slngle unlt with an extended backbone (the ~-alanlne modification) i~ as follows:

PNA DNA Tm 10 H-Tlo~LysNH2 (dA)lo 73C

H-T4(~T)T5-LysNH2 (dA)10 57C

H-T4(~T)T5-LysNH2 (dA)4(dG)(dA)5 47C
H-T4(~T)T5-LysNH2 (dA)4(dC)(dA)s 49C

H-T4(~T)T5-LySNH2 (dA)4(dT)(dA)5 47C

Although the melting temperature decreaseQ, the data demonstrates that base specific recognltlon ls retalned.

Iodination Procedure - Radiolabelling A 5 ~g portion of Tyr-PNA-T10-Lys-NH2 is dissolved in 40 ,ul 100 mM Na-phosphate, pH 7.0, and 1 mCi Nal25I and 2 ~1 chloramine-T (50 mM in CH3CN) are added. The solution is left at 20C for 10 min and then passed through a 0.5 + 5 cm Sephadex G10 column. The first 2 fractions (100 ,ul each) containing radioactivity are collected and purified by HPLC:
reversed phase C-18 using a 0-60% CH3CN gradient in 0.1 CF3COOH in H20. The 125I-PNA elutes right after the PNA peak.
The solvent is removed under reduced pressure.

,';'~
:., fA: ~ ' -loo- 2l~i`0 ) Binding of PNA~-Tlo/T9C/T8C2 to double ~tranded DN~ target~
Alo/AgG/A8G2 (Figure 20).
A mixture of 200 cps double stranded 32P-labeled EcoRI-S PvuII fragment (the large fragment labeled at the 3'-end of the EcoRI site) of the indlcated plasmld, 0.5 ~g carrler calf thymus DNA, and 300 ng the indlcated PNA ln 100 ~l buffer (200 mM NaCl, 50 mM Na-acetate, pH 4.5, 1 mM ZnS04) was incubated at 37C for 120 min. 50 units of nuclease S1 were added and incubated at 20C for 5 min. The reaction was stopped by addition of 3 ~l 0.5 M EDTA and the DNA was precipitated by addition of 250 ~1 2% potassium acetate ln ethanol. The DNA
was analyzed by electrophoresis in 10% polyacrylamide sequencing gels and the radiolabelled DNA bands visualized by autoradiography. The complete band patterns produced show the production by strand displacement of single stranded DNA which is attacked by the nuclease to produce a mixture of shorter oligonucleotides. Comparlson of the results for the three PNA's used in each case shows the selectivity for each target which is obtained.
The target plasmid were prepared by cloning of the appropriate oligonucleotides into pUCl9. Target Alo: oligo-nucleotides GATCCAloG & GATCCTloG cloned into the BamHI site (plasmid designated pT10). Target A5GA4: oligonucleotides TCGACT4CT5G & TCGACA5GA4G cloned imto the SalI site (plasmid pT9C). Target A2GA2GA4: oligonucleotides GA2GA2GA4TGCA &
GT~CT2CT2CTGCA into the PstI sit~ (plasmid pT8C2). The positions of the targets in the gel are indicated by bars to the left. A/G is an A+G sequence ladder of target PlO.

~nhibition of restriction enzyme cleavage by PNA (Figure 23).
A 2 ~g portion of plasmid pT10 wa~ mixed with the indicated amount of PNA-Tlo in 20 ~l TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.4) and incubated at 37C for 120 min. 2 ~1 10 x concentrated buffer (10 mM Tris-HCl, p~ 7.5, 10 mM, MgCl2, 50 mM NaCl, 1 mM DTT) and PvuII (2 units) and ~amHI

: :' '' .. ' . ' ' ..
.
~,',, ~ ' "; '"' ' "' ~x . ' , ' , ' .
.- , . . .

-101- 2lO9¢.Q i (2 units) were added and the incubation was contlnued for 60 min. The DNA was analyzed by gel electrophoresls ln 5~
polyacrylamide and the DNA was visuallzed by ethldium bromlde staining.
In the presence of a signlflcant proportlon of PNA (0.2, 0.6), the cleavage pattern of enzyme ~am HI was changed indicating that the enzyme was inhibited by the presence of PNA alongside the cleavage site.

~inetics of PNA-T1o - dsDNA strand displacement complex formation (Figure 21).
A mixture of 200 cps double stranded 32P-labeled EcoRI-PvuII fragment of pT10 (the large fragment labeled at the 3'-end of the EcoRI site), 0.5 ~g carrier calf thymus DNA, and 300 ng of PNA-Tlo~LysNH2 in 100 ,ul buffer (200 mM NaCl, 50 mM
Na-acetate, pH 4.5, 1 mM ZnS04) were incubated at 37C. At the times indicated, 50 U of S1 nuclease was added to each of 7 samples and incubation was continued for 5 mln at 20C. Any single stranded DNA produced by strand displacement is digested by the nuclease. The DNA was then precipitated by addition of 250 ,ul 2% potassium acetate in ethanol and analyzed by electrophoresis in a 10~ polyacrylamide sequencing gel. The amount of strand displacement complex was calculated in arbritary units from the intensity of the S1-cleavage at the target sequence, as measured by densitometric scanning of autoradiographs. The formation of the complex over time can be seen.

Stability of PNA-dsDNA complexes (Figure 22).
A mixture of 200 cps 32P-pT10 fragment (as in Example 65), 0.5 ~g calf thymus DNA and 300 ng of the desired PNA
(either Tlo~LysNH2, T8-LysNH2 or T6-LysNH2) was i 100 ,ul 200 mM NaCl, 50 mM Na-acetate, pH 4.5, 1 mM ZnS04 for 60 min at 37C. A 2 ,ug portion of oligonucleotide GATCCAloG
was added to compete wi-th the PNA for the labelled oligonucleotide and each sample was heated for 10 min at the . , : .
; ~ ' " ' "' . . ' j~' '' ', ' '' '' ' ' , , ,''' ;' ' -102~ J

temperature indicated, cooled in ice for 10 min and warmed to 20C. 50 U of S1 nuclease was added and the quantlty of radio-activity liberated as single nucleotldes wa~ measured.
The expected Tm values for a Tlo DNA duplex would be 20C, for T8 ~ 16C, and for T6 ~ 12C. The corresponding PNA/DNA values are shown to be T1o > 70C, T8 ~ 60C, and Eor T6 ~ 37C.

Immobilisation of pNA
For the preparation of PNA-Sepharose 10 mg of cyanogen bromide activated Sepharose (Sigma) was lncubated with lO~g PNA in 100 ~1 50 mM Na-phosphate, pH 7.5 for 60 min at 37C.
The Sepharose was isolated by centrifugatlon and washed three times with 250 ,ul 50 mM Na-phosphate, pH 7.5.
~XAMPLE 68 Binding of 5'-32P-endlabeled oligonucleotide to PNA-SePharose 1 mg PNA -Sepharose (Example 67) in 100 ,ul TE was incubated with 50 cps (-100 ng) 32P-labeled oligonucleotide for 16 hr at 20C. The Sepharose was isolated by centrifugation and washed two times with 500 ,ul TE. Pound oligonucleotide was determined by liquid scintillation counting using the "Cerenkov" method. Results are shown in the Table below Eor three different PNA-Sepharose and four oligo-DNA's. The specificity of the capture by the immobilised PNA's is clearly seen, only one base pair mismatch being tolerated.

~ ' '""' ~ ' ,''.

-103- 2 ~ O;i ~ . . . . ............. . .. ._ I
% Binding of 32P-oliqo to PNA-Sepharose P~A on solid support (CNBr-Sepharose) T10 T9C T8C2 none 5 ¦ DNA
¦ A10 51 45 15 8 ¦ A9GIl 50 _ 52 8 I
l mix 11 13 14 15 In the table A10 is 5'-GATCC~AAAAAAAAAG,A9G is 5'-TCGACAAAAAGAAAAG, A8G2 is 5'-GAAGAAGAAACTGAC & mix is 5'-GATCACGCGTATACGCGT. The PNAs are: T10: H-TloLysNH2, T9C: H-T5CT4-LysNH2, T8C2: H-T2CT2CT4-LysNH2, none:ethanolamine.
EXAMPLE 69 (Figure 25a, b & c) Tem~erature dependence of stability of 32P-oligonucleotide-bi~ding to PNA-Sepharose Oligonucleotides were bound to PNA-Sepharose as described in Examples 67 and 68. In each case, the 32p_ oligonucleotide-PNA-Sepharose was subsequently washed at increasing temperatures. The Sepharose was lsolated by centrifugation, the radioactivity determined by "Cerenkov"
counting, and the Sepharose was again taken up in 500 ,ul TE, incubated at the next desired temperature, centrifuged etc.
The figure shows the results normalised to initial binding.
The oligonucleotide and PNA-Sepharose were as described in the Table of Example 68. The shifts between the curves show the lowered stability of the oligonucleotide binding when one mismatch is present.

Inhibition of TranQcription by PNA (Figure 26) A mixture of 100 ng plasmid DNA (cleaved with restriction enzyme PvuII (see below) and 100 ng of PNA in 15 ~ .`: ' - '. ' . . ' ! . ' ~;':, ' ~. '` ` .

` , - , '' .,,"~

-104- 2~ 3 ,ul 10 mM Tris-HCl, 1 mM EDTA, pH 7.4 was incubated at 37C for 60 min. Subsequently, ~ ~1 5 x concentrated buffer (0.2 M
Tris-HCl (pH 8.0), 40 mM MgC12, 10 mM spermldlne, 125 mM NaCl) were mixed with 1 ~1 NTP-mlx (10 mM ATP, 10 mM CTP, 10 mM GTP, 1 mM UTP, O. 1 ~Ci/~l 32P-UTP, 5 mM DTT, 2 ~g/ml tRNA, 1 ~g/ml heparin) and 3 units RNA polymerase. Incubatlon was contlnued for 10 min at 37C. The RNA was then precipitated by addltlon of 60 ul 2% potassium acetate in 96% ethanol at -20C and analyzed by electrophoresis in 8~ polyacrylamide sequenclng gels. RNA transcripts were visualized by autoradiography.
The plasmid used was: Lane 1 to 5; pAlOKS tthe Alo target is positioned on the transcribed strand). Lane 6 to 1~: pTlOKS
(the Alo target is positioned on the non-transcribed strand).
The plasmid was treated with the following restriction enzymes prior to the experiment: Lanes 1, 4, 6 and 9: PvuII, lanes 2, 5, 7 and 10: Xha I; lanes 3 and 8: BamHI. The samples of lanes 4, 5, 9 and 10 contained PNA, while the rest did not.
It can be seen from the gel that when PNA Tlo is bound to the transcribed strand of the plasmid, transcription of RNA is arrested at the PNA binding site. If the PNA is bound to the non-transcribed strand of the plasmid, transcription is not arrested.

Affinity PNA - Sepharose (Figure 27) 1 mg of PNA-Tlo Sepharose (see Example 67) in 100 ,ul TE
was incubated with ~ 50 cps of the following 32p_5._ endlabelled oligonucleotides:
1: 5'-GAT CCG GCA AAT CGG CAA TAC GGC ATA ACG GCT AAA
CGG CTT TAC GGC TTA TCG GCT ATT CGG CAT TTC GGC
AAT TCG, 2: 5'-GAT CCG GCT TAA CGG CAA TTC GCT TAT ACG GCA TAT
CGG CTA ATC GGC ATT ACG GCT TTT CGG G, 3: 5'-GAC AAA CAT ACA ATT TCA ACA GAA CCA AAA AAA AAA
AAA A, 4: 5'-ACT GAC TAC CTA GGT TTA CCG TGC CAG TCA, 5: 5'-GAA ACG GAT AGC TGC A

~.''~ ~' , ''',., . ', . ,,~
r.
.
:
~" ,' .

~105~ 9~0 ~

for 16 hrs at 20C. The Sepharose was lsolated by centrifuga-tion and washed 3 times wlth TE. Ollgonucleotldes were subsequently washed off wlth 500 ~l TE at increaslng temperatures, precipitated with 1 ml ethanol, 2% potas~lum acetate and analysed by electrophoresl~ ln 20~ polyacrylamlde, 7 M urea gel run in TBE buffer and detected by autoradlography (-70C, 16 hrs. intensifying screen). The results are shown in Figure 26. The lanes are as follows:-Lane l: oligonucleotides not bound to the Sephadex;
Lane 2: oligonucleotides washed off at 40C;
Lane 3: oligonucleotides washed off at 60C;
Lane 4: oligonucleotides washed off at 80C.
Only plasmid 3 is complementary to the PNA. It can beseen that by washing at up to 80C essentially only the complementary plasmid is retained on the PNA-Sepharose. This example illustrates the extraction of an oligonucleotide from a mixture thereof by affinity capture using PNA.

Quantitative assay of a DNA sequence in a ds plasmid by pNA-strand displacement 3 ,ug plasmid DNA digested by the respective restriction enzymes indicated below in 10 ,ul 50 mM Tris-HC1, 1 mM EDTA, pH 7.4 was incubated with 5000 cpm (~ 10 ng) 125I-PNA-T10-Tyr and the quantity of cold PNA T1OTyr indicated by the total PNA
amounts given below for 60 mins at 37C. The DNA was precipitated with 25 ,ul ethanol, 2% potassium acetate, and subsequently analysed by electrophoresis in 6% polyacrylamide in TBE buffer. The gel was stained with ethidium bromide and subsequently subject to autoradiography (-70C, 16 hrs intensifying screen). The results are seen in Figure 28. "A"
is the ethidium stained gel and "b" is the corresponding autoradiogram. The plasmids used were:
Lanes 1 to 3: pTlo + HaeIII;
Lanes 4 to 6: pTlo x Hinfl;
35Lanes 7 to 9: pT1o x PvuII.

,j,. . .

~ .

-106- 2~0~l~)o ~

The total amount of PNA-T10-Tyr in each sample was:
Lanes l, 4 and 7: -10 ng;
Lanes 2, 5 and 8: 25 ng;
Lanes 3, 6 and 9: 250 ng.
The ethidium bromide gel (a) showg the size of the DNA
fragments produced (including DNA-PNA hybrids). The autoradograph (b) shows which band ln gel (a) contains PNA.
The presence of a strand displacement complex can be seen in lane 1 as can the effect on the intensity of this band of increasing the proportion of cold PNA in lanes 2 and 3.
Similar results are seen for each of the other two plasmids in lanes 4 to 6 and 7 to 9. The location of the PNA-DNA band in each case can be used to identify the plasmid and the based intensity can be used to quantitate the amount of plasmid present.
Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

"jj,,~ ""~ ~ ~" ~ j " ~o j ~ ,W.^ ~ <- ~'d'`'` ' '

Claims (26)

1. A nucleic acid analogue for use in the capture, recognition, detection, identification or quantitation of one or more chemical or microbiological entities, which analogue is (a) a peptide nucleic acid (PNA) comprising a polyamide backbone bearing a plurality of ligands at respective spaced locations along said backbone, said ligands being each independently naturally occurring nucleobases, non-naturally occurring nucleobases or nucleobase-binding groups, each said ligand being bound directly or indirectly to a nitrogen atom in said backbone, and said ligand bearing nitrogen atoms mainly being separated from one another in said backbone by from 4 to 8 intervening atoms;
(b) a nucleic acid analogue capable of hybridising to a nucleic acid of complementary sequence to form a hybrid which is more stable against denaturation by heat than a hybrid between the conventional deoxyribonucleotide corresponding to said analogue and said nucleic acid; or (c) a nucleic acid analogue capable of hybridising to a double stranded nucleic acid in which one strand has a sequence complementary to said analogue, so as to displace the other strand from said one strand.
2. A nucleic acid analogue as claimed in Claim 1, having the general formula:

wherein:

n is at least 2, each of L1-Ln is independently selected from -the group consisting of hydrogen, hydroxy, (C1-C4)alkanoyl, naturally occurring nucleobases, non-naturally occurring nucleobases, aromatic moieties, DNA intercalators, nucleobase-binding groups and reporter ligands, at least one of L1-Ln being a naturally occurring nucleobase, a non-naturally occurring nucleobase, a DNA intercalator, or a nucleobase-binding group;
each of A1-An is a single bond, a methylene group or a group of formula:

or where:
X is O, S, Se, NR3, CH2 or C(CH3)2;
Y is a single bond, O, S or NR4;
each of p and q is an integer from 1 to 5, the sum p+q being not more than 10;
each of r and s is zero or an integer from 1 to 5, the sum r+s being not more than 10;
each R1 and R2 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl which may be hydroxy- or alkoxy- or alkylthio-substituted, hydroxy, alkoxy, alkylthio, amino and halogen; and each R3 and R4 is independently selected from the group consisting of hydrogen, (C1-C4)alkyl, hydroxy- or alkoxy- or alkylthio-substituted (C1-C4)alkyl, hydroxy, alkoxy, alkylthio and amino;
each of B1-Bn is N or R3N+, where R3 is as defined above;

each of C1-Cn is CR6R7, CHR6CHR7 or CR6R7CH2, where R6 is hydrogen and R7 is selected from the group consisting of the side chains of naturally occurring alpha amino acids, or R6 and R7 are independently selected from the group consisting of hydrogen, (C2-C6)alkyl, aryl, aralkyl, heteroaryl, hydroxy, (C1-C6)alkoxy, (C1-C6)alkylthio, NR3R4 and SR5, where R3 and R4 are as defined above, and R5 is hydrogen, (C1-C6)alkyl, hydroxy-, alkoxy-, or alkylthio- substituted (C1-C6)alkyl, or R6 and R7 taken together complete an alicyclic or heterocyclic system;
each of D1-Dn is CR6R7, CH2CR6R7 or CHR6CHR7, where R6 and R7 are as defined above;
each of G1-Gn-1 is -CONR3-, -CSNR3-, -SONR3- or -SO2NR3-, in either orientation, where R3 is as defined above;
Q is -CO2H, -CONR'R'', -SO3H or -SO2NR'R'' or an activated derivative of -CO2H or -SO3H; and I is -NHR'''R'''' or -NR'''C(O)R'''', where R', R", R''' and R'''' are independently selected from the group consisting of hydrogen, alkyl, amino protecting groups, reporter ligands, intercalators, chelators, peptides, proteins, carbohydrates, lipids, steroids, oligonucleotides and soluble and non-soluble polymers.
3. A nucleic acid analogue as claimed in Claim 2, having the general formula:

wherein:
each L is independently selected from the group consisting of hydrogen, phenyl, naturally occurring nucleobases, and non-naturally occurring nucleobases;
each R7 is independently selected from the group consisting of hydrogen and the side chains of naturally occurring alpha amino acids;
n is an integer from 1 to 60, each k and m is, independently, zero or one; and each 1 is independently from zero to 5;
Rh is OH, NH2 or -NHLysNH2; and Ri is H or COCH3.
4. A nucleic acid analogue as claimed in Claim 3, having the general formula:

wherein:
each L is independently selected from the group consisting of the nucleobases thymine, adenine, cytosine, guanine, and uracil;
each R7 is hydrogen; and n is an integer from 1 to 30.
5. A nucleic acid analogue as claimed in any one of Claims 1 to 4, incorporating or conjugated to a detectable label.
6. A labelled nucleic acid analogue as claimed in Claim 5, wherein said label is a radio isotope label, an enzyme label, biotin, a fluorophore, a chemilumlnescence label, an antigen, an antibody or a spin label.
7. The use of nucleic acid analogue as defined in any one of Claims 1 to 6 in the capture, recognition, detection, identification or quantitation of one or more chemical or microbiological entities.
8. A method of capturing a nucleic acid comprising contacting under hybridising conditions said nucleic acid with a nucleic acid analogue as claimed in any one of Claims 1 to 6 immobilised to a solid support, which nucleic acid analogue has a sequence of ligands suitable to hybridise to said nucleic acid.
9. A method as claimed in Claim 8, wherein said captured nucleic acid is detected, recognised, quantitated or identified by treatment with a nucleic acid recognition agent whilst bound to said immobilised nucleic acid analogue.
10. A method as claimed in Claim 9, wherein the captured nucleic acid has a first region hybridised to said immobilised nucleic acid analogue and a second region which is not so hybridised and is treated with a labelled nucleic acid or nucleic acid analogue which is adapted to hybridise to at least part of said second region and said label is detected.
11. A method as claimed in Claim 8, for capturing a mRNA
wherein said immobilised nucleic acid analogue comprises sequential ligands hybridisable to poly A tails of said mRNA
to capture said mRNA.
12. A method as claimed in Claim 11, wherein said sequential ligands are thymine.
13. A method as claimed in any one of Claims 8 or 11 or 12, wherein said nucleic acid once captured is released from said immobilised nucleic acid analogue by subjecting the immobilised nucleic acid analogue and captured nucleic acid to dehybridising conditions.
14. A nucleic acid analogue as claimed in any one of Claims 1 to 6, immobilised to a solid support.
15. An immobilised nucleic acid analogue as claimed in Claim 14, incorporated in an affinity capture column.
16. A method of recognition, detection or quantitation of a target nucleic acid comprising hybridising said target to a labelled nucleic acid analogue as claimed in Claim 5 or Claim 6 of sufficiently complementary sequence to hybridise therewith under hybridising conditions and detecting or quantitating said label of the nucleic acid analogue 50 hybridised to said target.
17. A method as claimed in Claim 16, wherein said target nucleic acid is immobilised on a substrate prior to said hybridisation.
18. A method as claimed in Claim 17, wherein said target nucleic acid is immobilised to said substrate by the hybridisation of a first region thereof to a capture nucleic acid or nucleic acid analogue having a sequence sufficiently complementary to said first region to hybridise therewith and which is itself immobilised to said substrate and wherein said labelled nucleic acid analogue hybridises to a second region of said target.
19. A method for displacing one strand from a nucleic acid duplex comprising hybridising to said duplex a nucleic acid analogue having an affinity for the other strand of said duplex sufficient to be able to displace said one strand therefrom.
20. A method of detecting, identifying or quantitating a double stranded target nucleic acid comprising hybridising thereto a displacing nucleic acid analogue capable of displacing one strand from a double stranded target in which the other strand is of complementary sequence to said displacing nucleic acid analogue, wherein said displacing nucleic acid analogue is of sufficiently complementary sequence to said other strand of said double stranded target to hybridise thereto so as to displace said one strand of said target in single stranded form, and detecting or quantitating the presence of said one displaced strand.
21. A method as claimed in Claim 20, wherein the displaced strand is broken down into fragments and the presence of said fragments is detected.
22. A method as claimed in Claim 21, wherein said displaced strand is broken down by attack by a nuclease.
23. A kit for use in a diagnostics procedure and comprising at least one labelled nucleic acid analogue as claimed in Claim 5 or Claim 6, and at least one detection reagent for detecting said labelled nucleic acid analogue.
24. A kit as claimed in Claim 23, further including a nucleic acid analogue as claimed in any one of Claims 1 to 4 immobilised on a solid support.
25. A kit comprising an immobilised nucleic acid analogue as claimed in any one of Claims 1 to 4, in combination with at least one nucleic acid recognition agent for detecting the presence of nucleic acid captured in use by said nucleic acid analogue.
26. A kit as claimed in Claim 25, wherein said nucleic acid recognition agent is a labelled nucleic acid or a labelled nucleic acid analogue.
CA002109805A 1991-05-24 1992-05-22 The use of nucleic acid analogues in diagnostics and analytical procedures Abandoned CA2109805A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DK0987/91 1991-05-24
DK98691A DK98691D0 (en) 1991-05-24 1991-05-24 OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
DK98791A DK98791D0 (en) 1991-05-24 1991-05-24 PROCEDURE FOR SEQUENCE-SPECIFIC RECOGNITION OF A DOUBLE-STRENGTH POLYNUCLEOTIDE
DK0986/91 1991-05-24
DK0510/92 1992-04-15
DK92510A DK51092D0 (en) 1991-05-24 1992-04-15 OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF

Publications (1)

Publication Number Publication Date
CA2109805A1 true CA2109805A1 (en) 1992-11-26

Family

ID=27220741

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002109320A Expired - Lifetime CA2109320C (en) 1991-05-24 1992-05-22 Peptide nucleic acids
CA002109805A Abandoned CA2109805A1 (en) 1991-05-24 1992-05-22 The use of nucleic acid analogues in diagnostics and analytical procedures

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002109320A Expired - Lifetime CA2109320C (en) 1991-05-24 1992-05-22 Peptide nucleic acids

Country Status (16)

Country Link
US (11) US6395474B1 (en)
EP (5) EP1411063B1 (en)
JP (6) JP2758988B2 (en)
KR (1) KR0133131B1 (en)
AT (3) ATE205504T1 (en)
AU (2) AU666480B2 (en)
BR (1) BR9206049A (en)
CA (2) CA2109320C (en)
DE (2) DE69232055T2 (en)
DK (3) DK51092D0 (en)
ES (2) ES2164052T3 (en)
FI (1) FI118424B (en)
GR (1) GR3025018T3 (en)
HU (1) HU221003B1 (en)
NO (2) NO312516B1 (en)
WO (2) WO1992020703A1 (en)

Families Citing this family (359)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852182A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals Inc. Thiol-derivatized oligonucleosides
US5783682A (en) * 1990-07-27 1998-07-21 Isis Pharmaceuticals, Inc. Oligonucleotide mimics having nitrogen-containing linkages
US6414112B1 (en) 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
US5641625A (en) * 1992-05-22 1997-06-24 Isis Pharmaceuticals, Inc. Cleaving double-stranded DNA with peptide nucleic acids
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6451968B1 (en) 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US5766855A (en) * 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
US6713602B1 (en) * 1991-05-24 2004-03-30 Ole Buchardt Synthetic procedures for peptide nucleic acids
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US6441130B1 (en) 1991-05-24 2002-08-27 Isis Pharmaceuticals, Inc. Linked peptide nucleic acids
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
WO1993012135A1 (en) 1991-12-12 1993-06-24 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
MX9207334A (en) * 1991-12-18 1993-08-01 Glaxo Inc NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
EP1044987B1 (en) * 1991-12-24 2006-02-15 Isis Pharmaceuticals, Inc. Gapped 2'-modified oligonucleotides
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6033884A (en) * 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
US6770738B1 (en) 1992-05-22 2004-08-03 Isis Pharmaceuticals, Inc. Higher order structure and binding of peptide nucleic acids
GB9211979D0 (en) * 1992-06-05 1992-07-15 Buchard Ole Uses of nucleic acid analogues
US7825215B1 (en) 1993-04-26 2010-11-02 Peter E. Nielsen Substituted nucleic acid mimics
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
GB9311386D0 (en) * 1993-06-02 1993-07-21 Pna Diagnostics As Nucleic acid analogue assay procedures
WO1994028720A1 (en) * 1993-06-11 1994-12-22 Isis Pharmaceuticals, Inc. Oligomers for modulating ras oncogene
WO1995004748A1 (en) * 1993-08-09 1995-02-16 Isis Pharmaceuticals, Inc. Oligomers for modulating viral processes
US5527675A (en) * 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (en) * 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
DE4331011A1 (en) * 1993-09-13 1995-03-16 Bayer Ag C-branched oligomers that bind nucleic acids for therapy and diagnostics
EP0720615B1 (en) * 1993-09-21 2000-07-26 Amersham Pharmacia Biotech UK Limited Elongation, amplification and sequence determination using a chimeric oligonucleotide
WO1998003542A1 (en) * 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6710164B1 (en) * 1993-11-22 2004-03-23 Peter E. Nielsen Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
GB2284209A (en) 1993-11-25 1995-05-31 Ole Buchardt Nucleic acid analogue-induced transcription of RNA from a double-stranded DNA template
GB2284208A (en) * 1993-11-25 1995-05-31 Pna Diagnostics As Nucleic acid analogues with a chelating functionality for metal ions
GB2285445A (en) * 1993-12-06 1995-07-12 Pna Diagnostics As Protecting nucleic acids and methods of analysis
GB2289677A (en) * 1993-12-06 1995-11-29 Pna Diagnostics As Labelling of nucleic acid analogue-peptide chimerae
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DE69430704T2 (en) * 1993-12-22 2003-01-30 Perseptive Biosystems Inc GUANINE SYNTHONES FOR THE SYNTHESIS OF NUCLEIC ACIDS AND METHOD FOR THE PRODUCTION THEREOF
DK145493D0 (en) * 1993-12-23 1993-12-23 Dako As ANTIBODY
US5539083A (en) * 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
DE4408531A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag PNA synthesis using an amino protecting group labile to weak acids
DE4408533A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag PNA synthesis using a base-labile amino protecting group
DE4408528A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag Peptide oligonucleotide derivatives, their preparation and use
DE4408534A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag Substituted N-ethyl-glycine derivatives for the production of PNA and PNA / DNA hybrids
US6919441B2 (en) 1994-03-14 2005-07-19 Aventis Pharma Deutschland Gmbh Polyamide-oligonucleotide derivatives, their preparation and use
WO1995029921A1 (en) * 1994-04-29 1995-11-09 Perseptive Biosystems, Inc. Activated esters of 1-phenylpyrazolin-5-one for labelling amine-functionalized molecules
JPH10500310A (en) 1994-05-19 1998-01-13 ダコ アクティーゼルスカブ PNA probes for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis
US5629152A (en) * 1994-08-01 1997-05-13 Isis Pharmaceuticals, Inc. Trisubstituted β-lactams and oligo β-lactamamides
DE4427980A1 (en) * 1994-08-08 1996-02-15 Bayer Ag Nucleic acid binding oligomers for therapy and diagnostics
US6558633B1 (en) 1994-09-21 2003-05-06 Isis Pharmaceuticals, Inc. Chemical reaction apparatus and methods
JP3307945B2 (en) * 1994-10-06 2002-07-29 アイシス・ファーマシューティカルス・インコーポレーテッド Peptide nucleic acid conjugate
US5629178A (en) * 1994-10-28 1997-05-13 Genetics & Ivf Institute Method for enhancing amplification in the polymerase chain reaction employing peptide nucleic acid (PNA)
UA48150C2 (en) * 1994-11-02 2002-08-15 Ай-Сі-Ен Фармасьютикалз Amino acid or amino alcohol derivatives, oligonucleotide
AU4159396A (en) * 1994-11-14 1996-06-06 Chiron Corporation Synthesis of peptide nucleic acids (pnas) and analogues via submonomer approach
CA2207629A1 (en) * 1994-12-22 1996-06-27 Abbott Laboratories Methods of immobilizing oligonucleotides to solid support materials and methods of using support bound oligonucleotides
US6475721B2 (en) * 1995-03-04 2002-11-05 Boston Probes, Inc. Sequence specific detection of nucleic acids using a solid carrier bound with nucleic acid analog probes
ES2157426T3 (en) * 1995-03-04 2001-08-16 Pna Diagnostics As MODULATION OF THE UNION PROPERTIES OF UNION COPARTICIPES OF A NUCLEIC ACID.
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
CA2223088A1 (en) 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
EP0840741B1 (en) * 1995-06-07 2004-04-28 Perseptive Biosystems, Inc. Pna-dna chimeras and pna synthons for their preparation
AU4327296A (en) * 1995-06-22 1996-05-15 Dako A/S Recombinant antibody capable of binding to pna/nucleic acid complexes
EP0840751A1 (en) * 1995-06-22 1998-05-13 Dako A/S Monoclonal antibody capable of binding to pna/nucleic acid complexes
GB9519299D0 (en) * 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy
JPH11512617A (en) * 1995-10-06 1999-11-02 パーセプテイブ・バイオシステムズ・インコーポレイテツド Method, apparatus and kit for hybridization analysis using peptide nucleic acid probe
EP1477572A3 (en) * 1995-10-06 2006-02-15 Perseptive Biosystems, Inc. Methods and kit for hybridization analysis using peptide nucleic acid probes
DE69637086T2 (en) 1995-10-12 2008-01-10 Lansdorp, Peter M., Vancouver METHOD FOR DETECTING MULTIPLE COPIES OF A REPEAT SEQUENCE IN A NUCLEIC ACID MOLECULE
US6001966A (en) * 1995-10-19 1999-12-14 Proligo Llc Method for solution phase synthesis of oligonucleotides and peptides
US5874532A (en) 1997-01-08 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for solution phase synthesis of oligonucleotides and peptides
WO1997014793A1 (en) * 1995-10-20 1997-04-24 Trustees Of Boston University Nucleic acid clamps
US5888733A (en) * 1995-11-16 1999-03-30 Dako A/S In situ hybridization to detect specific nucleic acid sequences in eucaryotic samples
WO1997018325A1 (en) * 1995-11-16 1997-05-22 Dako A/S In situ hybridization to detect specific nucleic acid sequences in eucaryotic samples
CA2190430A1 (en) * 1995-12-12 1997-06-13 Margret Barbara Basinski Method for measuring genetic messages
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
US20030069195A1 (en) * 1996-03-01 2003-04-10 Farrar Gwenyth Jane Suppression of polymorphic alleles
US6020126A (en) * 1996-03-21 2000-02-01 Hsc, Reasearch And Development Limited Partnership Rapid genetic screening method
WO1997036005A1 (en) * 1996-03-26 1997-10-02 Lynx Therapeutics, Inc. Oligonucleotide treatments and compositions for human melanoma
US20040234999A1 (en) * 1996-04-02 2004-11-25 Farrar Gwenyth Jane Genetic suppression and replacement
GB9606961D0 (en) 1996-04-02 1996-06-05 Farrar Gwyneth J Genetic strategy III
US8551970B2 (en) * 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
GB9608803D0 (en) * 1996-04-27 1996-07-03 Univ Newcastle Mitochondrial dna defects
SE506700C2 (en) * 1996-05-31 1998-02-02 Mikael Kubista Probe and Methods for Analysis of Nucleic Acid
US20050032068A1 (en) * 2002-11-05 2005-02-10 Prakash Thazha P. Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050118605A9 (en) * 1996-06-06 2005-06-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
DE19637339A1 (en) * 1996-09-13 1998-03-19 Hoechst Ag Methods for amplifying nucleic acids
US5919638A (en) * 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
US5908845A (en) * 1996-10-30 1999-06-01 Segev; David Polyether nucleic acids
US20050202499A1 (en) 1996-10-31 2005-09-15 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US6444202B1 (en) 1996-11-25 2002-09-03 Bundesrepublic Deutschland, Vertreten Durch Den Bundesminister Fur Gesundheit Processed polypeptides with IL-16 activity, processes for their production and their use
US6117973A (en) 1997-02-24 2000-09-12 Georgia Tech Research Corp. PNA monomers with electron donor or acceptor
WO1998037232A2 (en) * 1997-02-24 1998-08-27 Georgia Tech Research Corporation Method for determining a nucleic acid
US6692912B1 (en) * 1997-03-05 2004-02-17 Matrix Technologies Corporation Nucleic acid-containing polymerizable complex
US5932711A (en) * 1997-03-05 1999-08-03 Mosaic Technologies, Inc. Nucleic acid-containing polymerizable complex
US6015887A (en) * 1997-04-11 2000-01-18 Isis Pharmaceuticals, Inc. Chiral peptide nucleic acids and methods for preparing same
SE522077C2 (en) * 1997-09-05 2004-01-13 Lightup Technologies Ab Method of selecting sequence of probe for nucleic acid hybridization
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
NZ501289A (en) * 1997-05-28 2001-06-29 Nielsen Peter E Conjugated peptide nucleic acids having enhanced cellular uptake
EP0881228B1 (en) * 1997-05-30 2005-08-10 PNA Diagnostics A/S 2- or 3-Dimensional Geometric Structures of Peptide Nucleic Acids
AU8147798A (en) * 1997-06-16 1999-01-04 University Of North Carolina At Chapel Hill, The Peptido oligonucleotides (pons) and their combinatorial libraries
US5962665A (en) 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
JPH11332595A (en) * 1997-07-09 1999-12-07 Masao Karube Detection of dna with probe pna
DK0897991T3 (en) * 1997-08-22 2005-07-25 Pna Diagnostics Aps Small triplex-forming PNA oligos
US6300318B1 (en) 1997-09-16 2001-10-09 Peter E. Nielsen Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor
DE19741739B4 (en) * 1997-09-22 2006-04-27 Nanogen Recognomics Gmbh Supramolecular mating system, its production and use
US6989270B1 (en) 1997-10-17 2006-01-24 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6723560B2 (en) 1998-10-08 2004-04-20 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response
US6007992A (en) * 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
DE19816550A1 (en) 1997-12-24 1999-06-24 Roche Diagnostics Gmbh Universally applicable structure of an analysis element and its use for analyte determination
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
US6326479B1 (en) * 1998-01-27 2001-12-04 Boston Probes, Inc. Synthetic polymers and methods, kits or compositions for modulating the solubility of same
WO1999049293A2 (en) * 1998-03-24 1999-09-30 Boston Probes, Inc. Methods, kits and compositions pertaining to detection complexes
US20040186071A1 (en) * 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US20040063618A1 (en) * 2002-09-30 2004-04-01 Muthiah Manoharan Peptide nucleic acids having improved uptake and tissue distribution
DE19824900B4 (en) 1998-06-04 2006-05-04 Roche Diagnostics Gmbh DNA detection via a strand-annealing complex
US6664045B1 (en) * 1998-06-18 2003-12-16 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the detection of microorganisms
JP2002520008A (en) 1998-07-09 2002-07-09 バイオセプト インコーポレイテッド Use of an improved universal library of peptide nucleic acids to optimize DNA sequence hybridization
US6548651B1 (en) 1998-11-11 2003-04-15 Pantheco A/S Modified peptide nucleic acid (PNA) molecules
AU3274600A (en) * 1999-03-18 2000-10-09 Exiqon A/S One step sample preparation and detection of nucleic acids in complex biologicalsamples
US20020049173A1 (en) * 1999-03-26 2002-04-25 Bennett C. Frank Alteration of cellular behavior by antisense modulation of mRNA processing
US6824866B1 (en) 1999-04-08 2004-11-30 Affymetrix, Inc. Porous silica substrates for polymer synthesis and assays
DE19927783A1 (en) 1999-06-18 2000-12-21 Roche Diagnostics Gmbh Element for determining an analyte in a liquid, corresponding determination method using the element and kit for determining an analyte
AU6629200A (en) * 1999-08-25 2001-03-19 Philip P Garner Alpha-helical peptide nucleic acid alpha-pna
CA2384407C (en) 1999-08-30 2009-10-20 Roche Diagnostics Gmbh 2-azapurine compounds and their use
US6348583B1 (en) * 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US6994964B1 (en) 1999-09-01 2006-02-07 Affymetrix, Inc. Macromolecular arrays on polymeric brushes and methods for preparing the same
US6660845B1 (en) * 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
WO2001058240A2 (en) 2000-02-10 2001-08-16 Massachusetts Eye And Ear Infirmary Photodynamic therapy for treating conditions of the eye
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US20040014644A1 (en) * 2000-03-14 2004-01-22 Vladimir Efimov Oligonucleotide analogues and methods of use for modulating gene expression
AU2001247414A1 (en) * 2000-03-14 2001-09-24 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US6936443B2 (en) 2000-04-03 2005-08-30 Cytyc Corporation Detection and typing of human papillomavirus using PNA probes
ATE456668T1 (en) 2000-04-03 2010-02-15 Cytyc Corp DETECTION AND TYPING OF PAPILLOMA VIRUS USING PNA PROBE
US7211381B1 (en) 2000-04-04 2007-05-01 Abbott Laboratories β2 andrenergic polymorphism detection
US6593092B2 (en) 2000-04-04 2003-07-15 Abbott Laboratories Beta 2 adrenergic polymorphism detection
DE10019136A1 (en) * 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamide nucleic acid derivatives, agents and processes for their preparation
DE10019135A1 (en) 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamide nucleic acid derivatives, agents and processes for their preparation
US6887664B2 (en) 2000-06-06 2005-05-03 Applera Corporation Asynchronous primed PCR
ATE384731T1 (en) 2000-08-03 2008-02-15 Hoffmann La Roche NUCLEIC ACID BINDING COMPOUNDS WITH PYRAZOLO 3, 4-D PYRIMIDINE ANALOGUES OF PURINE-2,6-DIAMINE AND THEIR USE
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1315519B1 (en) 2000-08-08 2010-12-29 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for treating cancer or liver fibrosis
US7183394B1 (en) * 2000-08-11 2007-02-27 Garner Philip P Helical nucleopeptides
ATE544473T1 (en) * 2000-11-09 2012-02-15 Cold Spring Harbor Lab CHIMERIC MOLECULES FOR MODULATION OF GENE EXPRESSION
EP1357112A4 (en) * 2000-12-26 2005-08-17 Applied Biosystems Japan Ltd Novel functional peptide nucleic acid monomer and process for producing the same
CA2436665C (en) 2001-01-29 2012-01-10 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
GB0102388D0 (en) * 2001-01-31 2001-03-14 Secr Defence Polymers
EP1236804A1 (en) 2001-03-02 2002-09-04 Boehringer Mannheim Gmbh A method for determination of a nucleic acid using a control
CA2439750A1 (en) 2001-03-09 2002-09-19 Boston Probes, Inc. Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation
KR100886095B1 (en) 2001-04-16 2009-02-27 와이어쓰 홀딩스 코포레이션 Novel Streptococcus pneumoniae open reading frames encoding polypeptide antigens and a composition comprising the same
ATE527376T1 (en) 2001-05-18 2011-10-15 Boston Probes Inc PNA PROBE, PROBE KITS, PROCEDURES AND KITS RELATED TO CANDIDA DETECTION
WO2002097134A2 (en) * 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Modified peptide nucleic acid
US7053195B1 (en) 2001-06-12 2006-05-30 Syngenta Participatious Ag Locked nucleic acid containing heteropolymers and related methods
EP1925672A1 (en) 2001-06-22 2008-05-28 Syngeta Participations AG Abiotic stress responsive polynucleotides and polypeptides
US6921812B1 (en) 2001-07-03 2005-07-26 Isis Pharmaceuticals, Inc. Methods of modulating pharmacokinetics of oligonucleotides
US6852491B2 (en) 2001-09-04 2005-02-08 Abbott Laboratories Amplification and detection reagents for HIV-1
JP2005524384A (en) 2001-09-24 2005-08-18 ボストン プローブス,インコーポレイテッド Methods, kits and compositions for the suppression of detectable probe binding to randomly distributed repetitive sequences in genomic nucleic acids
EP1442137A4 (en) 2001-11-07 2005-08-31 Applera Corp Universal nucleotides for nucleic acid analysis
AU2002362013B2 (en) 2001-11-21 2008-04-24 Applied Biosystems, Llc. Digital assay
KR100464261B1 (en) 2002-01-24 2005-01-03 주식회사 파나진 A Novel Monomer For Synthesis of PNA Oligomer And A Process For Producing The Same
US20040063109A2 (en) 2002-01-25 2004-04-01 Applera Corporation Single-tube, ready-to-use assay kits, and methods using same
AU2003230717A1 (en) * 2002-03-21 2003-10-08 Boston Probes, Inc. Pna oligomers, oligomers sets, methods and kits pertaining to the detection of bacillus anthracis
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof
US7052840B2 (en) 2002-04-03 2006-05-30 Capitol Genomix, Inc. Reversible association of nucleic acid with a carboxylated substrate
US7026120B2 (en) 2002-04-15 2006-04-11 Abbott Laboratories Probes for detecting tumor cells
KR20030084444A (en) 2002-04-26 2003-11-01 주식회사 파나진 A Novel Monomer For Synthesis of PNA Oligomer And A Process For Producing The Same
US7015317B2 (en) 2002-05-02 2006-03-21 Abbott Laboratories Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
CA2484010A1 (en) * 2002-05-17 2003-12-04 Applera Corporation Pna probes, probe sets, methods and kits pertaining to the determination of listeria
US20030220844A1 (en) * 2002-05-24 2003-11-27 Marnellos Georgios E. Method and system for purchasing genetic data
ATE449103T1 (en) 2002-09-08 2009-12-15 Applera Corp SOLID PHASE BONDED PNA DIMERS AND THEIR SYNTHESIS
CA2502610A1 (en) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Bead bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries
WO2004036188A2 (en) * 2002-10-18 2004-04-29 Cylene Pharmaceuticals, Inc. Processes for identifying quadruplex-targeted antiviral molecules
WO2004044132A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US9150606B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP1562971B1 (en) * 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
WO2004048596A2 (en) 2002-11-21 2004-06-10 Epicentre Technologies Methods for using primers that encode one strand of a double-stranded promoter
US20040259132A1 (en) * 2002-11-22 2004-12-23 Henrik Stender Peptide nucleic acid probes for analysis of pseudomonas (sensu stricto)
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US7736909B2 (en) 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
CA2488584C (en) * 2003-01-30 2011-10-11 Applera Corporation Methods, mixtures, kits and compositions pertaining to analyte determination
DK1597366T3 (en) * 2003-02-11 2013-02-25 Antisense Therapeutics Ltd Modulation of expression of insulin-like growth factor receptor I
US20040171149A1 (en) * 2003-02-11 2004-09-02 Wraight Christopher J. Modulation of insulin like growth factor I receptor expression
KR101111568B1 (en) 2003-02-21 2012-03-05 에자이 알앤드디 매니지먼트 가부시키가이샤 Signal amplification method for detecting mutant gene
EP1631677B1 (en) * 2003-05-20 2010-11-17 Investigen, Inc. System for detecting polynucleotides
WO2005012546A2 (en) * 2003-07-25 2005-02-10 Andreas Braun Methods for isolating and identifying novel target-specific structuremers for use in the biological sciences
JPWO2005010181A1 (en) * 2003-07-25 2007-09-27 株式会社クレディアジャパン Nucleic acid detection method
US20060198800A1 (en) * 2003-08-14 2006-09-07 Natalie Dilallo Skin care compositions including hexapeptide complexes and methods of their manufacture
WO2005016364A1 (en) * 2003-08-14 2005-02-24 Guthy-Renker Corporation Skin care composition including hexapeptide complexes and methods of their manufacture
WO2005074417A2 (en) * 2003-09-03 2005-08-18 Salk Institute For Biological Studies Multiple antigen detection assays and reagents
US20050148087A1 (en) * 2004-01-05 2005-07-07 Applera Corporation Isobarically labeled analytes and fragment ions derived therefrom
WO2005067646A2 (en) 2004-01-07 2005-07-28 Hitachi Chemical Research Center, Inc. Primers and probes for the detection of hiv
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005098040A2 (en) 2004-03-24 2005-10-20 Applera Corporation Ligation and amplification reactions for determining target molecules
CA2564838A1 (en) 2004-04-28 2005-11-10 Eisai R&D Management Co., Ltd. Hybridization method
WO2005111235A2 (en) * 2004-05-04 2005-11-24 Dak Denmark A/S Methods for detecting chromosome aberrations
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
AU2005252663B2 (en) * 2004-06-03 2011-07-07 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US20060057611A1 (en) 2004-06-30 2006-03-16 Applera Corporation Log-linear amplification
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US7306785B2 (en) * 2004-09-23 2007-12-11 General Electric Company Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using
WO2007044031A2 (en) * 2004-12-06 2007-04-19 Bioveris Corporation Methods and compositions for detecting bacillus anthracis
WO2006063355A2 (en) * 2004-12-11 2006-06-15 Cytogenix , Inc. Cell free biosynthesis of high-quality nucleic acid and uses thereof
US20060228726A1 (en) 2005-01-06 2006-10-12 Martin Patrick K Polypeptides having nucleic acid binding activity and compositions and methods for nucleic acid amplification
US7229769B2 (en) * 2005-03-25 2007-06-12 Illumina, Inc. Compositions and methods for detecting protease activity
US20060257902A1 (en) 2005-03-25 2006-11-16 Ambion, Inc. Methods and compositions for depleting abundant RNA transcripts
CN101495647B (en) 2005-06-02 2014-12-17 阿德万德克斯公司 Peptide nucleic acid probes for analysis of microorganisms
EP1893777B1 (en) 2005-06-07 2014-10-01 Luminex Corporation Methods for detection and typing of nucleic acids
EP1919930B1 (en) 2005-07-01 2016-09-14 Dako Denmark A/S New nucleic acid base pairs
US20070059713A1 (en) 2005-09-09 2007-03-15 Lee Jun E SSB-DNA polymerase fusion proteins
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
WO2007073149A1 (en) 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
EP2010677A4 (en) * 2006-02-24 2010-04-14 Investigen Inc Methods and compositions for detecting polynucleotides
US7927804B2 (en) 2006-03-15 2011-04-19 Eisai & Managment Co., Ltd. Method of forming signal probe-polymer
EP2677039B8 (en) 2006-05-10 2022-10-05 DxTerity Diagnostics Incorporated Detection of nucleic acid targets using chemically reactive oligonucleotide probes
US20100196336A1 (en) 2006-05-23 2010-08-05 Dongsu Park Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2035831B1 (en) 2006-06-30 2013-08-14 Applied Biosystems, LLC Methods of analyzing binding interactions
JP2009545317A (en) 2006-08-01 2009-12-24 アプライド バイオシステムズ, エルエルシー Analyte and nucleic acid detection
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
US20080131880A1 (en) * 2006-11-22 2008-06-05 Bortolin Laura T PNA-DNA oligomers and methods of use thereof
WO2008070525A1 (en) 2006-12-04 2008-06-12 Luminex Corporation Oxocarbonamide peptide nucleic acids and methods of using same
CN102851369B (en) 2006-12-13 2015-01-21 卢米耐克斯公司 Systems and methods for multiplex analysis of PCR in real time
US9938641B2 (en) * 2006-12-18 2018-04-10 Fluidigm Corporation Selection of aptamers based on geometry
EP2118310B1 (en) * 2006-12-29 2013-03-06 Applied Biosystems, LLC Systems and methods for detecting nucleic acids
EP2069525A1 (en) * 2006-12-29 2009-06-17 Applied Biosystems, LLC Systems and methods for detecting nucleic acids
US7803543B2 (en) 2007-01-19 2010-09-28 Chang Gung University Methods and kits for the detection of nucleotide mutations using peptide nucleic acid as both PCR clamp and sensor probe
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
US7771947B2 (en) * 2007-02-23 2010-08-10 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
AU2008218939B2 (en) * 2007-02-23 2014-05-08 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
WO2008127921A2 (en) 2007-04-13 2008-10-23 Abbott Laboratories Primer and probe sequences for detecting chlamydia trachomatis
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
EP3023436A1 (en) 2007-07-03 2016-05-25 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
WO2009017833A2 (en) 2007-08-02 2009-02-05 Arresto Biosciences Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
EP2202319A4 (en) 2007-10-24 2010-10-20 Eisai R&D Man Co Ltd Nucleic acid probe, and method for production of probe polymer
JPWO2009057702A1 (en) 2007-10-31 2011-03-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 Polymer for detecting target substance and method for detecting target substance
US8916531B2 (en) * 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
US8017338B2 (en) 2007-11-20 2011-09-13 Life Technologies Corporation Reversible di-nucleotide terminator sequencing
KR101588736B1 (en) 2008-01-10 2016-01-26 리서치 디벨롭먼트 파운데이션 Vaccines and diagnostics for Ehrlichia chaffeensis
EP3360972B1 (en) 2008-01-17 2019-12-11 Sequenom, Inc. Single molecule nucleic acid sequence analysis processes
KR101072899B1 (en) * 2008-01-21 2011-10-17 주식회사 파나진 Synthesis of peptide nucleic acids conjugated with amino acids and their application
US8709726B2 (en) 2008-03-11 2014-04-29 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
KR20090098710A (en) 2008-03-14 2009-09-17 주식회사 씨티아이바이오 Peptide nucleic acid derivatives with good cell penetration and affinity for nucleic acid
WO2009147537A2 (en) 2008-05-27 2009-12-10 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
ES2705694T3 (en) 2008-06-13 2019-03-26 Codexis Inc Method of synthesis of polynucleotide variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
WO2010027326A1 (en) 2008-09-03 2010-03-11 Nanyang Technological University Peptide nucleic acid monomers and oligomers
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
WO2010033248A2 (en) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Neutral nanotransporters
WO2010037124A1 (en) 2008-09-29 2010-04-01 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
DK2337860T3 (en) 2008-10-15 2016-08-29 Axolabs Gmbh A method for the detection of oligonucleotides
JP5805538B2 (en) 2008-11-07 2015-11-04 リサーチ ディベロップメント ファウンデーション Compositions and methods for inhibiting Cripto / GSP78 complex formation and signaling
US8715732B2 (en) * 2009-01-05 2014-05-06 Cornell University Nucleic acid hydrogel via rolling circle amplification
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US7964355B2 (en) 2009-02-17 2011-06-21 Investigen, Inc. Assays based on detection of photobleaching reaction products from dye catalytic complex
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
US8063193B2 (en) 2009-03-27 2011-11-22 Abbott Laboratories Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof
CN102449169B (en) 2009-04-01 2016-03-16 德克斯特里蒂诊断公司 The probe amplification (CLPA) of chemistry join dependency
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
JP5828837B2 (en) 2009-06-02 2015-12-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
EP2789689B1 (en) 2009-06-29 2016-04-27 Luminex Corporation Chimeric primers with hairpin conformations and methods of using same
WO2011011630A2 (en) 2009-07-23 2011-01-27 Codexis, Inc. Nitrilase biocatalysts
EP2462230B1 (en) * 2009-08-03 2015-07-15 Recombinetics, Inc. Methods and compositions for targeted gene modification
KR20120063488A (en) 2009-08-21 2012-06-15 길리아드 바이오로직스, 인크. Catalytic domains from lysyl oxidase and loxl2
US8759259B2 (en) 2009-10-16 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for producing cyclic peptoid libraries
EP2507391B1 (en) 2009-12-02 2016-08-17 Dako Denmark A/S Compositions and methods for performing hybridizations with no denaturation
EP2516680B1 (en) 2009-12-22 2016-04-06 Sequenom, Inc. Processes and kits for identifying aneuploidy
WO2011087789A2 (en) 2009-12-22 2011-07-21 Becton, Dickinson And Company Methods for the detection of microorganisms
EP2550000A4 (en) 2010-03-24 2014-03-26 Advirna Inc Reduced size self-delivering rnai compounds
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
MX352460B (en) 2011-01-11 2017-11-24 Seegene Inc Detection of target nucleic acid sequences by pto cleavage and extension assay.
CN103534358B (en) 2011-03-29 2015-03-25 Seegene株式会社 Detection of target nucleic acid sequence by PTO cleavage and extension-dependent cleavage
WO2012138955A2 (en) 2011-04-08 2012-10-11 Ly Danith H CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS
CN103717750B (en) 2011-04-29 2017-03-08 塞昆纳姆股份有限公司 The quantitation of minority nucleic acid substances
MX342067B (en) 2011-05-04 2016-09-09 Seegene Inc Detection of target nucleic acid sequences by po cleavage and hybridization.
CA2836577C (en) 2011-05-17 2019-06-25 Dxterity Diagnostics Incorporated Methods and compositions for detecting target nucleic acids
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
GB201117482D0 (en) 2011-10-11 2011-11-23 Univ Dundee Targetiing of miRNA precursors
US11118226B2 (en) 2011-10-21 2021-09-14 Agilent Technologies, Inc. Hybridization compositions and methods
EP2594942A1 (en) 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Long rigid spacers to enhance binding kinetics in immunoassays
WO2013085026A1 (en) 2011-12-09 2013-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for detecting nucleotide mutation, and detection kit
EP4155401A1 (en) 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
AU2013228226B2 (en) 2012-03-05 2016-06-02 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence by PTO cleavage and extension assay
EP2851425A1 (en) 2012-05-15 2015-03-25 Eisai R&D Management Co., Ltd. Rna detection method and detection kit
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
CN104540944A (en) 2012-05-21 2015-04-22 斯克利普斯研究所 Ribosomal polynucleotides and related expression systems
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
WO2014011928A1 (en) 2012-07-13 2014-01-16 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
WO2014033314A1 (en) 2012-09-03 2014-03-06 Uab Bioseka Antisense oligonucleotide targeting bacterial glucosyltransferases
US10006909B2 (en) 2012-09-28 2018-06-26 Vibrant Holdings, Llc Methods, systems, and arrays for biomolecular analysis
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2929050A1 (en) 2012-12-10 2015-10-14 AdvanDx, Inc. Use of probes for mass spectrometric identification of microorganisms or cells and associated conditions of interest
AU2014200958B2 (en) 2013-02-25 2016-01-14 Seegene, Inc. Detection of nucleotide variation on target nucleic acid sequence
US9289502B2 (en) 2013-03-08 2016-03-22 Emerald Therapeutics, Inc. Preparation of oligo conjugates
WO2014168711A1 (en) 2013-03-13 2014-10-16 Sequenom, Inc. Primers for dna methylation analysis
KR101943623B1 (en) 2013-03-13 2019-01-30 주식회사 씨젠 Quantification of Target Nucleic Acid Using Melting Peak Analysis
US9347095B2 (en) 2013-03-15 2016-05-24 Bio-Rad Laboratories, Inc. Digital assays for mutation detection
EP2971158B1 (en) 2013-03-15 2018-11-14 Abbott Molecular Inc. Detection of bisulfite converted nucleotide sequences
WO2014169206A2 (en) 2013-04-11 2014-10-16 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
US10221216B2 (en) 2013-04-11 2019-03-05 Carnegie Mellon University Template-directed γPNA synthesis process and γPNA targeting compounds
CN105339388B (en) 2013-07-12 2021-06-15 Emd密理博公司 Method for determining the removal of viruses from a sample containing a target protein using activated carbon
KR101863943B1 (en) 2013-07-15 2018-06-01 주식회사 씨젠 Detection of Target Nucleic Acid Sequence by PTO Cleavage and Extension-Dependent Immobilized Oligonucleotide Hybridization
LT6214B (en) 2013-10-07 2015-08-25 Uab "Bioseka" Antisense oligonucleotide for prevention of atherosclerosis and cardivascular infections
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
WO2015057998A1 (en) 2013-10-16 2015-04-23 The University Of British Columbia Device for formulating particles at small volumes
KR101757473B1 (en) 2013-10-18 2017-07-13 주식회사 씨젠 Detection of Target Nucleic Acid Sequence on Solid Phase by PTO Cleavage and Extension using hCTO Assay
WO2015070050A1 (en) 2013-11-08 2015-05-14 Baylor Research Institute Nuclear loclization of glp-1 stimulates myocardial regeneration and reverses heart failure
EP3099799B1 (en) 2014-01-28 2019-05-15 Dice Molecules SV. LLC Arrays of monoliths with attached recognition compounds
EP3736344A1 (en) 2014-03-13 2020-11-11 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
WO2015172058A1 (en) 2014-05-08 2015-11-12 Carnegie Mellon University Left-handed gamma-peptide nucleic acids, methods of synthesis and uses therefor
EP3154696B1 (en) 2014-06-10 2020-04-08 DxTerity Diagnostics Incorporated Devices and methods for collecting and stabilizing biological samples
CN106414738A (en) 2014-06-24 2017-02-15 雅培分子公司 Detection of single nucleotide polymorphisms in human kras
CN106715718B (en) 2014-07-24 2021-07-06 雅培分子公司 Compositions and methods for detecting and analyzing mycobacterium tuberculosis
EP3633047B1 (en) 2014-08-19 2022-12-28 Pacific Biosciences of California, Inc. Method of sequencing nucleic acids based on an enrichment of nucleic acids
EP3259346A4 (en) 2015-02-20 2018-07-11 Baylor College of Medicine P63 inactivation for the treatment of heart failure
SG10201912085WA (en) 2015-06-12 2020-02-27 Alector Llc Anti-cd33 antibodies and methods of use thereof
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
EP3322483A4 (en) 2015-07-14 2019-01-02 Abbott Molecular Inc. Compositions and methods for identifying drug resistant tuberculosis
KR20180054639A (en) 2015-08-28 2018-05-24 알렉터 엘엘씨 Anti-SIGLEC-7 Antibodies and Methods of Use Thereof
US11046999B2 (en) 2015-09-16 2021-06-29 PetaOmics, Inc. Methods and compositions for genomic target enrichment and selective DNA sequencing
KR20180084782A (en) 2015-10-14 2018-07-25 엑스-써마 인코포레이티드 Compositions and methods for reducing ice crystal formation
JP7441002B2 (en) 2015-10-14 2024-02-29 バイオ-パス ホールディングス, インコーポレイテッド p-ethoxy nucleic acids for liposome formulations
EP3368575A2 (en) 2015-10-29 2018-09-05 Alector LLC Anti-siglec-9 antibodies and methods of use thereof
AU2016385135B2 (en) 2016-01-06 2022-02-17 The University Of British Columbia Bifurcating mixers and methods of their use and manufacture
US20190177391A1 (en) 2016-03-31 2019-06-13 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
US10400274B2 (en) 2016-06-18 2019-09-03 Jan Biotech, Inc. Fluorogenic probes and their use in quantitative detection of target RNA sequences
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
ES2928654T3 (en) 2016-09-16 2022-11-21 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
CN114907272A (en) 2016-09-26 2022-08-16 卡耐基梅隆大学 Bivalent nucleobase compound and use thereof
US11147249B2 (en) 2016-12-08 2021-10-19 Alector Llc Siglec transgenic mice and methods of use thereof
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US10538808B2 (en) 2017-05-26 2020-01-21 Vibrant Holdings, Llc Photoactive compounds and methods for biomolecule detection and sequencing
EP3589658A1 (en) 2017-08-03 2020-01-08 Alector LLC Anti-cd33 antibodies and methods of use thereof
US11591645B2 (en) 2017-08-31 2023-02-28 Seegene, Inc. Evaluation of performance of components using a pair of dimer-forming primers
KR102345601B1 (en) 2017-09-29 2021-12-30 주식회사 씨젠 Detection of target nucleic acid sequences by PTO cleavage and extension-dependent extension analysis
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
CA3086479A1 (en) * 2017-12-21 2019-06-27 Carnegie Mellon University Template-directed nucleic acid targeting compounds
EP3830123A1 (en) 2018-07-27 2021-06-09 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
AU2019342197A1 (en) 2018-09-21 2021-04-15 President And Fellows Of Harvard College Methods and compositions for treating diabetes, and methods for enriching mRNA coding for secreted proteins
EP3997225A1 (en) 2019-07-10 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of epilepsy
US20230016983A1 (en) 2019-11-19 2023-01-19 lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Antisense oligonucleotides and thier use for the treatment of cancer
CA3185019A1 (en) 2020-05-29 2021-12-02 Front Range Biosciences, Inc. Methods and compositions for pathogen detection in plants
WO2022006019A1 (en) 2020-06-29 2022-01-06 Front Range Biosciences, Inc. Characterization of cannabis cultivars based on terpene synthase gene profiles
JP2023540429A (en) 2020-07-10 2023-09-25 アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) Methods and compositions for treating epilepsy
CA3218220A1 (en) * 2021-05-11 2022-11-17 Russell Lewis Mccurdy Replaceable floating attractant accessories for fishing line
WO2023043280A1 (en) 2021-09-17 2023-03-23 주식회사 씨젠 Detection of target nucleic acid sequence by using synthetic non-natural base-bearing tag oligonucleotide
CN114409890A (en) * 2022-02-28 2022-04-29 中国科学院长春应用化学研究所 Amino-functionalized polyethylene glycol derivative and preparation method thereof
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2910130A1 (en) 1979-03-15 1980-09-25 Franz Rossmoeller Electrical connections for wall-mounted cupboards - have conductor strips concealed inside vertical supports with branch extensions alongside brackets
DE2910129C2 (en) 1979-03-15 1986-01-23 Oskar 4354 Datteln Fleck Strip for sealing the gap between the eaves lath of a roof and the overlying eaves-side roof cladding panels
JPS5927900A (en) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk Oligonucleotide derivative and its preparation
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) * 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
DE3650349T2 (en) * 1985-03-15 1995-12-14 Antivirals Inc IMMUNOTEST FOR POLYNUCLEOTID AND METHOD.
EP0972779A3 (en) 1987-10-28 2004-10-20 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
WO1990002749A1 (en) 1988-09-01 1990-03-22 Forskningscenter Risø Peptide synthesis method and solid support for use in the method
JPH02156895A (en) * 1988-12-08 1990-06-15 Sumitomo Heavy Ind Ltd Production of 5'-nucleotides by halophil
JPH0635469B2 (en) * 1989-09-13 1994-05-11 信 高橋 Diethylenetriamine triacetic acid compound, production intermediate thereof and production method thereof
US5340716A (en) * 1991-06-20 1994-08-23 Snytex (U.S.A.) Inc. Assay method utilizing photoactivated chemiluminescent label
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
DK51092D0 (en) 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US6414112B1 (en) * 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US6451968B1 (en) * 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
MX9207334A (en) 1991-12-18 1993-08-01 Glaxo Inc NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM
US6770738B1 (en) * 1992-05-22 2004-08-03 Isis Pharmaceuticals, Inc. Higher order structure and binding of peptide nucleic acids
WO1993024507A1 (en) * 1992-05-28 1993-12-09 Gilead Sciences, Inc. Conformationally restrained oligomers containing amide or carbamate linkages for sequence-specific binding
US5705333A (en) * 1994-08-05 1998-01-06 The Regents Of The University Of California Peptide-based nucleic acid mimics(PENAMS)
US6472209B1 (en) * 1997-10-17 2002-10-29 Mayo Foundation For Medical Education And Research Using polyamide nucleic acid oligomers to engender a biological response

Also Published As

Publication number Publication date
EP1411063B1 (en) 2006-07-19
CA2109320A1 (en) 1992-11-25
DK0586618T3 (en) 1998-02-09
EP1411063A1 (en) 2004-04-21
JPH06509063A (en) 1994-10-13
EP1074559B1 (en) 2011-07-06
US20120115136A1 (en) 2012-05-10
AU1880692A (en) 1992-12-30
ATE515569T1 (en) 2011-07-15
CA2109320C (en) 2003-07-22
AU666480B2 (en) 1996-02-15
EP1162206A3 (en) 2004-04-14
DK51092D0 (en) 1992-04-15
EP0586474A1 (en) 1994-03-16
HUT66597A (en) 1994-12-28
US6201103B1 (en) 2001-03-13
EP1162206A2 (en) 2001-12-12
EP0586618A1 (en) 1994-03-16
JP2003235590A (en) 2003-08-26
FI935208A0 (en) 1993-11-23
NO934122L (en) 1994-01-11
JP2009069158A (en) 2009-04-02
NO934235D0 (en) 1993-11-23
EP0586474B1 (en) 2001-09-12
NO934122D0 (en) 1993-11-15
JP3982828B2 (en) 2007-09-26
DK0586474T3 (en) 2001-12-31
US5977296A (en) 1999-11-02
ES2107552T3 (en) 1997-12-01
ATE155483T1 (en) 1997-08-15
DE69220946T2 (en) 1998-01-15
BR9206049A (en) 1994-12-27
WO1992020703A1 (en) 1992-11-26
DE69232055T2 (en) 2002-06-06
DE69220946D1 (en) 1997-08-21
AU1884392A (en) 1992-12-30
NO312516B1 (en) 2002-05-21
JP2758988B2 (en) 1998-05-28
US20030180734A1 (en) 2003-09-25
US7378485B2 (en) 2008-05-27
FI935208A (en) 1993-11-23
ES2164052T3 (en) 2002-02-16
US6710163B1 (en) 2004-03-23
JP2007306926A (en) 2007-11-29
US20020160383A1 (en) 2002-10-31
HU221003B1 (en) 2002-07-29
US20040059087A1 (en) 2004-03-25
JP2008253251A (en) 2008-10-23
NO313201B1 (en) 2002-08-26
US20060046255A1 (en) 2006-03-02
DE69232055D1 (en) 2001-10-18
FI118424B (en) 2007-11-15
US6395474B1 (en) 2002-05-28
GR3025018T3 (en) 1998-01-30
US20060160731A1 (en) 2006-07-20
EP1074559A1 (en) 2001-02-07
EP0586618B1 (en) 1997-07-16
ATE205504T1 (en) 2001-09-15
WO1992020702A1 (en) 1992-11-26
NO934235L (en) 1994-01-20
JPH06506945A (en) 1994-08-04
HU9303023D0 (en) 1994-01-28
KR0133131B1 (en) 1998-04-14
US6357163B1 (en) 2002-03-19

Similar Documents

Publication Publication Date Title
AU666480B2 (en) The use of nucleic acid analogues in diagnostics and analytical procedures
US5714331A (en) Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5766855A (en) Peptide nucleic acids having enhanced binding affinity and sequence specificity
US5786461A (en) Peptide nucleic acids having amino acid side chains
US5539082A (en) Peptide nucleic acids
US6228982B1 (en) Double-stranded peptide nucleic acids
US6414112B1 (en) Peptide nucleic acids having 2,6-diaminopurine nucleobases
EP0773950B1 (en) Linked peptide nucleic acids
AU717387B2 (en) Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6713602B1 (en) Synthetic procedures for peptide nucleic acids
US6710164B1 (en) Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US20030105286A1 (en) Linked peptide nucleic acids

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued